Markers of neuronal differentiation and morphogenesis

FIELD OF THE INVENTION

[0002] The invention relates to a combination comprising a plurality of cDNAs which are markers of neuronal differentiation and morphogenesis and may be used in the diagnosis, prognosis, treatment, and evaluation of therapies for conditions, diseases, disorders, and syndromes associated with neuronal differentiation and morphogenesis.

BACKGROUND OF THE INVENTION

[0003] The hippocampus is part of the brain's limbic system which controls emotional behavior, motivational drive, and other physiological functions. The limbic system includes the limbic cortex, hippocampus, amygdala, hypothalamus, and anterior thalamus. The hippocampus plays an important role in learning and memory. Stimulation of the hippocampus can cause behavioral responses including rage, passivity, and excess sex drive. Weak electrical stimulation can cause hippocampal seizures. Individuals who lose hippocampal function retain memory for events that occurred prior to the loss, but only have immediate memory for all events after the loss (anterograde amnesia). Numerous studies of the effects of ablation of the hippocampus of rodent, primate, and other non-human species have been reported. Morphological changes in the hippocampus, including cell loss, are associated with epilepsy, schizophrenia, Alzheimer's disease, and certain amnesiac or memory problems or syndromes (Jack (1994) Epilepsia 35:S21-S29). Research with animal models show that glucocorticoids secreted during periods of stress can damage the hippocampus and impair the ability of hippocampal neurons to survive neurological insults (Sapolsky (1993) Behav Brain Res 57:175-182). Sustained hypersecretion of glucocorticoids from the adrenal cortex may damage the hippocampus; for example, hippocampal atrophy has been reported in patients with Cushing's syndrome.

[0004] Other disturbances to the environmental milieu of the brain may also contribute to changes in the phenotype of neurons, glia, oligodendrocytes, and microglia. Examples of cellular factors which have been shown to affect the morphology of cultured neuronal and glial cells include cytokines, growth factors, cellular and serum proteases, and steroid hormones. Bacterial toxins which induce cytokines may also contribute, either directly, or indirectly to changes in neural cell phenotype (reviewed by Reichlin (1998) Ann NY Acad Sci 840:301-316).

[0005] During normal brain development, most neurons undergo mitosis during the prenatal and the initial postnatal periods. Until as recently as 1998, it was thought that cells increased in size, but not in number, in most parts of the mature brain. Both Gray and Sundstrom (1998; Brain Res 790:52-59) and Kempermann et al. (1998; Curr Biol 8:939-942) have reported that neuronal cell proliferation can occur in the dentate gyrus of adult rodent and primate hippocampus.

[0006] A number of proteins are expressed specifically in neuronal cells. For example, amyloid precursor protein (APP) is a component of a complex protein network that may function in axonal elongation, dendritic arborisation and neuronal cell migration. Neuronal protein 3.1 is expressed at high levels in the embryonic brain and in the adult cerebellum, hippocampus and olfactory bulb. Hox 1.3 is expressed in fully differentiated neurons including the Purkinje neurons of the cerebellum, the pyramidal and dentate neurons of the hippocampus, and the motor neurons of the spinal cord (De Strooper et al. (2000) J Cell Sci 113:1857-1870; Studler et al. (1993) Eur J Neurosci 5:614-623; and Odenwald et al. (1987) Genes Dev 1:482-96).

[0007] Totipotent embryonic stem (ES) cells isolated from mammalian embryos retain the potential to reform an embryo. When ES cells are replaced inside a carrier embryo, they resume normal development and contribute to all tissues of the live-born animal. ES cells are the preferred cells used in the creation of experimental knockout rodent strains. Recently, the role of the LIM homeobox gene, Lhx5, was reported to control hippocampal morphogenesis and neuronal differentiation using a knockout mouse model (Zhao et al. (1999) Science 284:1155-1158).

[0008] Mouse ES cells have also been used to study the differentiation of various cell and tissues types in vitro; these include neural cells, hematopoietic lineages, and cardiomyocytes (Bain et al. (1995) Dev Biol 168:342-357; Wiles and Keller (1991) Development 111:259-267; and Klug et al. (1996) J Clin Invest 98:216-224). Recent developments in technical capabilities now demonstrate that ES cells derived from human blastocysts may also be manipulated in vitro to differentiate into eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types (Thomson (1998) Science 282:1145-1147).

[0009] In early experiments, it was reported that differentiated neuronal and glial cells derived from retinoic acid-treated mouse ES cells were positive for the neuron-, astrocyte- and oligodendrocyte-specific antigens, MAP2, GFAP, and O4, respectively. Some neuronal cells were also positive for acetylcholinesterase activity or glutamic acid decarboxylase expression (Fraichard et al. (1995) J Cell Sci 108:3181-3188). More recently, additional markers of neuronal differentiation were identified in retinoic acid-treated mouse ES cells including Pax-6, Islet-½, Lim-3, HB-9, Phox2b, and EN1 (Renoncourt et al. (1998) Mech Dev 79:185-197). Other cellular markers undoubtedly are present during neuronal differentiation, but their identity is as yet unknown. Furthermore, developmental signaling and growth factor pathways are shared by both neuronal and thymic cells which suggests that there are many common pathways both during development and following tissue maturation. It is even likely that the blood-brain barrier evolved in order to prevent inappropriate neuronal dismorphology induced by serum-, leukocyte-, or lymphocyte-derived factors.

[0010] Identification of additional neuronal markers, in particular those which may regulate or modulate neuronal differentiation and morphogenesis, would enable the production of neuronal cells in culture. Such cultures are useful in transplants and in the development of gene therapies. In addition, detection of changes in activity of such markers is useful in early diagnosis and treatment of disorders associated with neuronal differentiation and morphogenesis.

SUMMARY OF THE INVENTION

[0011] The invention provides a combination comprising a plurality of cDNAs wherein the cDNAs are SEQ ID NOs: 1-2217 of the Sequence Listing which are differentially expressed in neuronal differentiation and morphogenesis and complements of SEQ ID NOs: 1-2217. The invention also provides a combination comprising a plurality of mouse cDNAs, wherein the cDNAs are SEQ ID NOs: 1-1365 and the complements thereof. The invention additionally provides a combination comprising a plurality of mouse cDNAs, wherein the cDNAs are SEQ ID NOs: 1366-2217 and the complements thereof. In one embodiment, mouse cDNAs having the nucleic acid sequences of SEQ ID NOs: 1-102 are increased greater than 5-fold, and the mouse cDNAs having the nucleic acid sequences of SEQ ID NOs: 1303-1365 are decreased greater than 5-fold. In another embodiment, mouse cDNAs having the nucleic acid sequences of SEQ ID NOs: 1-19 are increased greater than 10-fold, and the human cDNAs having the nucleic acid sequences of SEQ ID NOs: 1353-1365 are decreased greater than 10-fold In one aspect, the human cDNA is a homolog of a mouse cDNA whose expression is increased greater than 5-fold and has a nucleic acid sequence selected from SEQ ID NOs: 1366, 1367, 1369, 1377, 1379, 1396, 1417, 1424, 1429, 1434, 1450, 1468, 1470, 1475, 1487, 1492, 1497, 1508, 1512, 1522, 1533, 1552, 1560, 1596, 1607, 1614, 1622, 1635, 1653, 1654, 1660, 1662, 1678, 1679, 1680, 1710, 1713, 1716, 1717, 1770, 1771, 1795, 1814, 1815, 1816, 1817, 1819, 1831, 1834, 1837, 1878, 1880, 1887, 1916, 1924, 1927, 1948, 1950, 1976, 2019, 2022, 2039, 2041, 2060, 2060, 2063, 2084, 2127, 2127, 2154, 2164, 2182, 2183, or is decreased greater than 5-fold and has a nucleic acid sequence selected from SEQ ID NOs: 1376, 1388, 1389, 1426, 1518, 1527, 1529, 1548, 1578, 1586, 1604, 1629, 1630, 1661, 1671, 1672, 1684, 1720, 1720, 1766, 1777, 1794, 1838, 1847, 1851, 1857, 1869, 1870, 1892, 1904, 1905, 1931, 1968, 1983, 2001, 2038, 2053, 2054, 2088, 2111, 2141, 2144, and 2165. In another aspect, the human cDNA is a homolog of a mouse cDNA whose expression is increased greater than 10-fold and has a nucleic acid sequence selected from SEQ ID NOs: 1379, 1607, 1653, 1654, 1678, 1679, 1713, 1771, 1976, 2022, 2127, 2164, or decreased greater than 10-fold and has a nucleic acid sequence selected from SEQ ID NOs: 1376, 1527, 1629, 1766, 1931, 2001, 2088, and 2144.

[0012] The invention provides a cDNA array comprising the combination and a substrate. The invention also provides a method of using an array to detect the presence of at least one nucleic acid in a sample comprising contacting the array with the sample containing nucleic acids under conditions which allow formation of hybridization complexes between the nucleic acids of the sample and the cDNAs of the array; and detecting any hybridization complexes so formed. In one aspect, the sample is from a subject with a disorder associated with neuronal differentiation and morphogenesis. In another aspect, hybridization complexes are compared with standards to diagnose a disorder associated with neuronal differentiation and morphogenesis. In one embodiment, the disorder is Alzheimer's disease; in another embodiment, the disorder is Parkinson's Disease; and in yet another embodiment, the disorder is cancer.

[0013] The invention also provides a method of using a cDNA array to screen a plurality of molecules or compounds to identify a molecule or compound which specifically binds to a cDNA of the array comprising contacting the array with a plurality of molecules or compounds under conditions to allow specific binding; and detecting specific binding, wherein a molecule or compound which specifically binds a cDNA of the array is identified. In one aspect, molecules or compounds are selected from DNA molecules, enhancers, mimetics, peptide nucleic acids, proteins, repressors, RNA molecules, and transcription factors. The invention further provides a method for obtaining a full length cDNA from a library of expressed or genomic nucleic acid sequences comprising arranging the library sequences on a substrate; hybridizing a cDNA selected from the Sequence Listing with the library sequences under conditions which allow hybridization; detecting hybridization between the cDNA and library sequence; isolating the library sequence, and sequencing the library sequence, and repeating these steps until a full length cDNA is obtained.

[0014] The invention provides an isolated human cDNA selected from SEQ ID NOs: 1367, 1372, 1376, 1377, 1383, 1389, 1390, 1397, 1400, 1401, 1406, 1408, 1412, 1413, 1415, 1416, 1420, 1438, 1444, 1460, 1462, 1467, 1470, 1476, 1477, 1485, 1489, 1491, 1497, 1500, 1501, 1503, 1512, 1517, 1541, 1544, 1551, 1553, 1555, 1557, 1565, 1566, 1572, 1576, 1577, 1579, 1580, 1581, 1582, 1583, 1585, 1588, 1598, 1599, 1601, 1603, 1609, 1610, 1612, 1620, 1625, 1632, 1634, 1642, 1643, 1649, 1658, 1686, 1690, 1691, 1693, 1708, 1721, 1727, 1730, 1731, 1738, 1746, 1748, 1756, 1757, 1786, 1789, 1797, 1823, 1825, 1829, 1830, 1847, 1852, 1864, 1866, 1875, 1882, 1887, 1889, 1894, 1895, 1901, 1938, 1949, 1954, 1960, 1961, 1965, 1966, 2002, 2019, 2043, 2046, 2054, 2066, 2067, 2069, 2071, 2072, 2078, 2079, 2100, 2105, 2121, 2125, 2139, 2151, 2154, 2157, 2170, 2171, 2183, 2184, 2186, 2187, 2208, and 2211 as presented in the Sequence Listing. The invention also provides an expression vector containing the cDNA, a host cell containing the expression vector, and a method for producing a protein comprising culturing the host cell under conditions for the expression of protein and recovering the protein from the host cell culture. The invention additionally provides a method for identifying a molecule or compound which specifically binds a cDNA comprising contacting a cDNA with a plurality of molecules and compounds under conditions which allow specific binding, and recovering the bound cDNA, wherein the molecule or compound is identified. The invention further provides a method for using a cDNA to purify a the molecule or compound from a sample comprising contacting the cDNA with a sample under conditions which allow specific binding between the cDNA and a molecule or compound, recovering the bound cDNA, and separating the cDNA wherein the molecule of compound is purified from the sample.

[0015] The invention provides a purified protein encoded by a cDNA of the invention. In one embodiment the protein is encoded by a cDNA selected from SEQ ID NOs: 1367, 1372, 1376, 1377, 1383, 1389, 1390, 1397, 1400, 1401, 1406, 1408, 1412, 1413, 1415, 1416, 1420, 1438, 1444, 1460, 1462, 1467, 1470, 1476, 1477, 1485, 1489, 1491, 1497, 1500, 1501, 1503, 1512, 1517, 1541, 1544, 1551, 1553, 1555, 1557, 1565, 1566, 1572, 1576, 1577, 1579, 1580, 1581, 1582, 1583, 1585, 1588, 1598, 1599, 1601, 1603, 1609, 1610, 1612, 1620, 1625, 1632, 1634, 1642, 1643, 1649, 1658, 1686, 1690, 1691, 1693, 1708, 1721, 1727, 1730, 1731, 1738, 1746, 1748, 1756, 1757, 1786, 1789, 1797, 1823, 1825, 1829, 1830, 1847, 1852, 1864, 1866, 1875, 1882, 1887, 1889, 1894, 1895, 1901, 1938, 1949, 1954, 1960, 1961, 1965, 1966, 2002, 2019, 2043, 2046, 2054, 2066, 2067, 2069, 2071, 2072, 2078, 2079, 2100, 2105, 2121, 2125, 2139, 2151, 2154, 2157, 2170, 2171, 2183, 2184, 2186, 2187, 2208, and 2211. The invention also provides a method for using a protein to screen a plurality of molecules or compounds to identify a molecule or compound which specifically binds the protein comprising combining the protein with a plurality of molecules or compounds under conditions to allow specific binding, recovering the bound protein, and separating the protein, thereby obtaining a molecule or compound which specifically binds the protein. In one embodiment, the molecules and compounds to be screened are selected from agonists, antagonists, antibodies, DNA molecules, small molecule drugs, immunoglobulins, inhibitors, mimetics, peptide nucleic acids, peptides, pharmaceutical agents, proteins, RNA molecules, ribozymes, and the like. In one aspect, the molecule or compound acts as a agonist, enhancer, inducer, or promoter in a test system. In another aspect, the molecule or compound acts as an antagonist or inhibitor in a test system.

[0016] The invention provides a method of using a protein to prepare and purify an antibody which specifically binds the protein comprising immunizing an animal with the protein under conditions to elicit an antibody response; isolating animal antibodies; contacting the protein with isolated antibodies under conditions to formation of an antibody:protein complex; and dissociating antibody from the complex, thereby obtaining purified antibody which specifically binds the protein. The invention also provides a method for using an antibody to detect expression of a protein which specifically binds the antibody in a sample, the method comprising combining the antibody with a sample under conditions which allow the formation of antibody:protein complexes; and detecting complex formation, wherein complex formation indicates expression of the protein which specifically binds the protein in the sample. In one embodiment, complex formation is compared with standards and is diagnostic for a disorder of neuronal differentiation and morphogenesis. The invention also provides a method for using an antibody to immunopurify a protein comprising attaching the antibody to a substrate; contacting the antibody with a sample containing the protein, thereby forming an antibody:protein complex; dissociating the antibody:protein complex; and collecting the purified protein. The invention further provides a composition comprising a cDNA, a protein, an antibody that specifically binds a protein or peptide, or a molecule or compound that specifically binds the cDNA, protein, or antibody and a pharmaceutical carrier for use in treating a disorder of neuronal differentiation or morphogenesis.

DESCRIPTION OF THE COMPACT DISC-RECORDABLE (CD-R)

[0017] CD-R 1 is labeled: “pa26sqls.txt US, Copy 1,” was created on Jan. 30, 2002, and contains: pa26sqls.txt the Sequence Listing formatted in plain ASCII text. The file for the Sequence Listing is entitled pt01xxs1.txt, created on Jan. 30, 2002 and is 3.15 KB in size.

[0018] CD-R 2 is an exact copy of CD-R 1. CD-R 2 is labeled: “pa26sqls.txt US, Copy 2,” and was created on Jan. 30, 2002.

[0019] The CD-R labeled as: “pa26sqls.txt US, CRF,” contains the Sequence Listing formatted in plain ASCII text. The file for the Sequence Listing is entitled pa26sqls.txt was created on Jan. 30, 2002 and is 3.15 KB in size.

[0020] The content of the Sequence Listing named above and as described below, submitted in duplicate on two (2) CD-Rs (labeled “pa26sqls.txt US, Copy 1” and “pa26sqls.txt US, Copy 2”), and the CRF (labeled “pa26sqls.txt US, CRF”) containing the Sequence Listing, are incorporated by reference herein, in their entirety.

DESCRIPTION OF THE TABLES

[0021] A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.

[0022] The Sequence Listing is a compilation of nucleic acid sequences obtained by sequencing clone inserts (isolates) of different cDNAs and identified using hybridization of samples against the cDNAs on a glass array. Each sequence is identified by a sequence identification number (SEQ ID NO) and by an Incyte ID number. The Incyte ID number represents a clone containing the cDNA insert. The Sequence Listing provides sequences of exemplary mouse cDNAs expressed in neuronal differentiation and morphogenesis, SEQ ID NOs: 1-1365, and their homologous human cDNAs, SEQ ID NOs: 1366-2217.

[0023] Table 1 shows the cDNAs, whose expression in retinoic acid-treated mouse ES cells is increased or decreased, SEQ ID NOs: 1-1365. Column 1 lists the SEQ ID NOs for each mouse cDNA. Column 2 shows the ratio of differential expression calculated from expression in the retinoic acid-treated sample divided by expression in the matched, untreated sample at the same time point in the experiment. Column 3 shows the description and IMAGE ID for each mouse cDNA.

[0024] Table 2 shows the cDNAs, whose expression in retinoic acid-treated mouse ES cells is increased or decreased and their human homologs. Column 1 lists the SEQ ID NO for each mouse cDNA. Column 2 lists the IMAGE clone ID of each mouse cDNA. Column 3 lists the GenBank ID for each mouse cDNA. Column 4 lists the Incyte template ID for the human cDNA that is identified as a homolog of the mouse cDNA. Column 5 lists the SEQ ID NO for the human cDNA. Column 6 lists the e values for the BLAST2 identified homolog of the Incyte human template. Column 7 shows the description of each Incyte human template. If no Incyte human template homolog was identified by BLAST2, no entry was made.

DETAILED DESCRIPTION OF THE INVENTION

[0025] Before the nucleic acid sequences and methods are presented, it is to be understood that this invention is not limited to the particular machines, methods, and materials described. Although particular embodiments are described, machines, methods, and materials similar or equivalent to these embodiments may be used to practice the invention. The preferred machines, methods, and materials set forth are not intended to limit the scope of the invention which is limited only by the appended claims.

[0026] The singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. All technical and scientific terms have the meanings commonly understood by one of ordinary skill in the art. All publications are incorporated by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are presented and which might be used in connection with the invention. Nothing in the specification is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0027] Definitions

[0028] “Antibody” refers to intact immunoglobulin molecule, a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a recombinant antibody, a humanized antibody, single chain antibodies, a Fab fragment, an F(ab′)2 fragment, an Fv fragment; and an antibody-peptide fusion protein.

[0029] “Antigenic determinant” refers to an immunogenic epitope, structural feature, or region of an oligopeptide, peptide, or protein which is capable of inducing formation of an antibody which specifically binds the protein. Biological activity is not a prerequisite for immunogenicity.

[0030] “Array” refers to an ordered arrangement of at least two cDNAs, proteins, or antibodies on a substrate. At least one of the cDNAs, proteins, or antibodies represents a control or standard, and the other cDNA, protein, or antibody is of diagnostic or therapeutic interest. The arrangement of two to about 40,000 cDNAs, proteins, or antibodies on the substrate assures that the size and signal intensity of each labeled complex, formed between each cDNA and at least one nucleic acid, each protein and at least one ligand or antibody, or each antibody and at least one protein to which the antibody specifically binds, is individually distinguishable.

[0031] “Cancer” refers to adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers or tumors of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, colon, esophagus, gall bladder, ganglia, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, small intestine, spleen, stomach, testis, thymus, thyroid, and uterus.

[0032] A “combination” comprises at least two and up to about 2217 sequences as presented in the Sequence Listing.

[0033] “Complementary” describes the relationship between two single-stranded nucleotide sequences that anneal by base-pairing (5′-A-G-T-3′ pairs with its complement 3′-T-C-A-5′).

[0034] “cDNA” refers to an isolated polynucleotide, nucleic acid molecule, or any fragment or complement thereof. It may have originated recombinantly or synthetically, be double-stranded or single-stranded, and represent coding and noncoding 3′ or 5′ sequence, and generally it lacks introns. The cDNA may be combined with carbohydrate, lipids, protein or other materials to perform a particular activity such as diagnosis or to form a useful composition for mammalian therapy.

[0035] A “composition” refers to the cDNA and a labeling moiety; a purified protein and a pharmaceutical carrier or a heterologous, labeling or purification moiety; an antibody and a labeling moiety or pharmaceutical agent; and the like.

[0036] “Differential expression” refers to an increased or upregulated or a decreased or downregulated expression as detected by absence, presence, or at least two-fold change in the amount of transcribed messenger RNA, translated protein, or complexed antibody in a sample.

[0037] “Disorder” refers to conditions, diseases or syndromes associated with neuronal differentiation and morphogenesis including Alzheimer's disease, autism, cancer, ischemic cerebrovascular disease, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia, and stroke.

[0038] An “expression profile” is a representation of gene expression in a sample. A nucleic acid expression profile is produced using sequencing, hybridization, or amplification technologies and mRNAs or cDNAs from a sample. A protein expression profile mirrors the nucleic acid expression profile and uses labeling moieties or antibodies to quantify the protein expression in a sample. The nucleic acids, proteins, or antibodies may be used in solution or attached to a substrate, and their detection is based on methods and labeling moieties well known in the art.

[0039] “Fragment” refers to at least 18 consecutive nucleotides of a cDNA of the Sequence Listing or its complement or to a portion of an antibody.

[0040] “Hybridization complex” refers to a complex between two nucleic acid molecules by virtue of the formation of hydrogen bonds between purines and pyrimidines.

[0041] “Identity” as applied to nucleic acid or protein sequences, refers to the quantification (usually percentage) of nucleotide or residue matches between at least two sequences aligned using a standardized algorithm such as Smith-Waterman alignment (Smith and Waterman (1981) J Mol Biol 147:195-197), CLUSTALW (Thompson et al. (1994) Nucleic Acids Res 22:4673-4680), or BLAST2 (Altschul et al. (1997) Nucleic Acids Res 25:3389-3402). BLAST2 may be used in a standardized and reproducible way to insert gaps in one of the sequences in order to optimize alignment and to achieve a more meaningful comparison between them. Similarity is an analogous score, but it is calculated with conservative substitutions of residues taken into account; for example, substitution of a valine for a isoleucine or leucine.

[0042] “Isolated or purified” refers to a cDNA, protein, or antibody that is removed from its natural environment or from cell culture and that is separated from other components with which it is associated.

[0043] “Labeling moiety” refers to any reporter molecule whether a visible or radioactive label, stain or dye than can be attached to or incorporated into a cDNA or protein. Visible labels and dyes include but are not limited to anthocyanins, β glucuronidase, BIODIPY, Coomassie blue, Cy3 and Cy5, digoxigenin, FITC, green fluorescent protein, luciferase, spyro red, silver, and the like. Radioactive markers include radioactive forms of hydrogen, iodine, phosphorous, sulfur, and the like.

[0044] “Ligand” refers to any agent, molecule, or compound which will bind specifically to a complementary site on a cDNA, protein, or antibody of the invention. Such ligands stabilize, modulate, or disrupt the activity of cDNAs, proteins, or antibodies and may be composed of inorganic and/or organic substances including minerals, cofactors, nucleic acids, proteins, carbohydrates, fats, and lipids.

[0045] “Probe” refers to a cDNA that hybridizes to a nucleic acid molecule in a sample or on a substrate. A probe is used to detect, amplify, lengthen or quantify cDNAs, endogenous genes, or transcript mRNAs by employing conventional, molecular biology techniques. Probes are the reporter molecules of hybridization reactions including Southern, northern, in situ, dot blot, array, and like technologies.

[0046] “Protein” refers to a polypeptide or any portion thereof. A “portion” of a protein refers to that length of amino acid sequence which would retain at least one biological activity, a domain identified by PFAM or PRINTS analysis or an antigenic epitope of the protein identified using Kyte-Doolittle algorithms of the PROTEAN program (DNASTAR, Madison Wis.). An “oligopeptide” is an amino acid sequence from about five residues to about 15 residues that is used as part of a fusion protein to produce an antibody.

[0047] “Sample” may contain polynucleotides, proteins, agonists, antagonists, and antibodies and refers to a bodily fluid; a soluble fraction of a cell preparation or media in which cells were grown; a chromosome, an organelle, or membrane isolated or extracted from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue; a tissue print; a fingerprint, skin or hair; and the like.

[0048] “Specific binding” refers to the interaction between two molecules. In the case of a cDNA, specific binding may involve hydrogen bonding between sense and antisense strands or between one strand and a protein which affects its replication or transcription, intercalation of a molecule or compound into the major or minor groove of the DNA molecule, or interaction with at least one molecule which functions as a transcription factor, enhancer, repressor, and the like. In the case of a protein, specific binding may involve interactions with cDNAs, as described above or with molecules or compounds such as agonists, antibodies, antagonists, and the like. Specific binding is dependent upon the presence of structural features that allow chemical or molecular interactions between molecules.

[0049] “Substrate” refers to any rigid or semi-rigid support to which molecules or compounds are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores.

[0050] A “transcript image” (TI) is a profile of gene transcription activity in a particular tissue at a particular time. TI provides assessment of the relative abundance of expressed polynucleotides in the cDNA libraries of an EST database as described in U.S. Pat. No. 5,840,484, incorporated herein by reference.

[0051] “Variant” refers to a nucleic acid molecule or protein whose sequence diverges from SEQ ID NOs: 1-2217 or their encoded proteins. Nucleic acid sequence divergence may result from natural or intentional mutational changes such as deletions, additions, and substitutions of one or more nucleotides or residues or from differential splicing. Intentional nucleotide mutations may be introduced recombinantly to accommodate differences in codon usage among species. Each deletion, addition, and substitution may occur alone, or in combination, one or more times in a given sequence.

[0052] The Invention

[0053] The invention provides a combination comprising a plurality of cDNAs which are markers of neuronal differentiation and morphogenesis. The cDNAs comprise at least a fragment of SEQ ID NOs: 1-2217 as presented in the Sequence Listing. The invention also provides a combination of mouse cDNAs, SEQ ID NOs: 1-1365, which were differentially expressed in mouse embryonic stem cells 16 days after treatment with RA. The invention provides a combination of mouse cDNAs whose expression is increased, SEQ ID NOs: 1-673, or decreased, SEQ ID NOs: 674-1365, following treatment. The invention also provides a combination of cDNAs whose expression is increased, SEQ ID NOs: 1-102, or decreased, SEQ ID NOs: 1303-1365, greater than 5-fold following treatment. The invention also provides a combination of cDNAs whose expression is increased, SEQ ID NOs: 1-19, or decreased, SEQ ID NOs: 1353-1365, greater than 10-fold following treatment. The invention also provides a combination comprising a plurality human cDNAs, SEQ ID NOs: 1366-2217, which have high sequence homology to the differentially expressed mouse sequences.

[0054] As shown in Table 1, sequences encoding developmental regulatory proteins e.g., growth factors (SEQ ID NO: 3, IMAGE ID 464598; SEQ ID NO: 20, IMAGE ID 367780), amyloid beta precursor protein (SEQ ID NO: 15, IMAGE ID 535652), and F-spondrin neural plate protein (SEQ ID NO: 69, IMAGE ID 762240), have expression levels increased by more than 5-fold compared with untreated ES cells. In addition, sequences encoding extracellular matrix proteins e.g., extracellular matrix protein 1 (SEQ ID NO: 5, IMAGE ID 874833), procollagen (SEQ ID NO: 6, IMAGE ID 420322), pleiotrophin (SEQ ID NO: 7, IMAGE ID 478168), and signal transduction proteins e.g., protein tyrosine kinase (SEQ ID NO: 42, IMAGE ID 401456), beta-2 microglobulin (SEQ ID NO: 90, IMAGE ID 572542) and calpain-like protease (SEQ ID NO: 34, IMAGE ID 747101), have expression levels increased by more than 5-fold in retinoic acid-treated cells compared with untreated cells. 102 IMAGE clones showed at least a 5-fold increase in expression when retinoic acid-treated ES cells were compared with untreated ES cells. Another 18 IMAGE unannotated clones showed at least a 5-fold increase in expression when retinoic acid-treated ES cells were compared with untreated ES cells These mouse sequences may be used as markers of neuronal differentiation and morphogenesis in mouse tissues or mammalian model systems.

[0055] As shown in Table 1, sequences encoding proteins promoting cell growth, including DNA replication proteins, e.g., replication factor C (SEQ ID NO: 1337, IMAGE ID 572970), mismatch repair protein MutS (SEQ ID NO: 1322, IMAGE ID 945359); proteins that regulate cell cycle progression e.g., cyclin B1 (SEQ ID NO: 1336, IMAGE ID 751977), cyclin E (SEQ ID NO: 1332, IMAGE ID 833511) and other growth-related proteins (SEQ ID NO: 1312, IMAGE ID 575434), showed at least a 5-fold decrease in expression when retinoic acid-treated ES cells were compared with untreated ES cells. Developmental regulatory proteins e.g., JM1 protein (SEQ ID NO: 1349, IMAGE ID 833919), F-Boc protein FBX115 ubiquitin ligase regulator (SEQ ID NO: 1361, IMAGE ID 833477); extracellular matrix proteins e.g., cadherin (SEQ ID NO: 1305, IMAGE ID 776133), spectrin (SEQ ID NO: 1344, IMAGE ID 403735), and signal transduction proteins e.g., asialoglycoprotein receptor 1 (SEQ ID NO: 1353, IMAGE ID 949512, KIAA0116 (SEQ ID NO: 1318, IMAGE ID 533085), showed at least a 5-fold decrease in expression when retinoic acid-treated ES cells were compared with untreated ES cells. 63 IMAGE clones showed at least a 5-fold decrease in expression when retinoic acid-treated ES cells were compared with untreated ES cells. Eight unannotated IMAGE clones showed at least a 5-fold decrease in expression when retinoic acid-treated ES cells were compared with untreated ES cells. These mouse sequences may be used as markers of neuronal differentiation and morphogenesis in mouse tissues or mammalian model systems.

[0056] As shown in Table 1, sequences encoding developmental regulatory proteins e.g., dual-specific nuclear matrix tyrosine protein kinase (SEQ ID NO: 502, IMAGE ID 354506), neuronal-associated protein (SEQ ID NO: 125, IMAGE ID 356215); cytoskeletal proteins e.g., myosin light chain (SEQ ID NO: 589, IMAGE ID 330370), actin-binding protein (SEQ ID NO: 174, IMAGE ID 408110); transcription factors e.g., KIAA0613 enigma/LIM2 (SEQ ID NO: 585, IMAGE ID 336726), GATA-GT2 Zn-finger (SEQ ID NO: 221, IMAGE ID 368189); extracellular matrix proteins e.g., GalBeatGalNAcAlpha sialyltransferase (SEQ ID NO: 361, IMAGE ID 481883), extracellular protein precursor (SEQ ID NO: 113, IMAGE ID 746798); and signal transduction proteins e.g., serine/threonine protein kinase 11 (SEQ ID NO: 161, IMAGE ID 388477) and Ftp-1 tyrosine phosphatase (SEQ ID NO: 206, IMAGE ID 400530), showed between a 2fold and a 5-fold increase in expression when retinoic acid-treated ES cells were compared with untreated ES cells. 165 unannotated IMAGE clones showed between a 2fold and a 5-fold increase in expression when retinoic acid-treated ES cells were compared with untreated ES cells. These mouse sequences may be used as markers of neuronal differentiation and morphogenesis in mouse tissues or mammalian model systems.

[0057] As shown in Table 1, sequences encoding proteins promoting cell growth e.g., Rac GTPase-activating protein (SEQ ID NO: 743, IMAGE ID 577676), regulator of chromosome condensation (SEQ ID NO: 1182, IMAGE ID 422799); developmental regulatory proteins e.g., KIAA0314 (SEQ ID NO: 1142, IMAGE ID 335017), neuronal pentraxin receptor (SEQ ID NO: 729, IMAGE ID 352795); transcription factors e.g., centaurin alpha (SEQ ID NO: 1186, IMAGE ID 437602), pirin NF-1 (SEQ ID NO: 1181, IMAGE ID 332396); extracellular matrix proteins e.g., Gar1 low molecular weight neurofilament APP-binding protein (SEQ ID NO: 997, IMAGE ID 475814), calpain p94 (SEQ ID NO: 1284, IMAGE ID 574491); and signal transduction proteins e.g., Nedd-4-like ubiquitin protein ligase regulator of Notch signaling pathway (SEQ ID NO: 832, IMAGE ID 354910, bisphosphate 3′nucleotidase 1 (SEQ ID NO: 957, IMAGE ID 439411), showed between a 2fold and a 5-fold decrease in expression when retinoic acid-treated ES cells were compared with untreated ES cells. 130 unannotated IMAGE clone sequences showed between a 2fold and a 5-fold decrease in expression when retinoic acid-treated ES cells were compared with untreated ES cells. These mouse sequences may be used as markers of neuronal differentiation and morphogenesis in mouse tissues or mammalian model systems.

[0058] The sequences of the mouse IMAGE clones were used to identify human templates from the LLFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.) using BLAST2 with an e value cutoff of p<10−5. As shown in Table 2, SEQ ID NOs: 1366-2217 are considered to be human homologs of the mouse sequences SEQ ID NOs: 1-1365. As shown in Table 2, SEQ ID NOs: 1383, 1415, 1444, 1460, 1462, 1476, 1477, 1485, 1500, 1503, 1517, 1544, 1555, 1557, 1565, 1585, 1603, 1612, 1632, 1634, 1642, 1708, 1731, 1738, 1756, 1797, 1852, 1864, 1901, 1960, 2002, 2019, 2079, 2154, and 2208 are considered to be homologs of known human genes as described in the seventh column of Table 2. These human sequences are useful as markers of neuronal differentiation and morphogenesis in human tissues or tissue samples.

[0059] In addition, results from two samples that had been treated identically were compared to determine the range of normal variation of gene expression patterns between the samples. In one analysis, where two different samples were prepared from identically treated tissues, gene expression patterns of cDNAs which were increased or decreased not more than 1.7-fold were within the 95% confidence limits of a Poisson normal distribution. In a separate analysis, gene expression patterns of cDNAs which were increased or decreased more than 2-fold accounted for less than 5% of the total hybridizable sample nucleic acid molecules in two identically-treated tissue samples.

[0060] Refinement of treatment methods of cultured ES cells allowed the identification of a transitory period during which the phenotype of undifferentiated ES cells changed to a differentiated cell type comprising mainly phenotypically normal neurons (neuromorphogenesis). As shown in Table 1, the apparent neuronal phenotype of the differentiated ES cells was confirmed by increased levels of neuron-specific cellular markers, such as neuronal protein 3.1 (g1171753), amyloid β (A4) precursor protein (g112929), as well as two mouse ESTs, IMAGE: 463135 (homologous to rat IGF-II precursor) and IMAGE:639481 (homologous to rat IGF-binding protein 3). In contrast, the same analysis identified a number of proliferation- and retinoic acid-regulated transcripts whose levels were decreased including G2/mitotic-specific cyclin B1, uridine phosphorylase, and two mouse ESTs, IMAGE: 893933 and “EST highly similar to retinoic acid-regulated protein pH 34”, as shown in Table 1.

[0061] Mouse nucleic acids that are increased or decreased at least 2-fold at least once during the time course were identified. These molecules are SEQ ID NOs: 1-1365 provided in the Sequence Listing. Human nucleotide molecules highly homologous to the mouse nucleotide molecules were also identified. These molecules are SEQ ID NOs: 1366-2464 provided in the Sequence Listing.

[0062] Human neuronal cellular markers, such as neuronal DHP-sensitive, voltage-dependent, calcium channel alpha-2b subunit (SEQ ID NO: 1891); basic transcription factor 2 p44, neuronal apoptosis inhibitory protein (naip) and survival motor neuron protein (SEQ ID NO: 1719); calpain-like protease CANPX (SEQ ID NO: 1533); neurofilament-66 (SEQ ID NO: 1479); semaphorin III family homolog (SEQ ID NO: 1640); vascular endothelial cell growth factor 165 receptor/neuropilin (VEGF165) (SEQ ID NO: 1770); glia-derived nexin (SEQ ID NO: 2127); KIAA0287 (SEQ ID NO: 1976); retinal short-chain dehydrogenase/reductase (SEQ ID NO: 1607); P311 Human (3.1) (SEQ ID NO: 1678, 1679, 1680); amyloid A4(751) (SEQ ID NO: 1713); alpha-B-crystallin (SEQ ID NO: 1924); vascular endothelial cell growth factor 165 (SEQ ID NO: 1770); NMDA receptor glutamate-binding chain (SEQ ID NO: 1844, 2182); KIAA1114 (SEQ ID NO: 1948); calpain-like protease CANPX (SEQ ID NO: 1533, 1698); KIAA0913 (SEQ ID NO: 2175); neutral calponin (SEQ ID NO: 1443, 2156); KIAA0438 (SEQ ID NO: 1824); Hox2.2 gene for a homoeobox protein (SEQ ID NO: 2213); KIAA0992 (SEQ ID NO: 2162); peripheral myelin protein 22 (GAS3) (SEQ ID NO: 1997); KIAA1224 (SEQ ID NO: 2185); MAP kinase activated protein kinase (SEQ ID NO: 1772); KIAA0382 (SEQ ID NO: 1677); amyloid precursor protein homolog HSD-2 (SEQ ID NO: 1765); KIAA1075 (SEQ ID NO: 1422); KIAA0987 (SEQ ID NO: 1928); KIAA0251 (SEQ ID NO: 1763); KIAA1249 (SEQ ID NO: 1606); KIAA0280 (SEQ ID NO: 1460); KIAA1048 (SEQ ID NO: 1845); KIAA0964 (SEQ ID NO: 1387); human genomic DNA of 21q22.2 Down Syndrome region (SEQ ID NO: 1897); KIAA1094 (SEQ ID NO: 1855); tactile protein (SEQ ID NO: 1989); S100 alpha protein (SEQ ID NO: 1987); KIAA0623 (SEQ ID NO: 1547); KIAA0630 (SEQ ID NO: 1995); KIAA1008 (SEQ ID NO: 1696); KIAA1007 (SEQ ID NO: 1563); calpain-like protease (htra-3) (SEQ ID NO: 1698); KIAA0011 (SEQ ID NO: 1982); KIAA1080 (SEQ ID NO: 2052); KIAA0136 (SEQ ID NO: 1988); KIAA0518 (SEQ ID NO: 2012); KIAA0595 (SEQ ID NO: 1528); KIAA0281 (SEQ ID NO: 2163); KIAA0156 (SEQ ID NO: 1626); KIAA0560 (SEQ ID NO: 1478); KIAA0253 (SEQ ID NO: 1441); KIAA1177 (SEQ ID NO: 1667, 1668); KIAA1261 (SEQ ID NO: 1930); glutathione transferase (GSTA3) (SEQ ID NO: 2210); KIAA1259 (SEQ ID NO: 1873); KIAA0274 (SEQ ID NO: 2085); KIAA1089 (SEQ ID NO: 1832); chaperonin containing t-complex polypeptide 1 (SEQ ID NO: 1854); KIAA0778 (SEQ ID NO: 1464); KIAA0111 (SEQ ID NO: 2160); KIAA0589 (SEQ ID NO: 1996); KIAA0314 (SEQ ID NO: 1856); KIAA1273 (SEQ ID NO: 2009); glutamate dehydrogenase (SEQ ID NO: 1941); KIAA0956 (SEQ ID NO: 2023); KIAA0631 (SEQ ID NO: 1591, 2079); KIAA0432 (SEQ ID NO: 1865); KIAA0007 (SEQ ID NO: 1920); KIAA0888 (SEQ ID NO: 1527); KIAA0314 (SEQ ID NO: 1856); KIAA0020 (SEQ ID NO: 1749); KIAA0116 (SEQ ID NO: 1672); glutamine PRPP amidotransferase (GPAT) (SEQ ID NO: 1905); and KIAA0888 (SEQ ID NO: 1527) were also identified, as shown in Table 2.

[0063] As shown in Table 2, human cDNAs which are highly homologous to mouse sequences which co-expressed with known neuronal markers during neuronal differentiation and morphogenesis were identified. These sequences include SEQ ID NOs: 1367, 1372, 1376, 1377, 1389, 1390, 1400, 1406, 1408, 1412, 1413, 1420, 1438, 1467, 1470, 1489, 1491, 1497, 1501, 1512, 1541, 1551, 1553, 1566, 1576, 1577, 1579, 1580, 1581, 1582, 1583, 1588, 1598, 1599, 1609, 1620, 1625, 1643, 1658, 1686, 1690, 1691, 1721, 1727, 1730, 1746, 1748, 1757, 1786, 1789, 1823, 1825, 1830, 1847, 1866, 1875, 1887, 1894, 1949, 1954, 1965, 1966, 2043, 2046, 2054, 2066, 2067, 2069, 2071, 2072, 2078, 2100, 2121, 2125, 2139, 2151, 2157, 2170, 2171, 2183, 2184, 2186, and 2187.

[0064] The invention provides a specific and useful method for diagnosing a disease associated with differential gene expression during neuronal differentiation and morphogenesis. The cDNAs of the invention define a differential expression pattern against which to compare the expression pattern of biopsied and/or treated tissues. Experimentally, differential expression of the cDNAs can be evaluated by other methods including, but not limited to, differential display by spatial immobilization or by gel electrophoresis, genome mismatch scanning, representational discriminant analysis, clustering, transcript images, and other array technologies. These methods may be used alone or in combination to verify the differential expression patterns that characterize a particular tissue, disorder, or therapy.

[0065] Transcript images for SEQ ID NOs: 1376 and 2164 are shown in EXAMPLE X. These TIs validate the differential expression patterns revealed by the array data and show that SEQ ID NOs: 1376 and 2164, when used in a tissue specific and clinically relevant manner, are diagnostic for germinal tumors (teratocarcinoma and embryonal carcinoma) and meningioma, respectively. The cDNAs can also be used to evaluate the efficacy of a particular treatment administered to a subject with germinal tumor or meningioma, respectively.

[0066] cDNAs and Their Uses

[0067] The cDNAs of the invention can be genomic DNA, mRNA, or any RNA-like or DNA-like material such as peptide nucleic acids, branched DNAs and the like. cDNA probes can be sense or antisense strand. In one embodiment, cDNAs are plasmids, and the sequence of interest is the cDNA insert.

[0068] Nucleotide analogs can be incorporated into cDNAs by methods well known in the art. The only requirement is that the incorporated nucleotide analogs must base pair with adenine, cytosine, guanine, thymine, or uracil. For example, guanine can be substituted with hypoxanthine which base pairs with cytosine. However, these base pairs are less stable than those between guanine and cytosine. Alternatively, adenine can be substituted with 2,6-diaminopurine which can form stronger base pairs with thymidine than those between adenine and thymidine. Additionally, cDNAs can include nucleotides that have been derivatized chemically or enzymatically. Typical chemical modifications include derivatization with acyl, alkyl, aryl or amino groups.

[0069] cDNAs can be synthesized or immobilized on a substrate. Synthesis on the surface of a substrate may be accomplished using a chemical coupling procedure and a piezoelectric printing apparatus as described by Baldeschweiler et al. (PCT publication WO95/251116). Alternatively, the cDNAs can be synthesized on a substrate surface using a self-addressable electronic device that controls when reagents are added as described in U.S. Pat. No. 5,605,662; incorporated herein by reference. cDNAs can be immobilized by covalent means such as by chemical bonding procedures or TV irradiation. In one such method, a cDNA is bound to a glass surface which has been modified to contain epoxide or aldehyde groups. In another case, a cDNA probe is placed on a polylysine coated surface and then UV cross-linked as described by Shalon et al. (WO95/35505). In yet another method, a cDNA is actively transported from a solution to a given position on a substrate by electrical means (Heller, supra). Alternatively, cDNAs, clones, plasmids or cells can be arranged on a filter. In the latter case, cells are lysed, proteins and cellular components degraded, and the DNA is coupled to the filter by UV cross-ling.

[0070] Furthermore, cDNAs do not have to be directly bound to the substrate, but rather can be bound to the substrate through a linker group. The linker groups are typically about 6 to 50 atoms long to provide exposure of the attached probe. Preferred linker groups include ethylene glycol oligomers, diamines, diacids and the like. Reactive groups on the substrate surface react with a terminal group of the linker to bind the linker to the substrate. The other terminus of the linker is then bound to the cDNA.

[0071] cDNAs can be attached to a substrate by sequentially dispensing reagents for probe synthesis on the substrate surface or by dispensing preformed DNA fragments to the substrate surface. Typical dispensers include a micropipette delivering solution to the substrate with a robotic system to control the position of the micropipette with respect to the substrate. There can be a multiplicity of dispensers so that reagents can be delivered to the reaction regions efficiently.

[0072] The cDNAs may be used for a variety of purposes. For example, the combination of the invention may be used on an array. The array can be used in high-throughput methods such as for detecting a related cDNA or protein in a sample, screening a plurality of molecules or compounds to identify a ligand, or diagnosing a particular condition, disease, or disorder of neuronal differentiation and morphogenesis. Alternatively, a cDNA complementary to a given sequence of the sequence listing can inhibit or inactivate a therapeutically relevant and closely related gene.

[0073] When the combination of the invention is employed on an array, the cDNAs are organized in an ordered fashion so that each element is present at a specified location on the substrate. Because the cDNAs are at specified locations on the substrate, the hybridization patterns and intensities, which together create a unique expression profile, can be interpreted in terms of expression levels of particular genes and can be correlated with a particular metabolic process, condition, disorder, disease, stage of disease, or treatment.

[0074] The cDNAs themselves or fragments of SEQ ID NOs: 1-1365 are useful in hybridization or amplification technologies to identify changes in expression pattern of the same or similar sequences in model systems. The cDNAs or fragments of SEQ ID NOs: 1366-2217 are useful in hybridization or amplification technologies to identify changes in expression pattern of the same or similar sequences in normal versus diseased tissues.

[0075] Hybridization

[0076] The cDNAs, oligonucleotides, fragments, or complements thereof may be used in various hybridization technologies. The cDNAs may be naturally occurring, recombinant, or chemically synthesized; based on genomic or cDNA sequences; and labeled using a variety of reporter molecules by either PCR or enzymatic techniques. Commercial kits are available for labeling and cleanup of such cDNAs or probes. Radioactive (Amersham Pharmacia Biotech (APB), Piscataway N.J.), fluorescent (Qiagen Operon, Alameda Calif.), and chemiluminescent labeling (Promega, Madison Wis.), are well known in the art. Alternatively, a cDNA is cloned into a commercially available vector, and probes are produced by transcription. The probe is synthesized and labeled by addition of an appropriate polymerase, such as T7 or SP6 polymerase, and at least one labeled nucleotide.

[0077] A probe may be designed or derived from unique regions of the cDNA, such as the 3′ untranslated region or from a conserved motif, and used in protocols to identify naturally occurring molecules encoding the same protein, allelic variants, or related molecules. The probe may be DNA or RNA, is usually single stranded and should have at least 50% sequence identity to any of the nucleic acid sequences. The probe may comprise at least 18 contiguous nucleotides, or an oligonucleotide, of a cDNA. Such a probe may be used under hybridization or amplification conditions that allow binding only to an identical sequence or under conditions that allow binding to a related sequence with at least one nucleotide substitution or deletion. Discovery of related sequences may also be accomplished using a pool of degenerate probes and appropriate hybridization conditions. Generally, a probe for use in Southern or northern hybridizations may be from about 400 to about 4000 nucleotides long. Such probes may be single-stranded or double-stranded and may have high binding specificity in solution-based or substrate-based hybridizations.

[0078] The stringency of hybridization is determined by G+C content of the probe, salt concentration, and temperature. In particular, stringency is increased by reducing the concentration of salt or raising the hybridization temperature. In solutions used for some membrane based hybridizations, addition of an organic solvent such as formamide allows the reaction to occur at a lower temperature. Hybridization may be performed with buffets, such as 5× saline sodium citrate (SSC) with 1% sodium dodecyl sulfate (SDS) at 60 C., that permits the formation of a hybridization complex between nucleic acid sequences that contain some mismatches. Subsequent washes are performed with buffers such as 0.2×SSC with 0.1% SDS at either 45 C. (medium stringency) or 65-68 C. (high stringency). At high stringency, hybridization complexes will remain stable only where the cDNAs are completely complementary. In some membrane-based hybridizations, preferably 35% or most preferably 50%, formamide may be added to the hybridization solution to reduce the temperature at which hybridization is performed. Background signals may be reduced by the use of detergents such as Sarkosyl or TRITON X-100 (Sigma-Aldrich, St. Louis Mo.) and a blocking agent such as denatured salmon sperm DNA. Selection of components and conditions for hybridization are well known to those skilled in the art and are reviewed in Ausubel et al. (1997; Short Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., 6.11-6.19, 14.11-14.36, and A1-43).

[0079] Dot-blot, slot-blot, low density and high density arrays are prepared and analyzed using methods known in the art. Probes or array elements from about 18 consecutive nucleotides to about 5000 consecutive nucleotides are contemplated by the invention and used in array technologies. The preferred number of probes or array elements is at least about 40,000; a more preferred number is at least about 18,000; an even more preferred number is at least about 10,000; and a most preferred number is at least about 600 to about 800. The array may be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and SNPs. Such information may be used to determine gene function; to understand the genetic basis of a disorder; to diagnose a disorder; and to develop and monitor the activities of therapeutic agents being used to control or cure a disorder. (See, e.g., U.S. Pat. No. 5,474,796; PCT application WO95/11995; PCT application WO95/35505; U.S. Pat. No. 5,605,662; and U.S. Pat. No. 5,958,342.)

[0080] Screening Assays

[0081] A combination comprising a plurality of cDNAs or an isolated cDNA may be used to screen a library or a plurality of molecules or compounds for a ligand with specific binding affinity. The ligands may be DNA molecules, RNA molecules, peptide nucleic acids, mimetics, and proteins such as transcription factors, enhancers, repressors, and other proteins that regulate the activity, replication, transcription, or translation of nucleic acid molecules in the biological system. The assay involves combining a combination or a cDNA of the invention or complements thereof with the molecules or compounds under conditions that allow specific binding to at least one cDNA and detecting the bound cDNA to identify at least one ligand that specifically binds it.

[0082] In one embodiment, the cDNA of the invention may be incubated with a library of isolated and purified molecules or compounds and binding activity determined by methods well known in the art, e.g., a gel-retardation assay described in U.S. Pat. No. 6,010,849 or a commercially available reticulocyte lysate transcriptional assay. In another embodiment, the cDNA may be incubated with nuclear extracts from biopsied and/or cultured cells and tissues. Specific binding between the cDNA and a molecule or compound in the nuclear extract is initially determined by gel shift assay and may be later confirmed by raising antibodies against that molecule or compound. When these antibodies are added into the assay, they cause a supershift in the gel-retardation assay.

[0083] In another embodiment, the cDNA may be used to purify a molecule or compound using affinity chromatography methods well known in the art. In one embodiment, the cDNA is chemically reacted with cyanogen bromide groups on a polymeric resin or gel. Then a sample is passed over and reacts with or binds to the cDNA. The molecule or compound which is bound to the cDNA may be released from the cDNA by increasing the salt concentration of the flow-through medium and collected.

[0084] Protein Production and Uses

[0085] The cDNAs or their full length equivalents may be used to produce peptides or proteins using recombinant DNA technologies described herein and taught in Ausubel (supra; pp. 16.1-16.62). One of the advantages of producing proteins by these procedures is the ability to obtain an highly-enriched sample thereby maximizing production.

[0086] The invention also encompasses amino acid substitutions, deletions or insertions made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Such substitutions may be conservative in nature when the substituted residue has structural or chemical properties similar to the original residue (e.g., replacement of leucine with isoleucine or valine) or they may be nonconservative when the replacement residue is radically different (e.g., a glycine replaced by a tryptophan). Computer programs included in LASERGENE software (DNASTAR, Madison Wis.) or RasMol software (University of Massachusetts, Amherst Mass.) may be used to help determine which and how many amino acid residues in a particular portion of the protein may be substituted, inserted, or deleted without abolishing biological or immunological activity.

[0087] Expression of Encoded Proteins

[0088] Expression of a particular cDNA may be accomplished by cloning the cDNA into an appropriate vector and transforming this vector into an appropriate host cell. The cloning vector used for the construction of the human and rat cDNA libraries may also be used for expression. Such vectors usually contain a promoter and a polylinker useful for cloning, priming, and transcription. An exemplary vector may also contain the promoter for β-galactosidase, an amino-terminal methionine and the subsequent seven amino acid residues of β-galactosidase. The vector may be transformed into an appropriate host strain of E. coli. Induction of the isolated bacterial strain with isopropylthiogalactoside (IPTG) using standard methods will produce a fusion protein that contains an N terminal methionine, the first seven residues of β-galactosidase, about 15 residues of linker, and the protein encoded by the cDNA.

[0089] The cDNA may be shuttled into other vectors known to be useful for expression of protein in specific hosts. Oligonucleotides containing cloning sites and fragments of a cDNA sufficient to hybridize to stretches at both ends of the cDNA may be chemically synthesized by standard methods. These primers may then be used to amplify the desired fragments by PCR. The fragments may be digested with appropriate restriction enzymes under standard conditions and isolated using gel electrophoresis. Alternatively, similar fragments are produced by digestion of the cDNA with appropriate restriction enzymes and filled in with chemically synthesized oligonucleotides. Fragments of the coding sequence from more than one gene may be ligated together to produce a fusion protein which may be expressed.

[0090] Signal sequences that dictate secretion of soluble proteins are particularly desirable as component parts of a recombinant sequence. For example, a chimeric protein may be expressed that includes one or more additional purification-facilitating domains. Such domains include, but are not limited to, metal-chelating domains that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex, Seattle Wash.). The inclusion of a cleavable-linker sequence such as ENTEROKINASEMAX (Invitrogen, San Diego Calif.) between the protein and the purification domain may also be used to recover the protein.

[0091] Suitable expression hosts may include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, yeast cells such as Saccharomyces cerevisiae, and bacteria such as E. coli. For each of these cell systems, a useful expression vector may also include an origin of replication and one or two selectable markers to allow selection in bacteria as well as in a transfected eukaryotic host. Vectors for use in eukaryotic expression hosts may require the addition of 3′poly(A) tail if the cDNA lacks poly(A).

[0092] Additionally, the vector may contain promoters or enhancers that increase gene expression. Most promoters are host specific, and they include MMTV, SV40 or metallothionein promoters for CHO cells; trp, lac, tac or T7 promoters for bacterial hosts; or alpha factor, alcohol oxidase or PGH promoters for yeast. Adenoviral vectors with enhancers such as the rous sarcoma virus (RSV) enhancer or retroviral vectors with promoters such as the long terminal repeat (LTR) promoter may be used to drive protein expression in mammalian cell lines. Once homogeneous cultures of recombinant cells are obtained, large quantities of a secreted soluble protein may be recovered from the conditioned medium and analyzed using chromatographic methods well known in the art. An alternative method for the production of large amounts of secreted protein involves the transformation of mammalian embryos and the recovery of the recombinant protein from milk produced by transgenic cows, goats, sheep, and the like.

[0093] In addition to recombinant production, proteins may be produced using solid-phase techniques (Stewart et al. (1969) Solid-Phase Peptide Synthesis, W H Freeman, San Francisco Calif.; Merrifield (1963) J Am Chem Soc 5:2149-2154), manually, or using machines such as the ABI 431A Peptide synthesizer (Applied Biosystems (ABI), Foster City Calif.). Proteins produced by any of the above methods may be used as pharmaceutical compositions to treat disorders associated with underexpression.

[0094] Derivative refers to a cDNA or a protein that has been subjected to a chemical modification. Illustrative of such modifications would be replacement of a hydrogen by, for example, an acetyl, acyl, alkyl, amino, formyl, or morpholino group. Derivative cDNAs may encode proteins that retain the essential biological characteristics (such as catalytic and regulatory domains) of naturally occurring proteins.

[0095] Post-translational modification of a protein may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and the like. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cellular location, cell type, pH, enzymatic milieu, and the like.

[0096] Screening Assays

[0097] A protein encoded by the cDNA may be used to screen libraries or a plurality of molecules or compounds for a ligand with specific binding affinity or to purify a molecule or compound from a sample. The protein employed in such screening may be free in solution, affixed to an abiotic or biotic substrate, or located intracellularly. For example, viable or fixed prokaryotic host cells that are stably transformed with recombinant nucleic acids that have expressed and positioned a protein on their cell surface can be used in screening assays. The cells are screened against libraries or a plurality of ligands and the specificity of binding or formation of complexes between the expressed protein and the ligand may be measured. The ligands may be DNA, RNA, or peptide nucleic acid molecules, agonists, antagonists, antibodies, immunoglobulins, inhibitors, peptides, pharmaceutical agents, proteins, drugs, or any other test molecule or compound that specifically binds the protein. An exemplary assay involves combining the mammalian protein with molecules or compounds under conditions that allow specific binding and detecting the bound protein to identify at least one ligand that specifically binds the protein.

[0098] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies specifically compete with a test compound capable of binding the protein. One method for high throughput screening using very small assay volumes and very small amounts of test compound is described in U.S. Pat. No. 5,876,946. Molecules or compounds identified by screening may be used in a mammalian model system to evaluate their toxicity, diagnostic, or therapeutic potential.

[0099] Purification of a Ligand

[0100] The protein may be used to purify a ligand from a sample. A method for using a mammalian protein to purify a ligand would involve combining the protein with a sample under conditions to allow specific binding, recovering the bound protein, and using an appropriate chaotropic agent to separate the protein from the purified ligand.

[0101] Production of Antibodies

[0102] A protein encoded by a cDNA of the invention may be used to produce specific antibodies. Antibodies may be produced using an oligopeptide or any antigenic portion of the protein. Methods for producing antibodies include: 1) injecting an animal (usually goats, rabbits, or mice) with the protein, or an oligopeptide, to induce an immune response; 2) engineering hybridomas to produce monoclonal antibodies; 3) inducing in vivo production in the lymphocyte population; or 4) screening libraries of recombinant immunoglobulins. Recombinant immunoglobulins may be produced as taught in U.S. Pat. No. 4,816,567.

[0103] Antibodies produced using the proteins of the invention are useful for the diagnosis of prepathologic disorders as well as the diagnosis of chronic or acute diseases characterized by abnormalities in the expression, amount, or distribution of the protein. A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies specific for proteins are well known in the art. Immunoassays typically involve the formation of complexes between a protein and its specific binding molecule or compound and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific protein is preferred, but a competitive binding assay may also be employed.

[0104] Immunoassay procedures may be used to quantify expression of the protein in cell cultures, in subjects with a particular disorder or in model animal systems under various conditions. Increased or decreased production of proteins as monitored by immunoassay may contribute to knowledge of the cellular activities associated with developmental pathways, engineered conditions or diseases, or treatment efficacy. The quantity of a given protein in a given tissue may be determined by performing immunoassays on freeze-thawed detergent extracts of biological samples and comparing the slope of the binding curves to binding curves generated by purified protein.

[0105] Labeling of Molecules for Assay

[0106] A wide variety of reporter molecules and conjugation techniques are known by those skilled in the art and may be used in various cDNA, protein or antibody arrays or assays. Synthesis of labeled molecules may be achieved using Promega or APB kits for incorporation of a labeled nucleotide such as 32P-dCTP, Cy3-dCTP or Cy5-dCTP or amino acid such as 35S-methionine. cDNAs, proteins, or antibodies may be directly labeled with a reporter molecule by chemical conjugation to amines, thiols and other groups present in the molecules using reagents such as BIODIPY or FITC (Molecular Probes, Eugene Oreg.).

[0107] The proteins and antibodies may be labeled for purposes of assay by joining them, either covalently or noncovalently, with a reporter molecule that provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported in the scientific and patent literature including, but not limited to U.S. Pat. No. 3,817,837; U.S. Pat. No. 3,850,752; U.S. Pat. No. 3,939,350; U.S. Pat. No. 3,996,345; U.S. Pat. No. 4,277,437; U.S. Pat. No. 4,275,149; and U.S. Pat. No. 4,366,241.

[0108] Diagnostics

[0109] The cDNAs may be used to detect and quantify altered gene expression; absence, presence, or excess expression of mRNAs; or to monitor mRNA levels during therapeutic intervention. The nucleic acid molecules can be used in diagnosis, prognosis, treatment, and evaluation of therapies for diseases associated with neuronal differentiation and morphogenesis, such as Alzheimer's disease, autism, cancer, ischemic cerebrovascular disease, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia, and stroke. These cDNAs can also be utilized as markers of treatment efficacy against the diseases noted above and other conditions and diseases over a period ranging from several days to months. The diagnostic assay may use hybridization or amplification technology to compare gene expression in a biological sample from a patient to standard samples in order to detect altered gene expression. Qualitative or quantitative methods for this comparison are well known in the art.

[0110] For example, the cDNA may be labeled by standard methods and added to a biological sample from a patient under conditions for the formation of hybridization complexes. After an incubation period, the sample is washed and the amount of label (or signal) associated with hybridization complexes, is quantified and compared with a standard value. If the amount of label in the patient sample is significantly altered in comparison to the standard value, then the presence of the associated condition, disease or disorder is indicated.

[0111] In order to provide a basis for the diagnosis of a condition, disease or disorder associated with gene expression, a normal or standard expression profile is established. This may be accomplished by combining a biological sample taken from normal subjects, either animal or human, with a probe under conditions for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained using normal subjects with values from an experiment in which a known amount of a substantially purified target sequence is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a particular condition, disease, or disorder. Deviation from standard values toward those associated with a particular condition is used to diagnose that condition.

[0112] Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies and in clinical trial or to monitor the treatment of an individual patient. Once the presence of a condition is established and a treatment protocol is initiated, diagnostic assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in a normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

[0113] Expression Profiles

[0114] An expression profile can be based on differential expression of nucleic acid or proteins as measured using a number of different experimental technologies. Experimentally, differential expression of the cDNAs can be evaluated by other methods including, but not limited to, differential display by spatial immobilization or by gel electrophoresis, genome mismatch scanning, representational discriminant analysis, clustering, transcript images, and other array technologies. These methods may be used alone or in combination to verify the differential expression patterns that characterize a particular tissue, disorder, or therapy. Similarly the differential expression of proteins can be evaluated using protein or antibody arrays, ELISAs, FACS, RIAs and the like.

[0115] Researchers can assess and catalog the differences in gene expression between healthy and diseased tissues or cells. By analyzing changes in patterns of gene expression, disease can be diagnosed at earlier stages before the patient is symptomatic. The invention can be used to formulate a prognosis and to design a treatment regimen. The invention can also be used to monitor the efficacy of treatment. For treatments with known side effects, an array is employed to improve the treatment regimen. A dosage is established that causes a change in expression indicative of successful treatment. Expression patterns associated with the onset of undesirable side effects are avoided. This approach may be more sensitive and rapid than waiting for the patient to show inadequate improvement, or to manifest side effects, before altering the course of treatment.

[0116] In another embodiment, animal models which mimic a human disease can be used to characterize expression profiles associated with a particular condition, disorder or disease or treatment of the condition, disorder or disease. Novel treatment regimens may be tested in these animal models using arrays to establish and then follow expression profiles over time. In addition, arrays may be used with cell cultures or tissues removed from animal models to rapidly screen large numbers of candidate drug molecules, looking for ones that produce an expression profile similar to those of known therapeutic drugs, with the expectation that molecules with the same expression profile will likely have similar therapeutic effects. Thus, the invention provides the means to rapidly determine the molecular mode of action of a drug.

[0117] Assays Using Antibodies

[0118] Antibodies directed against antigenic determinant of a protein encoded by a cDNA of the invention may be used in assays to quantify the amount of protein found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The antibodies may be used with or without modification, and labeled by joining them, either covalently or noncovalently, with a labeling moiety.

[0119] Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS). Such immunoassays typically involve the formation of complexes between the protein and its specific antibody and the measurement of such complexes. These and other assays are described in Pound (1998; Immunochemical Protocols, Humana Press, Totowa N.J.). The method may employ a two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes, or a competitive binding assay. (See, e.g., Coligan et al. (1997) Current Protocols in Immunology, Wiley-Interscience, New York N.Y.; Pound, supra)

[0120] Therapeutics

[0121] The cDNAs may be used in gene therapy. The cDNAs may be delivered to a particular target organ, tissue, or cell population such as cells of the nervous system. Expression of the protein encoded by the cDNA may correct a disease state associated with reduction or loss of endogenous target protein. cDNAs may be delivered to specific cells in vitro, and then the cells transferred surgically to the intended tissue or delivered by the circulatory system The cDNAs are delivered to cells or tissues using vectors such as retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, and bacterial plasmids. Non-viral methods of gene delivery include cationic liposomes, polylysine conjugates, artificial viral envelopes, and direct injection of DNA (Anderson (1998) Nature 392:25-30; Dachs et al. (1997) Oncol Res 9:313-325; Chu et al. (1998) J Mol Med 76(3-4):184-192; August et al. (1997) Gene Therapy (Advances in Pharmacology, Vol. 40), Academic Press, San Diego Calif.).

[0122] In addition, expression of a particular protein can be modulated through the specific binding of an antisense sequence to a nucleic acid which either encodes the protein or directs its expression. The antisense sequence can be DNA, RNA, or nucleic acid mimics and analogs. The modulated nucleic acid can be cellular mRNA and/or genomic DNA, and the binding of the antisense sequence can affect translation and/or transcription, respectively. Antisense sequences can be delivered intracellularly using viral vectors or non-viral vectors as described above (Weiss et al. (1999) Cell Mol Life Sci 55(3):334-358; Agrawal (1996) Antisense Therapeutics, Humana Press., Totowa N.J.).

[0123] Both the cDNAs and antisense sequences can be produced ex vivo by using any of the ABI nucleic acid synthesizers or other automated systems known in the art. cDNAs and antisense sequences can also be produced biologically by transforming an appropriate host cell with an expression vector containing the cDNA or any fragment or complement thereof.

[0124] Molecules which modulate the expression of a cDNA of the invention or activity of the encoded protein are useful as therapeutics for conditions and disorders associated with neuronal differentiation and morphogenesis. Such molecules include agonists which increase the expression or activity of the endogenous gene or encoded protein, respectively; or antagonists which decrease expression or activity of the gene or protein, respectively. In one aspect, an antibody which specifically binds the protein may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express the protein.

[0125] Additionally, any of the proteins or their ligands, or complementary nucleic acids may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to affect the treatment or prevention of the conditions and disorders associated with neuronal differentiation and morphogenesis. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Further, the therapeutic agents may be combined with pharmaceutically-acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Mack Publishing, Easton Pa.).

[0126] Model Systems

[0127] Animal models may be used as bioassays where they exhibit a phenotypic response similar to that of humans and where exposure conditions are relevant to human exposures. Mammals are the most common models, and most infectious agent, cancer, drug, and toxicity studies are performed on rodents such as rats or mice because of low cost, availability, lifespan, reproductive potential, and abundant reference literature. Inbred and outbred rodent strains provide a convenient model for investigation of the physiological consequences of underexpression or overexpression of genes of interest and for the development of methods for diagnosis and treatment of diseases. A mammal inbred to overexpress a particular gene (for example, secreted in milk) may also serve as a convenient source of the protein expressed by that gene.

[0128] Transgenic Animal Models

[0129] Transgenic rodents that overexpress or underexpress a gene of interest may be inbred and used to model human diseases or to test therapeutic or toxic agents. (See, e.g., U.S. Pat. No. 5,175,3 83 and U.S. Pat. No. 5,767,337.) In some cases, the introduced gene may be activated at a specific time in a specific tissue type during fetal or postnatal development. Expression of the transgene is monitored by analysis of phenotype, of tissue-specific mRNA expression, or of serum and tissue protein levels in transgenic animals before, during, and after challenge with experimental drug therapies.

[0130] Embryonic Stem Cells

[0131] Embryonic (ES) stem cells isolated from rodent embryos retain the potential to form embryonic tissues. When ES cells are placed inside a carrier embryo, they resume normal development and contribute to tissues of the live-born animal. ES cells are the preferred cells used in the creation of experimental knockout and knockin rodent strains. Mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and are grown under culture conditions well known in the art. Vectors used to produce a transgenic strain contain a disease gene candidate and a marker gene, the latter serves to identify the presence of the introduced disease gene. The vector is transformed into ES cells by methods well known in the art, and transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains.

[0132] ES cells derived from human blastocysts may be manipulated in vitro to differentiate into at least eight separate cell lineages. These lineages are used to study the differentiation of various cell types and tissues in vitro, and they include endoderm, mesoderm, and ectodernal cell types that differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes.

[0133] Knockout Analysis

[0134] In gene knockout analysis, a region of a gene is enzymatically modified to include a non-natural intervening sequence such as the neomycin phosphotransferase gene (neo; Capecchi (1989) Science 244:1288-1292). The modified gene is transformed into cultured ES cells and integrates into the endogenous genome by homologous recombination. The inserted sequence disrupts transcription and translation of the endogenous gene. Transformed cells are injected into rodent blastulae, and the blastulae are implanted into pseudopregnant dams. Transgenic progeny are crossbred to obtain homozygous inbred lines that lack a functional copy of the mammalian gene.

[0135] Knockin Analysis

[0136] ES cells can be used to create knockin humanized animals (pigs) or transgenic animal models (mice or rats) of human diseases. With knockin technology, a region of a human gene is injected into animal ES cells, and the human sequence integrates into the animal cell genome. Transformed cells are injected into blastulae and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of the analogous human condition. These methods have been used to model several human diseases.

[0137] As described herein, the uses of the cDNAs provided in the Sequence Listing and their encoded proteins are exemplary of known techniques and are not intended to reflect any limitation on their use in any technique that would be known to the person of average skill in the art. Furthermore, the cDNAs provided in this application may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known to the person of ordinary skill in the art, e.g., the triplet genetic code, specific base pair interactions, and the like. Likewise, reference to a method may include combining more than one method for obtaining or assembling full length cDNA sequences that will be known to those skilled in the art.

EXAMPLES

[0138] I Construction of cDNA Libraries

[0139] RNA was purchased from Clontech Laboratories (Palo Alto Calif.) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL reagent (Invitrogen). The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either isopropanol or ethanol and sodium acetate, or by other routine methods.

[0140] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly(A) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (Qiagen, Valencia Calif.), or an OLIGOTEX mRNA purification kit (Qiagen). Alternatively, poly(A) RNA was isolated directly from 5 tissue lysates using other kits, including the POLY(A)PURE mRNA purification kit (Ambion, Austin Tex.).

[0141] In some cases, Stratagene (La Jolla Calif.) was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Invitrogen) using the recommended procedures or similar methods known in the art. (See Ausubel, supra, Units 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (APB) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of the pBLUESCRIPT phagemid (Stratagene), pSPORT1 plasmid (Invitrogen), or pINCY plasmid (Incyte Genomics). Recombinant plasmids were transformed into XL 1-BLUE, XL1-BLUEMRF, or SOLR competent E. coli cells (Stratagene) or DH5α, DH10B, or ELECTROMAX DH10B competent E. coli cells (Invitrogen).

[0142] In some cases, libraries were superinfected with a 5× excess of the helper phage, M13K07, according to the method of Vieira et al. (1987; Methods Enzymol 153:3-11) and normalized or subtracted using a methodology adapted from Soares (1994; Proc Natl Acad Sci 91:9228-9232), Swaroop et al. (1991; Nucleic Acids Res 19:1954), and Bonaldo et al. (1996; Genome Res 6:791-806). The modified Soares normalization procedure was utilized to reduce the repetitive cloning of highly expressed high abundance cDNAs while maintaining the overall sequence complexity of the library. Modification included significantly longer hybridization times which allowed for increased gene discovery rates by biasing the normalized libraries toward those infrequently expressed low-abundance cDNAs which are poorly represented in a standard expression profile (Soares, supra).

[0143] II Isolation and Sequencing of cDNA Clones

[0144] Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using one of the following: the Magic or WIZARD MINIPREPS DNA purification system (Promega); the AGTC MINIPREP purification kit (Edge BioSystems, Gaithersburg Md.); the QIAWELL 8, QIAWELL 8 PLUS, or QIAWELL 8 ULTRA plasmid purification systems, or the REAL PREP 96 plasmid purification kit (Qiagen). Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4 C.

[0145] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao (1994) Anal Biochem 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

[0146] cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (ABI) or the DNA ENGINE thermal cycler (MJ Research, Watertown Mass.) in conjunction with the HYDRA microdispenser (Robbins Scientific, Sunnyvale Calif.) or the MICROLAB 2200 system (Hamilton, Reno Nev.). cDNA sequencing reactions were prepared using reagents provided by APB or supplied in sequencing kits such as the ABI PRISM BIGDYE cycle sequencing kit by ABI. Electrophoretic separation of cDNA sequencing reactions and detection of labeled nucleotides were carried out using the MEGABACE 1000 DNA sequencing system (APB); the ABI PRISM 373 or 377 sequencing system (ABI) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, supra, Unit 7.7).

[0147] III Extension of cDNA Sequences

[0148] Nucleic acid sequences were extended using Incyte cDNA clones and oligonucleotide primers. One primer was synthesized to initiate 5′ extension of the known fragment, and the other, to initiate 3′ extension of the known fragment. The initial primers were designed using OLIGO software (Molecular Insights, Cascade Colo.), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68 C. to about 72 C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

[0149] Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed. Preferred libraries are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred because they will contain more sequences with the 5′ and upstream regions of genes. A randomly primed library is particularly useful if an oligo d(T) library does not yield a full-length cDNA.

[0150] High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the DNA ENGINE thermal cycler (MJ Research). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg2+, (NH4)2SO4, and β-mercaptoethanol, Taq DNA polymerase (APB), ELONGASE enzyme (Invitrogen), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B (Incyte Genomics): Step 1: 94 C., 3 min; Step 2: 94 C., 15 sec; Step 3: 60 C., 1 min; Step 4: 68 C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 C., 5 min; Step 7: storage at 4 C. In the alternative, the parameters for primer pair T7 and SK+ (Stratagene) were as follows: Step 1: 94 C., 3 min; Step 2: 94 C., 15 sec; Step 3: 57 C., 1 min; Step 4: 68 C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 C., 5 min; Step 7: storage at 4 C.

[0151] The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN reagent (0.25% reagent in 1×TE, v/v; Molecular Probes) and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton Mass.) and allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1% agarose minigel to determine which reactions were successful in extending the sequence.

[0152] The extended nucleic acids were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC18 vector (APB). For shotgun sequencing, the digested nucleic acids were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with AGARACE enzyme (Promega). Extended clones were religated using T4 DNA ligase (New England Biolabs, Beverly Mass.) into pUC18 vector (APB), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37 C. in 384-well plates in LB/2× carbenicillin liquid media.

[0153] The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (APB) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94 C., 3 min; Step 2: 94 C., 15 sec; Step 3: 60 C., 1 min; Step 4: 72 C., 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72C., 5 min; Step 7: storage at 4 C. DNA was quantified using PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions described above. Samples were diluted with 20% dimethylsulfoxide (DMSO; 1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT cycle sequencing kit (APB) or the ABI PRISM BIGDYE terminator cycle sequencing kit (ABI).

[0154] IV Assembly and Analysis of Sequences

[0155] Component nucleotide sequences from chromatograms were subjected to PHRED analysis (Phil's Revised Editing Program; Phil Green, University of Washington, Seattle Wash.) and assigned a quality score. The sequences having at least a required quality score were subject to various pre-processing algorithms to eliminate low quality 3′ ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. Sequences were screened using the BLOCK 2 program (Incyte Genomics), a motif analysis program based on sequence information contained in the SWISS-PROT and PROSITE databases (Bairoch et al. (1997) Nucleic Acids Res 25:217-221; Attwood et al. (1997) J Chem Inf Comput Sci 37:417-424).

[0156] Processed sequences were subjected to assembly procedures in which the sequences were assigned to bins, one sequence per bin. Sequences in each bin were assembled to produce consensus sequences, templates. Subsequent new sequences were added to existing bins using the Basic Local Alignment Search Tool (BLAST; Altschul (1993) J Mol Evol 36:290-300; Altschul et al. (1990) J Mol Biol 215:403-410; Karlin et al. (1988) Proc Natl Acad Sci 85:841-845), BLASTn (v.1.4, WashU), and CROSSMATCH software (Green, supra). Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using PHRAP (Phil's Revised Alignment Program; Green, supra). Bins with several overlapping component sequences were assembled using DEEP PHRAP (Green, supra).

[0157] Bins were compared against each other, and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subjected to analysis by STITCHER/EXON MAPPER algorithms which analyzed the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types, disease states, and the like. These resulting bins were subjected to several rounds of the above assembly procedures to generate the template sequences found in the LIFESEQ GOLD database (Incyte Genomics).

[0158] The assembled templates were annotated using the following procedure. Template sequences were analyzed using BLASTn (v2.0, NCBI) versus GBpri (GenBank version 109). “Hits” were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value of 1×10−8. The hits were subjected to frameshift FASTx versus GENPEPT (GenBank version 109). In this analysis, a homolog match was defined as having an E-value of 1×10−8. The assembly method used above was described in U.S. Ser. No. 09/276,534, filed Mar. 25, 1999, incorporated by reference herein, and the LIFESEQ GOLD user manual (Incyte Genomics).

[0159] Preparation of Arrays

[0160] cDNAs were selected from The Institute for Genomic Research (TIGR) Mus.ET and NCBI GenBank mouse databases. All sequences from these sources were clustered by BLAST analysis and Smith Waterman alignment. Public domain IMAGE clones were selected to represent each of these clusters, non-redundancy and verifiable, high quality sequence were of primary concern. Therefore, the single 5′ most clone was selected as a representative of the sequence of interest, and a 5′ short read sequence was utilized to determine self-matches. Only clones that self-matched were placed on the Mouse GEM 1 array (Incyte Genomics). Sequence verified clones were mapped to clones in the public domain UniGene Mus musculus database. and the name of each clone was inherited from that process. Clones that were not clustered in the UniGene database were annotated as “IMAGE EST”. Additional annotation of the IMAGE ESTs was performed by BLAST2 analysis using blastn against other NCBI databases. To verify the sequence of each IMAGE clone, a single pass 5′ read of the sequence was produced and matched to the original sequence. Again, only clones that self-matched were placed on the array.

[0161] Purified cDNAs were immobilized on polymer-coated glass slides (Corning, Corning N.Y.) which were cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. The slides were etched in 4% hydrofluoric acid (VWR Scientific Products, West Chester Pa.), washed extensively in distilled water, and coated with 0.05% ainiopropyl silane (Sigma-Aldrich) in 95% ethanol. Coated slides were cured in a 110 C. oven. cDNAs were applied to the coated glass substrate using a procedure described in U.S. Pat. No. 5,807,522, incorporated herein by reference. One microliter of the cDNA at an average concentration of 100 ng/ul was loaded into the open capillary printing element by a high-speed robotic apparatus which then deposited about 5 nl of cDNA per slide.

[0162] Arrays were UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene), and then washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites were blocked by incubation of arrays in 0.2% casein in phosphate buffered saline (Tropix, Bedford Mass.) for 30 minutes at 60 C. followed by washes in 0.2% SDS and distilled water.

[0163] VI Preparation of Sample cDNAs

[0164] Mouse ES cells (E14; Hooper et al. (1987) Nature 326:292-295), derived from the inner cell mass of blastocyst stage mouse embryos, were harvested from cultures that were optimized for retention of totipotence. ES cells were cultured on a feeder layer of mitotically inactivated mouse embryonic fibroblasts in medium containing selected fetal bovine serum and β-mercaptoethanol (Hasty et al. (1991) Mol Cell Biol 11:5586-5591). Es cells were dissociated into single cells, and the fibroblasts were removed by incubating the cell suspension in a series of three tissue culture dishes for 1 to 2 hours at a time. Fibroblasts are selectively adherent to the substrate. By the third incubation period, very few adherent cells were observed. ES cells were then placed in non-adhesive petri dishes in culture medium lacking β-mercaptoethanol but containing all other components. Growth of ES cells on a nonadhesive substrate promotes the formation of multicellular aggregates known as embryoid bodies. The cells formed such aggregates after one day in culture, and the aggregates grew by accretion and proliferation over the next 4 days. The medium was changed every second day. After 4 days of culture, 5×10−7M all trans retinoic acid (RA; Sigma-Aldrich) was introduced into the culture medium and included in the medium for the next 4 days. Treatment with RA resulted in a high proportion of ES cells differentiating into neuronal-like cells (Bain et al. (1995) Dev Biol 168:342-357). After 8 days in culture, the aggregates were dissociated with trypsin and DNAse, then replated on collagen-coated dishes. Eight days later, when the cells showed extensive neurite outgrowth, the cells were harvested, and their RNA extracted.

[0165] RNA was prepared from cultures of undifferentiated cells and cultures containing ES cell-derived neurons. The mRNA was made from frozen pelleted cells by adding TRIZOL reagent (Invitrogen) and then letting the cells thaw. Total RNA was extracted using the RNA STAT-60 kit (Tel-Test, Friendswood Tex.). Poly(A) RNA was purified using the POLYATRACT mRNA isolation system (Promega). Each poly(A) RNA sample was reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-d(T) primer (21-mer), 1× first strand buffer, 0.03 units/μl RNAse inhibitor, 500 uM dATP, 500 uM dGTP, 500 uM dTTP, 40 uM dCTP, and 40 uM either dCTP-Cy3 or dCTP-Cy5 (APB). The reverse transcription reaction was performed in a 25 ml volume containing 200 ng poly(A) RNA using the GEMBRIGHT kit (Incyte Genomics). Specific control poly(A) RNAs (YCFR06, YCFR45, YCFR67, YCFR85, YCFR43, YCFR22, YCFR23, YCFR25, YCFR44, YCFR26) were synthesized by in vitro transcription from non-coding yeast genomic DNA. As quantitative controls, control mRNAs (YCFR06, YCFR45, YCFR67, and YCFR85) at 0.002 ng, 0.02 ng, 0.2 ng, and 2 ng were diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000, 1:1000, 1:100 (w/w) to sample mRNA, respectively. To sample differential expression patterns, control mRNAs (YCFR43, YCFR22, YCFR23, YCFR25, YCFR44, YCFR26) were diluted into reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 1:25, 25:1 (w/w) to sample mRNA. Reactions were incubated at 37 C. for 2 hr, treated with 2.5 ml of 0.5M sodium hydroxide, and incubated for 20 minutes at 85 C. to the stop the reaction and degrade the RNA. Two hundred nanograms of purified mRNA was used to produce fluorescently-labeled cDNA probes for competitive hybridization to arrays. For most experiments, probe from the parental undifferentiated cell line was labeled with Cy3, and used as the control in competitive hybridizations with Cy5-labeled probe from the experimental RA-treated cells. Probes were purified using two successive CHROMA SPIN 30 gel filtration spin columns (Clontech). Cy3- and Cy5-labeled reaction samples were combined as described below and ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml 5 M sodium acetate, and 300 ml of 100% ethanol. The probe was then dried to completion using a SpeedVAC system (Savant Instruments, Holbrook N.Y.) and resuspended in 14 μl 5×SSC/0.2% SDS.

[0166] VII Hybridization and Detection

[0167] Hybridization reactions contained 9 μl of probe mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products from pairs of matched time point experimental and control cells in 5×SSC, 0.2% SDS hybridization buffer. The target mixture was heated to 65 C. for 5 minutes and was aliquoted onto the surface of the Incyte Mouse GEM 1 array (Incyte Genomics) and covered with an 1.8 cm2 coverslip. The arrays were transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber was kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the arrays was incubated for about 6.5 hours at 60 C. The arrays were washed for 10 min at 45 C. in low stringency washbuffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45 C. in high stringency wash buffer (0.1×SSC), and dried.

[0168] Reporter-labeled hybridization complexes were detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light was focused on the array using a 20× microscope objective (Nikon, Melville N.Y.). The slide containing the array was placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm array used in the present example was scanned with a resolution of 20 micrometers.

[0169] In two separate scans, the mixed gas multiline laser excited the two fluorophores sequentially. Emitted light was split, based on wavelength, into two photomultiplier tube detectors (PMT R1477; Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes were used to filter the signals. The emission maxima of the fluorophores used were 565 nm for Cy3 and 650 nm for Cy5. Each array was typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus was capable of recording the spectra from both fluorophores simultaneously.

[0170] The sensitivity of the scans was calibrated using the signal intensity generated by a cDNA control species. Samples of the calibrating cDNA were separately labeled with the two fluorophores and identical amounts of each were added to the hybridization mixture. A specific location on the array contained a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000.

[0171] The output of the photomultiplier tube was digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Norwood, Mass.) installed in an IBM-compatible PC computer. The digitized data were displayed as an image where the signal intensity was mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data was also analyzed quantitatively. Where two different fluorophores were excited and measured simultaneously, the data were first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

[0172] A grid was superimposed over the fluorescence signal image such that the signal from each spot was centered in each element of the grid. The fluorescence signal within each element was then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis was the GEMTOOLS gene expression analysis program (Incyte Genomics). Results from the signal analysis were presented as data in a spreadsheet (EXCEL software; Microsoft, Redmond Wash.). Data were sorted according to differential expression and tabulated.

[0173] VIII Complementary Nucleic Acid Molecules

[0174] Molecules complementary to the cDNA, or a fragment thereof, are used to detect, decrease, or inhibit gene expression. Although use of oligonucleotides comprising from about 15 to about 30 base pairs is described, the same procedure is used with larger or smaller fragments or their derivatives. Oligonucleotides are selected using OLIGO software (National Biosciences) and SEQ ID NOs: 1-278. To inhibit transcription by preventing promoter binding, a complementary oligonucleotide is designed to bind to the most unique 5′ sequence, most preferably about 10 nueleotides before the initiation codon of the open reading frame. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the mRNA encoding the protein.

[0175] In addition to using antisense molecules constructed to interrupt transcription or translation, modifications of gene expression can be obtained by designing antisense molecules to genomic sequences (such as enhancers or introns) or even to trans-acting regulatory genes. Similarly, antisense inhibition can be achieved using Hogeboom base-pairing methodology, also known as “triple helix” base pairing. Antisense molecules involved in triple helix pairing compromise the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules.

[0176] Such antisense molecules are placed in expression vectors and used to transform preferred cells or tissues. This may include introduction of the expression vector into a cell line to test efficacy; into an organ, tumor, synovial cavity, or the vascular system for transient or short term therapy; or into a stem cell or other reproducing lineage for long term or stable gene therapy. Transient expression may last for a month or more with a non-replicating vector and for three months or more if appropriate elements for inducing vector replication are used in the transformation/expression system.

[0177] Stable transformation of appropriate dividing cells with a vector encoding the antisense molecule can produce a transgenic cell line, tissue, or organism (U.S. Pat. No. 4,736,866). Those cells that assimilate and replicate sufficient quantities of the vector to allow stable integration also produce enough antisense molecules to compromise or entirely eliminate activity of the endogenous nucleic acid.

[0178] IX Hybridization Technologies and Analyses

[0179] Hybridization technology utilizes a variety of substrates such as polymer coated glass slides and nylon membranes. Arranging elements on polymer coated slides is described in Example V; probe preparation and hybridization and analysis using polymer coated slides is described in examples VI and VII, respectively.

[0180] cDNAs are applied to a membrane substrate by one of the following methods. A mixture of cDNAs is fractionated by gel electrophoresis and transferred to a nylon membrane by capillary transfer. Alternatively, the cDNAs are individually ligated to a vector and inserted into bacterial host cells to form a library. The cDNAs are then arranged on a substrate by one of the following methods. In the first method, bacterial cells containing individual clones are robotically picked and arranged on a nylon membrane. The membrane is placed on LB agar containing selective agent (carbenicillin, kanamycin, ampicillin, or chloramphenicol depending on the vector used) and incubated at 37 C. for 16 hr. The membrane is removed from the agar and consecutively placed colony side up in 10% SDS, denaturing solution (1.5 M NaCl, 0.5 M NaOH), neutralizing solution (1.5 M NaCl, 1 M Tris, pH 8.0), and twice in 2×SSC for 10 min each. The membrane is then UV irradiated in a STRATALINKER UV-crosslinker (Stratagene).

[0181] In the second method, cDNAs are amplified from bacterial vectors by thirty cycles of PCR using primers complementary to vector sequences flanking the insert. PCR amplification increases a starting concentration of 1-2 ng nucleic acid to a final quantity greater than 5 μg. Amplified nucleic acids from about 400 bp to about 5000 bp in length are purified using SEPHACRYL-400 beads (APB). Purified nucleic acids are arranged on a nylon membrane manually or using a dot/slot blotting manifold and suction device and are immobilized by denaturation, neutralization, and UV irradiation as described above.

[0182] Hybridization probes derived from cDNAs of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA in membrane-based hybridizations. Probes are prepared by diluting the cDNAs to a concentration of 40-50 ng in 45 μl TE buffer, denaturing by heating to 100C. for five min, and briefly centrifuging. The denatured cDNA is then added to a REDIPRIME tube (APB), gently mixed until blue color is evenly distributed, and briefly centrifuged. Five microliters of [32P]dCTP is added to the tube, and the contents are incubated at 37 C. for 10 min. The labeling reaction is stopped by adding 5 μl of 0.2M EDTA, and probe is purified from unincorporated nucleotides using a PROBEQUANT G-50 microcolumn (APB). The purified probe is heated to 100 C. for five min, snap cooled for two min on ice.

[0183] Membranes are pre-hybridized in hybridization solution containing 1% Sarkosyl and 1× high phosphate buffer (0.5 M NaCl, 0.1 M Na2HPO4, 5 mM EDTA, pH 7) at 55 C. for two hr. The probe, diluted in 15 ml fresh hybridization solution, is then added to the membrane. The membrane is hybridized with the probe at 55 C. for 16 hr. Following hybridization, the membrane is washed for 15 min at 25 C. in 1 mM Tris (pH 8.0), 1% Sarkosyl, and four times for 15 min each at 25 C. in 1 mM Tris (pH 8.0). To detect hybridization complexes, XOMAT-AR film (Eastman Kodak, Rochester N.Y.) is exposed to the membrane overnight at −70 C., developed, and examined.

[0184] X Transcript Image

[0185] A transcript image was produced using the LIFESEQ GOLD database (Jan02release, Incyte Genomics). This process allowed assessment of the relative abundance of the expressed polynucleotides in all of the cDNA libraries of the database. Criteria for transcript imaging can be selected from category, number of cDNAs per library, library description, disease indication, clinical relevance of sample, and the like.

[0186] All sequences and cDNA libraries in the LIFESEQ GOLD database have been categorized by system, organ/tissue and cell type. For each category, the number of libraries in which the sequence was expressed were counted and shown over the total number of libraries in that category. For each library, the number of cDNAs were counted and shown over the total number of cDNAs in that library. In some transcript images, all normalized or subtracted libraries, which have high copy number sequences removed prior to processing, and all mixed or pooled tissues, which are considered non-specific in that they contain more than one tissue type or more than one subject's tissue, can be excluded from the analysis. Treated and untreated cell lines and/or fetal tissue can also be excluded where clinical relevance is emphasized. Conversely, fetal tissue can be emphasized wherever elucidation of inherited disorders or differentiation of particular adult or embryonic stem cells into tissues or organs such as heart, kidney, nerves or pancreas would be aided by removing clinical samples from the analysis.

[0187] The transcript images for SEQ ID NOs: 1376 and 2164 are shown below. The first column shows library name; the second column, the number of cDNAs sequenced in that library; the third column, the description of the library; the fourth column, absolute abundance of the transcript in the library; and the fifth column, percentage abundance of the transcript in the library.

1SEQ ID NO: 1376Category: Nervous SystemLibrary*cDNAsDescription of TissueAbundance% AbundanceHNT2NOM023158teratoCA line, hNT2, untreated70.2217HNT2NOT015782teratoCA line, hNT2, untreated70.1211HNT2TXF011144teratoCA line, NT2, t/cytokines10.0874HNT2TXC012067teratoCA line, hNT2, t/mouse leptin, RA10.0484HNT2NOM012860teratoCA line, hNT2, t/RA10.0350HNT2RAT014918teratoCA line, hNT2, t/RA10.0203HNT3AZT015219teratoCA line, NT2, t/5AZA-3d10.0192*Normalized and subtracted HNT2 samples were removed from the analysis for the reasons cited above.

[0188] As can be seen above, SEQ ID NO: 1376 was differentially expressed in the untreated hNT2 libraries. It was not significantly expressed in the treated hNT2 libraries above nor in any other brain or neuronal samples in the LIFESEQ GOLD database, and it was not expressed in the treated libraries HNT2AGT01, HNT2NOM03, HNT2TXT01, and HNTNNOMO1.

2SEQ ID NO: 1376Category: Male Reproductive SystemLibrary*cDNAsDescription of TissueAbundance% AbundanceTESTTUE022642testis tumor, embryonal CA, 31M, 5RP20.0757TESTTUT027437testis tumor, embryonal CA, 31M, EF40.0538*No libraries were removed from the analysis

[0189] SEQ ID NO: 1376 was not expressed in any cytologically normal or diseased prostate tissues (78 libraries), in seminoma (2 libraries) or uncharacterized tumor (1 library), or in cytologically normal (7 libraries) or necrotic testis (1 library).

[0190] In nervous system and male reproductive system, expression of SEQ ID NO: 1376 was limited to untreated teratocarcinoma cells and embryonal carcinoma of the testicles. It appears that these two kinds of germinal cancers are closely related, that embryonal cancers metastasize to the brain and elsewhere, and both the brain and testicular tumors respond to chemotherapy consisting of bleomycin, cisplatin, and vinblastine or etoposide (Yoshida and Morii (1998) J Neurosurg 88:761-3). When used in a tissue specific and clinically relevant manner, SEQ ID NO: 1376 is diagnostic of germinal tumors such as teratocarcinomas and embryonal carcinomas and can used to evaluate the efficacy of a particular treatment for this condition.

3SEQ ID NO: 2164Category: Nervous SystemLibrary*cDNAsDescription of TissueAbundance% AbundanceBRAITUT133757brain tumor, frontal, meningioma, 68M40.1065BRAITUT076240brain tumor, frontal, neuronal neoplasm, 32M20.0321BRAHDIT043190brain, hippocampus, AD10.0313BRAVTXT043922astrocytes, M/F, t/cytokines 4-6 hr10.0255BRAUTDR024706brain, amygdala/entorhinal cortex, 55F10.0212BRAENOT048909brain, parietal cortex, aw/CHF, 35M10.0112BRAITUT0313222brain tumor, frontal, astrocytoma, 17F10.0076BRAITUT0213385brain tumor, frontal, mets hypernephroma, 58M10.0075*Libraries of fetal, normalized or subtracted, mixed or pooled tissues, and cell lines removed from analysis

[0191] SEQ ID NO: 2164 was three-fold differentially expressed in the meningioma BRAITUT13. It was not expressed in Alzheimer's disease (10 libraries), astrocytoma (7 libraries), Huntington's disease (18 libraries), multiple sclerosis (3 libraries), and schizophrenia (9 libraries). When used in a tissue specific and clinically relevant manner, SEQ ID NO: 2164 is diagnostic of meningioma and could be used to evaluate the efficacy of a particular treatment for this condition.

[0192] XI Expression of the Encoded Protein

[0193] Expression and purification of a protein encoded by a cDNA of the invention is achieved using bacterial or virus-based expression systems. For expression in bacteria, cDNA is subcloned into a vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into bacterial hosts, such as BL21(DE3). Antibiotic resistant bacteria express the protein upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression in eukaryotic cells is achieved by infecting Spodoptera frugiperda (Sf9) insect cells with recombinant baculovirus, Autographica californica nuclear polyhedrosis virus. The polyhedrin gene of baculovirus is replaced with the cDNA by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of transcription.

[0194] For ease of purification, the protein is synthesized as a fusion protein with glutathione-S-transferase (GST; APB) or a similar alternative such as FLAG. The fusion protein is purified on immobilized glutathione under conditions that maintain protein activity and antigenicity. After purification, the GST moiety is proteolytically cleaved from the protein with thrombin. A fusion protein with FLAG, an 8-amino acid peptide, is purified using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak).

[0195] XII Production of Specific Antibodies

[0196] A denatured protein from a reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits following standard protocols. About 100 μg is used to immunize a mouse, while up to 1 mg is used to immunize a rabbit. The denatured protein is radioiodinated and incubated with murine B-cell hybridomas to screen for monoclonal antibodies. About 20 mg of protein is sufficient for labeling and screening several thousand clones.

[0197] In another approach, the amino acid sequence translated from a cDNA of the invention is analyzed using PROTEAN software (DNASTAR) to determine regions of high immunogenicity. The optimal sequences for immunization are usually at the C-terminus, the N-terminus, and those intervening, hydrophilic regions of the protein that are likely to be exposed to the external environment when the protein is in its natural conformation. Typically, oligopeptides about 15 residues in length are synthesized using an ABI 431 peptide synthesizer (ABI) using Fmoc-chemistry and then coupled to keyhole limpet hemocyanin (KLH; Sigma-Aldrich) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester. If necessary, a cysteine may be introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG.

[0198] Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with radioiodinated protein to identify those fusions producing a monoclonal antibody specific for the protein. In a typical protocol, wells of 96 well plates (FAST, Becton-Dickinson, Palo Alto Calif.) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled protein at 1 mg/ml. Clones producing antibodies bind a quantity of labeled protein that is detectable above background.

[0199] Such clones are expanded and subjected to 2 cycles of cloning at 1 cell/3 wells. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (APB). Monoclonal antibodies with affinities of at least 108 M−1, preferably 109 to 1010 M−1 or stronger, are made by procedures well known in the art.

[0200] XIII Purification of Naturally Occurring Protein Using Specific Antibodies

[0201] Naturally occurring or recombinant protein is substantially purified by immunoaffinity chromatography using antibodies specific for the protein. An immunoaffinity column is constructed by covalently coupling the antibody to CNBr-activated SEPHAROSE resin (APB). Media containing the protein is passed over the immunoaffinity column, and the column is washed using high ionic strength buffers in the presence of detergent to allow preferential absorbance of the protein. After coupling, the protein is eluted from the column using a buffer of pH 2-3 or a high concentration of urea or thiocyanate ion to disrupt antibody/protein binding, and the protein is collected.

[0202] XIV Screening Molecules for Specific Binding

[0203] The cDNAs, proteins or antibodies of the invention are labeled with 32P-dCTP, Cy3-dCTP, Cy5-dCTP (APB), or the proteins are labeled with BIODIPY or FITC (Molecular Probes). A library or a plurality of candidate molecules or compounds previously arranged on a substrate are incubated in the presence of labeled cDNA, protein or antibody. After incubation under conditions for a cDNA, protein, or antibody, the substrate is washed. Any position on the substrate retaining label, that indicates specific binding or complex formation, identifies a ligand. Data obtained using different concentrations of the cDNA, protein, or antibody are used to calculate affinity between the labeled molecule and the bound ligand.

[0204] All publications and patents mentioned in the specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

4TABLE 1SEQ ID NORATIODESCRIPTION {IMAGE ID}150.49IGF II IMAGE EST {IMAGE: 463135}231.49Insulin-like growth factor binding protein 5 {IMAGE: 671661}326.26Insulin-like growth factor 2 {IMAGE: 464598}422.90KIAA0287 IMAGE EST {IMAGE: 427016}518.95Extracellular matrix protein 1 {IMAGE: 874833}618.58Procollagen, type III, alpha 1 {IMAGE: 420322}718.54Pleiotrophin {IMAGE: 478168}818.50IGF-BP 3 IMAGE EST {IMAGE: 639481}917.66oxoacyl reductase (acyl carrier) IMAGE EST {IMAGE: 766482}1016.13Extracellular matrix protein 1 {IMAGE: 678765}1114.56NEURONAL PROTEIN 3.1 {IMAGE: 425866}1214.17Intergral membrane protein 2 {IMAGE: 532350}1312.81NEURONAL PROTEIN 3.1 {IMAGE: 374970}1412.80Homeo box B9 {IMAGE: 422746}1511.88Amyloid beta (A4) precursor protein {IMAGE: 535652}1610.93Serine protease-inhibitor 4 {IMAGE: 694987}1710.84Serine protease-inhibitor 4 {IMAGE: 464497}1810.62Insulin-like growth factor binding protein 5 {IMAGE: 418952}1910.06Follistatin-like {IMAGE: 671910}209.90Transforming growth factor, beta 2 {IMAGE: 367780}219.78Procollagen, type VI, alpha 1 {IMAGE: 352450}229.34Procollagen, type VI, alpha 1 {IMAGE: 334132}239.24Insulin-like growth factor 1 {IMAGE: 313322}249.13fibrilin-2 IMAGE EST {IMAGE: 536526}258.75Procollagen, type XI, alpha 1 {IMAGE: 423028}268.66IMAGE EST {IMAGE: 463046}278.66Mouse alpha-B crystallin mRNA {IMAGE: 672201}288.65Carboxypeptidase E {IMAGE: 407068}298.58IMAGE EST {IMAGE: 482955}308.58Matrix metalloproteinase 2 {IMAGE: 402738}318.35Tissue inhibitor of metalloproteinase 2 {IMAGE: 831964}328.35caldesmon IMAGE EST {IMAGE: 718665}337.96NEURONAL PROTEIN 3.1 {IMAGE: 733420}347.86M. musculus mRNA for calpain-like protease {IMAGE: 747101}357.83frizzled-like IMAGE EST {IMAGE: 734305}367.77IMAGE EST {IMAGE: 468900}377.75Procollagen, type I, alpha 1 {IMAGE: 536306}387.70Ufo oncogene homolog {IMAGE: 401608}397.55IMAGE EST {IMAGE: 426890}407.50Tissue inhibitor of metalloproteinase 3 {IMAGE: 580753}417.30caldesmon IMAGE EST {IMAGE: 385914}427.29protein tyrosine kinase IMAGE EST {IMAGE: 401456}437.26No homolog IMAGE EST {IMAGE: 465620}447.15apoptosis-related BP (Napor-1) IMAGE EST {IMAGE: 620221}457.13Annexin V {IMAGE: 426546}467.13ESTs, Weakly similar to similar to alpha-actinin [C. elegans] {IMAGE: 457000}477.07Nuclear factor I/X {IMAGE: 367660}487.05IMAGE EST {IMAGE: 353202}497.05ESTs, Highly similar to GLYPICAN-3 PRECURSOR [Rattus norvegicus] {IMAGE: 657264}506.94IMAGE EST {IMAGE: 406708}516.93M. musculus mRNA for NfiB1-protein (exon 1-12) {IMAGE: 481927}526.91fibrilin-2 IMAGE EST {IMAGE: 479405}536.85No homolog IMAGE EST {IMAGE: 463207}546.80Myristoylated alanine rich protein kinase C substrate {IMAGE: 618681}556.75bone morphogenic protein (BMP) precursor IMAGE EST {IMAGE: 403597}566.74NY—CO-33(2F) IMAGE EST {IMAGE: 463342}576.67IMAGE EST {IMAGE: 552603}586.66Neural ECM/chondrocyte ezrin IMAGE EST {IMAGE: 949246}596.60IMAGE EST {IMAGE: 400864}606.55SH3-containing, STAM-associated IMAGE EST {IMAGE: 424348}616.45U6-snRNA-associated Sm-like protein IMAGE EST {IMAGE: 315581}626.35neuropilin Mus musculus IER5 (Ier5) mRNA, complete cds {IMAGE: 808000}636.33IMAGE EST {IMAGE: 850078}646.30IMAGE EST {IMAGE: 876297}656.14Insulin-like growth factor binding protein 10 {IMAGE: 820167}666.11ESTs {IMAGE: 427289}676.10IMAGE EST {IMAGE: 443865}686.06BMP-3 precursor IMAGE EST {IMAGE: 478040}695.99F-spondrin, neural plate protein IMAGE EST {IMAGE: 762240}705.98contains neural cell-type regulatory region IMAGE EST {IMAGE: 464828}715.97myosin regulatory light chain 2 IMAGE EST {IMAGE: 479382}725.94NMDA receptor Glu-binding IMAGE EST {IMAGE: 764513}735.94M. musculus mRNA for K-glypican {IMAGE: 314639}745.89endothelial actin-binding IMAGE EST {IMAGE: 315775}755.82melanoma-, breast-, hepatocellular CA-associated Ag ESTs, Highly similar to NECDIN [Mus musculus]{IMAGE: 476509}765.81Ephrin B1 {IMAGE: 427319}775.64IMAGE EST {IMAGE: 427345}785.64Myristoylated alanine rich protein kinase C substrate {IMAGE: 617200}795.60IMAGE EST {IMAGE: 482995}805.58cystatin A-associated IMAGE EST {IMAGE: 721944}815.56PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE {IMAGE: 352804}825.54Mus musculus Bet1p homolog (mbet1) mRNA, complete cds {IMAGE: 333232}835.53ssDNA-binding ESTs {IMAGE: 634580}845.47nucleotide- and/or carbohydrate-binding IMAGE EST {IMAGE: 386417}855.42caldesmon IMAGE EST {IMAGE: 890760}865.39Elastin {IMAGE: 698181}875.37IGF II IMAGE EST {IMAGE: 422325}885.33transcobalamin II precursor IMAGE EST {IMAGE: 697010}895.27Glutathione-S-transferase, alpha 2 (Yc2) {IMAGE: 680894}905.25Beta-2 microglobulin {IMAGE: 572542}915.25Tissue inhibitor of metalloproteinase 2 {IMAGE: 902923}925.15IMAGE EST {IMAGE: 747941}935.14dopamine and/or nucleotide metabolism IMAGE EST {IMAGE: 423995}945.09splice variant glycogen phosphorylase isoform IMAGE EST {IMAGE: 807978}955.08caldesmon IMAGE EST {IMAGE: 385318}965.08ribosomal protein IMAGE EST {IMAGE: 352909}975.07No homolog IMAGE EST {IMAGE: 735413}985.05hu Tyr PK EPHB2 (neurogenesis-induced by RA) IMAGE EST {IMAGE: 746643}995.04hu profilin IMAGE EST {IMAGE: 464995}1005.02Mus musculus protein-tyrosine phosphatase mRNA, complete cds {IMAGE: 427642}1015.02Twist gene homolog, (Drosophila) {IMAGE: 479367}1025.01IMAGE EST {IMAGE: 401288}1034.99IMAGE EST {IMAGE: 332477}1044.96profilin II IMAGE EST {IMAGE: 581193}1054.95Homeo box A5 {IMAGE: 465937}1064.92stromelysin-3 precursor IMAGE EST {IMAGE: 692257}1074.90M. musculus mRNA for calpain-like protease {IMAGE: 478504}1084.90Retinol binding protein 1, cellular {IMAGE: 406897}1094.89KIAA0913 IMAGE EST {IMAGE: 578299}1104.87Mus musculus protein-tyrosine phosphatase mRNA, complete cds {IMAGE: 935557}1114.87UV B radiation-activated UV96 mRNA ESTs {IMAGE: 419146}1124.83GATA-GT2 Zn-finger DNA binding protein IMAGE EST {IMAGE: 672424}1134.81extracellular protein precursor IMAGE EST {IMAGE: 746798}1144.80ESTs {IMAGE: 330825}1154.79ESTs, Highly similar to RIBONUCLEASE PL3 PRECURSOR [Sus scrofa] {IMAGE: 803251}1164.76Mus musculus mRNA for annexin III {IMAGE: 573265}1174.72IMAGE EST {IMAGE: 523686}1184.70ESTs, Highly similar to ENDOTHELIAL ACTIN-BINDING PROTEIN [Homo sapiens] {IMAGE:873058}1194.65h2-calponin IMAGE EST {IMAGE: 695687}1204.63IMAGE EST {IMAGE: 670344}1214.63IMAGE EST {IMAGE: 481410}1224.63keratin and LIM-domain binding protein IMAGE EST {IMAGE: 619950}1234.62ESTs {IMAGE: 367785}1244.58ESTs, Highly similar to HYPOTHETICAL 13.5 KD PROTEIN C45G9.7 IN CHROMOSOME III[Caenorhabditis elegans] {IMAGE: 572510}1254.58neuronal-associated protein IMAGE EST {IMAGE: 356215}1264.55CD81 ANTIGEN {IMAGE: 775893}1274.55IMAGE EST {IMAGE: 846536}1284.54sarcosine/dimethylglycine dehydrogenase IMAGE EST {IMAGE: 420641}1294.54LL56-APP chromosome region ESTs {IMAGE: 762558}1304.54IMAGE EST {IMAGE: 478571}1314.54IMAGE EST {IMAGE: 617884}1324.49Mouse spi2 proteinase inhibitor (spi2/eb1) mRNA, 3′ end {IMAGE: 406295}1334.40Mus musculus sodium-calcium exchanger (NCX1) mRNA, complete cds {IMAGE: 808226}1344.40vinculin IMAGE EST {IMAGE: 765332}1354.38ESTs, Highly similar to homologue of Drosophila Fat protein [H. sapiens] {IMAGE: 888553}1364.37Lumican {IMAGE: 746644}1374.34neurodegenration-associated protein 1 IMAGE EST {IMAGE: 752144}1384.31IMAGE EST {IMAGE: 888571}1394.29Cyclin D2 {IMAGE: 424433}1404.29ESTs, Moderately similar to NECDIN [Mus musculus] {IMAGE: 401980}1414.26Transforming growth factor, beta induced, 68 kDa {IMAGE: 734101}1424.25drebrinE IMAGE EST {IMAGE: 367915}1434.25TALIN {IMAGE: 480684}1444.19Ste-20-like protein kinase IMAGE EST {IMAGE: 622914}1454.18UV-B-activated transcript, polyionic rod in melanoma IMAGE EST {IMAGE: 903370}1464.17ESTs, Highly similar to ENDOTHELIAL ACTIN-BINDING PROTEIN [Homo sapiens] {IMAGE:427360}1474.17IMAGE EST {IMAGE: 402800}1484.16IMAGE EST {IMAGE: 762159}1494.16IMAGE EST {IMAGE: 762339}1504.15NMDA-receptor glutamate-binding chain IMAGE EST {IMAGE: 439108}1514.15Keratin complex 1, acidic, gene 19 {IMAGE: 464060}1524.15IMAGE EST {IMAGE: 763103}1534.14protein kinase C-binding protein beta IMAGE EST {IMAGE: 535763}1544.13lipid-binding morphogenesis protein IMAGE EST {IMAGE: 820204}1554.12ESTs {IMAGE: 373000}1564.12IMAGE EST {IMAGE: 402995}1574.08methyl-CpG binding protein MBD2 ESTs {IMAGE: 891284}1584.08Murine Hox2.2 mRNA for a homeobox protein {IMAGE: 439758}1594.08IMAGE EST {IMAGE: 425409}1604.08TALIN {IMAGE: 334872}1614.08Serine/Threonine protein kinase 11 IMAGE EST {IMAGE: 388477}1624.08Myosin light chain, alkali, cardiac atria {IMAGE: 444059}1634.07frizzled homolog IMAGE EST {IMAGE: 619970}1644.06CD24a antigen {IMAGE: 421150}1654.06Avian erythroblastic leukemia viral (v-erb-a) oncogene homolog-like 3 {IMAGE: 420535}1664.06Transcription factor 12 {IMAGE: 405907}1674.04debrin IMAGE EST {IMAGE: 467560}1684.04CAG trinucleotide repeat protein IMAGE EST {IMAGE: 851638}1694.00membrane glycoprotein M6 major CNS myelin protein PLP/DM20 homolog IMAGE EST {IMAGE:735527}1703.99Npc1/mbac6/orphan nuclear hormone receptor/RAR-responsive/PHD-Zn-finger IMAGE EST {IMAGE:422403}1713.94Proprotein convertase subtilisin/kexin type 3 {IMAGE: 680455}1723.94Erythrocyte protein band 7.2 {IMAGE: 419756}1733.93nucleophosmin P-protein integral nuclear envelope inner membrane protein IMAGE EST {IMAGE:423593}1743.93actin-binding protein IMAGE EST {IMAGE: 408110}1753.92Ras-like protein 2 IMAGE EST {IMAGE: 573845}1763.91steroid oxidoreductase IMAGE EST {IMAGE: 427205}1773.87Cadherin 2 {IMAGE: 467313}1783.86Mouse calcineurin catalytic subunit mRNA, complete cds {IMAGE: 620546}1793.85PDGF-beta receptor-like tumor suppressor IMAGE EST {IMAGE: 463249}1803.84ESTs, Highly similar to CAMP-DEPENDENT PROTEIN KINASE TYPE I-ALPHA REGULATORYCHAIN [Homo sapiens] {IMAGE: 949663}1813.83Mus musculus MPS1 gene and mRNA, 3′ end {IMAGE: 747364}1823.80IMAGE EST {IMAGE: 482198}1833.78IMAGE EST {IMAGE: 317958}1843.77Mus musculus endothelial monocyte-activating polypeptide I mRNA, complete cds {IMAGE: 669969}1853.73Tenascin C {IMAGE: 736372}1863.73matrix-associated protein/hbrm IMAGE EST {IMAGE: 620101}1873.73M. musculus mRNA for selenoprotein P {IMAGE: 777018}1883.72receptor transcriptional regulator IMAGE EST {IMAGE: 572601}1893.69Twist gene homolog, (Drosophila) {IMAGE: 331264}1903.66OASIS protein IMAGE EST {IMAGE: 478428}1913.66P63 transmembrane protein ER-Golgi intermediate compartment IMAGE EST {IMAGE: 765338}1923.62IMAGE EST {IMAGE: 657528}1933.61ESTs {IMAGE: 425279}1943.59IMAGE EST {IMAGE: 734718}1953.59Mus musculus HIC-5 mRNA, complete cds {IMAGE: 426146}1963.58Zn-finger Mok-2 IMAGE EST {IMAGE: 385763}1973.57C1q C-chaincontains integrin receptor RGD site IMAGE EST {IMAGE: 426010}1983.57polyhomeotic mPH2 polycomb group homolog IMAGE EST {IMAGE: 388233}1993.55M. musculus mRNA for Ulip protein {IMAGE: 335572}2003.55Platelet derived growth factor receptor, alpha polypeptide {IMAGE: 479895}2013.55thyroid receptor interactor IMAGE EST {IMAGE: 385581}2023.54Mus musculus metalloprotease/disintegrin/cysteine rich protein precursor (MDC9) cDNA, complete cds{IMAGE: 644907}2033.53IMAGE EST {IMAGE: 482326}2043.53latrophilin IMAGE EST {IMAGE: 637078}2053.52IMAGE EST {IMAGE: 425777}2063.52Ftp-1 tyrosine phosphatase IMAGE EST {IMAGE: 400530}2073.52GABA receptor K/Cl cotransporter IMAGE EST {IMAGE: 634792}2083.52ESTs {IMAGE: 870973}2093.49Mouse calcineurin catalytic subunit mRNA, complete cds {IMAGE: 699236}2103.49hexo-, glucokinase regulator IMAGE EST {IMAGE: 466591}2113.48TALIN {IMAGE: 676376}2123.48ESTs {IMAGE: 621555}2133.47TIS11B PROTEIN {IMAGE: 671377}2143.47KIAA0444 Zn-finger helicase fucosyltransferase IMAGE EST {IMAGE: 833346}2153.44Cyclin G {IMAGE: 849762}2163.43adhesion/cytoskeletal IMAGE EST {IMAGE: 331794}2173.42Annexin VI, p68 {IMAGE: 775597}2183.42cathepsin C-like transmembrane protein IMAGE EST {IMAGE: 480854}2193.40phospholipase C guanylate cyclase regulator IMAGE EST {IMAGE: 404044}2203.39Mus musculus neural precursor cell expressed developmentally downregulated Nedd9 (Nedd9) mRNA,complete cds {IMAGE: 404536}2213.39GATA-GT2 Zn-finger IMAGE EST {IMAGE: 368189}2223.38ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 {IMAGE: 318735}2233.38endothelial actin-binding protein IMAGE EST {IMAGE: 466292}2243.36IMAGE EST {IMAGE: 652207}2253.36similar to infant human clone 23587 from brain IMAGE EST {IMAGE: 807727}2263.35ESTs, Highly similar to COMPLEMENT C1R COMPONENT PRECURSOR [Homo sapiens]{IMAGE: 720566}2273.34IMAGE EST {IMAGE: 871674}2283.34IMAGE EST {IMAGE: 777549}2293.32KIAA0992 neuronal SIH002 IMAGE EST {IMAGE: 763629}2303.32Secreted frizzled-related sequence protein 3 {IMAGE: 803404}2313.32semaphorin nucleolar trafficking P-protein MyD118 IMAGE EST {IMAGE: 466988}2323.31IMAGE EST {IMAGE: 483148}2333.31ESTs {IMAGE: 480236}2343.31protocadherin 2C ESTs {IMAGE: 850280}2353.31ALPHA-MANNOSIDASE II {IMAGE: 315962}2363.30Cyclin G {IMAGE: 523713}2373.30VITAMIN K-DEPENDENT PROTEIN S PRECURSOR {IMAGE: 681615}2383.28Mus musculus mRNA for collagen a1(V), complete cds {IMAGE: 425344}2393.27bone morphogenic protein-like IMAGE EST {IMAGE: 492502}2403.26Decay accelerating factor 1 {IMAGE: 407096}2413.25IMAGE EST {IMAGE: 634233}2423.24IMAGE EST {IMAGE: 478021}2433.24IMAGE EST {IMAGE: 660896}2443.22FBJ osteosarcoma oncogene {IMAGE: 426070}2453.21T-cell surface glycoprotein E2 precursor IMAGE EST {IMAGE: 693148}2463.21Matrix metalloproteinase 2 {IMAGE: 762791}2473.21IMAGE EST {IMAGE: 465043}2483.21IMAGE EST {IMAGE: 427469}2493.19B-cell translocation gene 2, anti-proliferative {IMAGE: 334106}2503.18reductase IMAGE EST {IMAGE: 419544}2513.18IMAGE EST {IMAGE: 479921}2523.18IMAGE EST {IMAGE: 735227}2533.17lysosomal acid lipase cholesteryl ester hydrolase precursor IMAGE EST {IMAGE: 618910}2543.16ESTs, Weakly similar to ACTIN POLYMERIZATION INHIBITOR [Gallus gallus] {IMAGE: 426965}2553.16Mouse spi2 proteinase inhibitor (spi2/eb1) mRNA, 3′ end {IMAGE: 640951}2563.15ESTs {IMAGE: 677488}2573.15Peripheral myelin protein, 22 kDa {IMAGE: 846064}2583.15IMAGE EST {IMAGE: 330595}2593.15Frizzled homolog 4, (Drosophila) {IMAGE: 808829}2603.15IMAGE EST {IMAGE: 464915}2613.14cadherin-related tumour-suppressor precursor IMAGE EST {IMAGE: 478336}2623.12Cathepsin C {IMAGE: 876326}2633.11Mus musculus DTEF-1 mRNA, complete cds {IMAGE: 367947}2643.10IMAGE EST {IMAGE: 581835}2653.09IMAGE EST {IMAGE: 333511}2663.09voltage-gated calcium channel alpha-1-G subunit IMAGE EST {IMAGE: 475631}2673.08ESTs, Weakly similar to TROPOMYOSIN, FIBROBLAST ISOFORM 2 [M. musculus] {IMAGE:643158}2683.08HIV1-like outer envelope glycoprotein IMAGE EST {IMAGE: 749482}2693.07IMAGE EST {IMAGE: 480454}2703.07IMAGE EST {IMAGE: 760918}2713.06IMAGE EST {IMAGE: 751020}2723.06Reticulocalbin {IMAGE: 444388}2733.06myocyte-specific enhancer-binding factor 2 IMAGE EST {IMAGE: 751385}2743.05h2-calponin IMAGE EST {IMAGE: 402348}2753.05nuclear targeting fetal brain HRIHFB2007 IMAGE EST {IMAGE: 420553}2763.04IMAGE EST {IMAGE: 622257}2773.04IMAGE EST {IMAGE: 920587}2783.03prenylated CAAX box 1 Na—CaK regulated IMAGE EST {IMAGE: 696542}2793.03LMP-2 IMAGE EST {IMAGE: 464575}2803.03M. musculus mRNA for MAP kinase-activated protein kinase 2 {IMAGE: 354859}2813.02convertase oxidoreductase IMAGE EST {IMAGE: 439383}2823.01receptor-tyrosinase IMAGE EST {IMAGE: 764649}2833.01IMAGE EST {IMAGE: 315890}2843.01lipocortin p68 IMAGE EST {IMAGE: 876698}2853.01metallocarboxypeptidase CPX-1 IMAGE EST {IMAGE: 736854}2863.01IMAGE EST {IMAGE: 722330}2873.00T-cell leukemia virus enhancer factor IMAGE EST {IMAGE: 444383}2883.00tropomyosin-4 IMAGE EST {IMAGE: 890486}2893.00kinase IMAGE EST {IMAGE: 680191}2902.99Nidogen {IMAGE: 698175}2912.98Mouse mRNA for plexin 2, complete cds {IMAGE: 922991}2922.97ESTs {IMAGE: 638401}2932.96IMAGE EST {IMAGE: 385853}2942.95ESTs {IMAGE: 388617}2952.95Homeo box, msh-like 2 {IMAGE: 444842}2962.95Mouse surfeit locus surfeit 4 protein mRNA, complete cds {IMAGE: 316113}2972.94Calcium channel, voltage-dependent, L type, alpha 2 delta subunit {IMAGE: 890932}2982.93myeloid cell line protein IMAGE EST {IMAGE: 420591}2992.93TOAD-64/unc-33 IMAGE EST {IMAGE: 331768}3002.93Zn-finger P-interacting IMAGE EST {IMAGE: 864361}3012.93ESTs, Moderately similar to lysosomal pepstatin insensitive protease [H. sapiens] {IMAGE: 574070}3022.93BIG-1 (TAG-1/F2 Ig) IMAGE EST {IMAGE: 334291}3032.92receptor IMAGE EST {IMAGE: 482677}3042.92ESTs {IMAGE: 524459}3052.91Zn-finger protein 36 IMAGE EST {IMAGE: 466781}3062.91Lysyl oxidase {IMAGE: 418645}3072.90IMAGE EST {IMAGE: 418766}3082.90ESTs, Highly similar to LZIP-1 and LZIP-2 [M. musculus] {IMAGE: 680426}3092.90ESTs, Moderately similar to lysosomal pepstatin insensitive protease [H. sapiens] {IMAGE: 776048}3102.90neuronal cell adhesion channel with kinase/oxidase activity IMAGE EST {IMAGE: 464603}3112.89IMAGE EST {IMAGE: 419265}3122.89NAD/FAD-binding IMAGE EST {IMAGE: 406999}3132.89C4/C2-activating component of Ra-reactive factor (p100) {IMAGE: 419455}3142.88NUCLEOBINDIN PRECURSOR {IMAGE: 390016}3152.88bup in lymphomagenesis co-regulates c-myc IMAGE EST {IMAGE: 331599}3162.88Amino acid transporter, cationic 2 (low affinity) {IMAGE: 693244}3172.87IMAGE EST {IMAGE: 408747}3182.87IMAGE EST {IMAGE: 775514}3192.86neuronal receptor fibrin-interacting IMAGE EST {IMAGE: 733937}3202.86IMAGE EST {IMAGE: 777555}3212.86p53-regulated PA26-T1/2/3 nuclear (nt-binding) protein IMAGE EST {IMAGE: 420049}3222.85neuronal calcium channel/electron transfer IMAGE EST {IMAGE: 720937}3232.85Kinesin heavy chain member 1A {IMAGE: 492514}3242.85Mus musculus mel (MEL91) mRNA, complete cds {IMAGE: 337618}3252.85IMAGE EST {IMAGE: 536634}3262.85intercellular signal transducer/transmitter Fz-1 IMAGE EST {IMAGE: 459284}3272.84myosin-interacting IMAGE EST {IMAGE: 408381}3282.84contains E. coli sequences IMAGE EST {IMAGE: 420484}3292.83ESTs, Moderately similar to bone-derived growth factor [H. sapiens] {IMAGE: 458802}3302.83IMAGE EST {IMAGE: 425742}3312.82death (apoptosis)-associated protein kinase-1 IMAGE EST {IMAGE: 932999}3322.82ESTs, Weakly similar to C01A2.5 [C. elegans] {IMAGE: 735647}3332.81Sec24 protein IMAGE EST {IMAGE: 634252}3342.81ESTs {IMAGE: 550700}3352.81galactoprotein b3 IMAGE EST {IMAGE: 597249}3362.81IMAGE EST {IMAGE: 620453}3372.81IMAGE EST {IMAGE: 464803}3382.81procollagen alpha2 chain IMAGE EST {IMAGE: 445075}3392.80collagen XIV IMAGE EST {IMAGE: 472722}3402.79ESTs {IMAGE: 738162}3412.79ESTs {IMAGE: 642114}3422.79Wingless-related MMTV integration site 3A {IMAGE: 426103}3432.79IMAGE EST {IMAGE: 764212}3442.78KIAA0382 KIAA0380 TIAM-1-like protein IMAGE EST {IMAGE: 523303}3452.78KIAA0671 IMAGE EST {IMAGE: 736017}3462.77IMAGE EST {IMAGE: 803488}3472.77Mus musculus FK506-binding protein (FKBP23) mRNA, complete cds {IMAGE: 656375}3482.77kinase growth modulator IMAGE EST {IMAGE: 920701}3492.76IMAGE EST {IMAGE: 492457}3502.76glycogen synthase kinase-3 beta IMAGE EST {IMAGE: 736232}3512.76Cell adhesion kinase {IMAGE: 424307}3522.76B-cell translocation gene 2, anti-proliferative {IMAGE: 583186}3532.75homeobox-containing similar to HoxA8, -B8, -D8 IMAGE EST {IMAGE: 418660}3542.74IMAGE EST {IMAGE: 493238}3552.74Amyloid beta (A4) precursor-like protein 2 {IMAGE: 876058}3562.74Mus musculus fibrillin 2 (fbn2) gene, complete cds {IMAGE: 617885}3572.74ESTs {IMAGE: 419185}3582.73IMAGE EST {IMAGE: 736526}3592.72Mus musculus liver carnitine palmitoyltransferase I mRNA, partial cds {IMAGE: 737898}3602.72Mus musculus mRNA for membrane type-2 matrix metalloproteinase, complete cds {IMAGE: 680964}3612.72beta-galactosidase alpha 2,6-sialyltransferase IMAGE EST {IMAGE: 481883}3622.71receptor IMAGE EST {IMAGE: 423599}3632.70IMAGE EST {IMAGE: 636407}3642.70AHPC/TSA protein thio-specific antioxidant peroxidase IMAGE EST {IMAGE: 481450}3652.70PITP kinase IMAGE EST {IMAGE: 599075}3662.70ESTs {IMAGE: 573052}3672.70ESTs {IMAGE: 464165}3682.70ESTs {IMAGE: 622039}3692.70Mouse procollagen type V alpha 2 (Col5a-2) mRNA, complete cds {IMAGE: 467107}3702.69MBLL C3H Zn-finger protein IMAGE EST {IMAGE: 807447}3712.69calcium-transporting ATPase plasma membrane IMAGE EST {IMAGE: 716523}3722.69kinase IMAGE EST {IMAGE: 733746}3732.69IMAGE EST {IMAGE: 817954}3742.68phosphatase PP2A 55 kDa regulatory subunit IMAGE EST {IMAGE: 466730}3752.68IMAGE EST {IMAGE: 763553}3762.68PEPTIDYL-PROLYL CIS-TRANS ISOMERASE C {IMAGE: 406947}3772.68cytoskeletal-associated lipid-interacting protein IMAGE EST {IMAGE: 622182}3782.68ephrin receptor/hormone signal mediator; splicing factor IMAGE EST {IMAGE: 422477}3792.67IMAGE EST {IMAGE: 949384}3802.67IMAGE EST {IMAGE: 777321}3812.67extracellular matrix-interacting, guanylate cyclase/ANF-like protein IMAGE EST {IMAGE: 475285}3822.66IMAGE EST {IMAGE: 493702}3832.65human fetal brain RIG-like 7-1 protein IMAGE EST {IMAGE: 536577}3842.65receptor-kinase protein IMAGE EST {IMAGE: 466255}3852.65N-copine I and III IMAGE EST {IMAGE: 466178}3862.65IMAGE EST {IMAGE: 464415}3872.65receptor tumour suppressor IMAGE EST {IMAGE: 423344}3882.63KIAA0964 IMAGE EST {IMAGE: 637333}3892.63Myosin heavy chain, skeletal muscle, embryonic {IMAGE: 439638}3902.63Cut (Drosphila)-like 1 {IMAGE: 458712}3912.63myeloid associated differentiation protein ESTs {IMAGE: 672859}3922.62Parathyroid hormone receptor {IMAGE: 467172}3932.61IMAGE EST {IMAGE: 400571}3942.61IMAGE EST {IMAGE: 355517}3952.61electron transfer IMAGE EST {IMAGE: 777529}3962.61pyruvate dehydrogenase kinase 2 p45 subunit IMAGE EST {IMAGE: 533405}3972.61IMAGE EST {IMAGE: 680761}3982.60IMAGE EST {IMAGE: 374296}3992.60tensin IMAGE EST {IMAGE: 774810}4002.60transmembrane protein adrenal-associated IMAGE EST {IMAGE: 582063}4012.59ESTs {IMAGE: 643905}4022.59IMAGE EST {IMAGE: 484125}4032.58DNA repair IMAGE EST {IMAGE: 332327}4042.58Guanine nucleotide binding protein, alpha stimulating {IMAGE: 717466}4052.58methyl-CpG binding protein MBD2 ESTs {IMAGE: 421592}4062.57Max-interacting transcriptional represser IMAGE EST {IMAGE: 583632}4072.57Glycoprotein galactosyltransferase alpha 1, 3 {IMAGE: 618535}4082.57phosphatidylinositol-3-kinase regulator IMAGE EST {IMAGE: 761605}4092.56AP-1 regulated gene product IMAGE EST {IMAGE: 693542}4102.56Prostaglandin E receptor EP1 subtype {IMAGE: 751958}4112.56c-Maf IMAGE EST {IMAGE: 749073}4122.56Mannosidase 2, alpha B1 {IMAGE: 484259}4132.56Fus-2 tumour suppressor IMAGE EST {IMAGE: 479920}4142.55ESTs {IMAGE: 891260}4152.55ESTs {IMAGE: 478904}4162.54thymus-associated proteins IMAGE EST {IMAGE: 597342}4172.54preprotakykinin peptide receptor IMAGE EST {IMAGE: 439399}4182.54IMAGE EST {IMAGE: 638302}4192.53Lamin A {IMAGE: 524119}4202.53glutamat aspartate transporter IMAGE EST {IMAGE: 864344}4212.53channel/receptor IMAGE EST {IMAGE: 695508}4222.53talin IMAGE EST {IMAGE: 467480}4232.52ESTs, Highly similar to TRANSLOCON-ASSOCIATED PROTEIN, GAMMA SUBUNIT [Rattusnorvegicus] {IMAGE: 404526}4242.52microtubule vesicle linker clip protein IMAGE EST {IMAGE: 439732}4252.51growth factor signalling antagonist IMAGE EST {IMAGE: 403274}4262.51CaM-regulated CoA-utilizing enzyme IMAGE EST {IMAGE: 426493}4272.51IMAGE EST {IMAGE: 576974}4282.50cytoskeleton-interacting protein IMAGE EST {IMAGE: 720567}4292.50trithorax homolog/Rb-related p130 homolog IMAGE EST {IMAGE: 478156}4302.49G-protein gamma7 subunit IMAGE EST {IMAGE: 641871}4312.49Protein tyrosine phosphatase, receptor type, A {IMAGE: 622319}4322.49zinc finger MBNL protein ESTs {IMAGE: 717910}4332.49nuclear proto-oncogene protease inhibitor lipid-binding IMAGE EST {IMAGE: 476653}4342.48ESTs {IMAGE: 387151}4352.48tumour suppressor IMAGE EST {IMAGE: 762532}4362.48ESTs {IMAGE: 762728}4372.48c-fos IMAGE EST {IMAGE: 439803}4382.48ESTs {IMAGE: 874540}4392.47GP25L2 protein IMAGE EST {IMAGE: 831744}4402.47IMAGE EST {IMAGE: 764518}4412.47Mus musculus brain fatty acid-binding protein (B-FABP) gene, complete cds {IMAGE: 436894}4422.47IMAGE EST {IMAGE: 473770}4432.46IMAGE EST {IMAGE: 438506}4442.46EF-hand calcium-binding p22 IMAGE EST {IMAGE: 580505}4452.46P24A membrane protein IMAGE EST {IMAGE: 582571}4462.46Erythrocyte protein band 7.2 {IMAGE: 481880}4472.46ESTs, Highly similar to GLYCINE AMIDINOTRANSFERASE PRECURSOR [R. norvegicus] {IMAGE:478521}4482.46KIAA0470 IMAGE EST {IMAGE: 421537}4492.45transmembrane receptor IMAGE EST { IMAGE: 809031}4502.45Sel1l-negative regulator of notch IMAGE EST {IMAGE: 390236}4512.44NDP transporter/receptor IMAGE EST {IMAGE: 733517}4522.44ESTs {IMAGE: 597547}4532.44laminin-beta IMAGE EST {IMAGE: 418495}4542.43Mus musculus caveolin-1 mRNA, complete cds {IMAGE: 331186}4552.43Mus musculus protein co-factor mRNA, complete cds {IMAGE: 694133}4562.43ESTs, Highly similar to hypertension-related protein [R. norvegicus] {IMAGE: 776562}4572.43Mus musculus WSB-1 mRNA, complete cds {IMAGE: 619201}4582.42GalBeatGalNAcAlpha sialyltransferase IMAGE EST {IMAGE: 418453}4592.42Mok-2 Zn-finger protein IMAGE EST {IMAGE: 440843}4602.41Mus musculus LIM protein FHL2 (Fhl2) mRNA, complete cds {IMAGE: 457264}4612.41IMAGE EST {IMAGE: 332687}4622.41ESTs {IMAGE: 598305}4632.41synaptomagnin, protein kinase C, and guanyl-binding protein IMAGE EST {IMAGE: 466905}4642.40arginine methyltransferase hnRNP IMAGE EST {IMAGE: 574888}4652.40ESTs, Moderately similar to Similar to a C. elegans protein in cosmid C14H10 [H. sapiens] {IMAGE:679641}4662.40IMAGE EST {IMAGE: 734062}4672.40IMAGE EST {IMAGE: 576216}4682.40MAD homolog 1 (Drosophila) {IMAGE: 620333}4692.39protease IMAGE EST {IMAGE: 441276}4702.39ApoA4-like, -regulating protein IMAGE EST {IMAGE: 476019}4712.39ESTs, Highly similar to ER LUMEN PROTEIN RETAINING RECEPTOR 2 [Homo sapiens] {IMAGE:354601}4722.39tropomyosin-like IMAGE EST {IMAGE: 474107}4732.39desmoplakin I and I IMAGE EST {IMAGE: 420709} I4742.38Mus musculus mRNA for Rab33B, complete cds {IMAGE: 621389}4752.38cell surface protein, yeast YKKO-like IMAGE EST {IMAGE: 717316}4762.38WD40 repeat protein IMAGE EST {IMAGE: 493109}4772.37Aryl-hydrocarbon receptor {IMAGE: 403384}4782.37IMAGE EST {IMAGE: 483024}4792.37BS69 IMAGE EST {IMAGE: 572889}4802.37ESTs, Moderately similar to developmentally regulated protein [R. norvegicus] {IMAGE: 733557}4812.37Protein kinase, cAMP dependent, catalytic, beta {IMAGE: 478265}4822.36src SH3-binding ADP-ribosylation factor-directed GTPase activating protein IMAGE EST {IMAGE:423915}4832.36IMAGE EST {IMAGE: 695447}4842.36IMAGE EST {IMAGE: 640875}4852.36N-acetylglucosamine-sulphatase precursor IMAGE EST {IMAGE: 480526}4862.36rearranged lipid-interacting cell surface protein IMAGE EST {IMAGE: 696489}4872.36ESTs {IMAGE: 639911}4882.36KIAA0581 phospholipase C-beta1b IMAGE EST {IMAGE: 874154}4892.36Complement component factor h {IMAGE: 777640}4902.36IMAGE EST {IMAGE: 888624}4912.35IMAGE EST {IMAGE: 762542}4922.35ESTs, Weakly similar to VILLIN [Gallus gallus] {IMAGE: 875543}4932.35IMAGE EST {IMAGE: 439959}4942.35IMAGE EST {IMAGE: 749144}4952.35ESTs, Weakly similar to RING zinc finger protein [M. musculus] {IMAGE: 922965}4962.33ESTs {IMAGE: 721040}4972.33IMAGE EST {IMAGE: 480149}4982.33prothymosin-like IMAGE EST {IMAGE: 596754}4992.33cell adhesion regulator-1 IMAGE EST {IMAGE: 920211}5002.32IMAGE EST {IMAGE: 457289}5012.32Chondroitin sulfate proteoglycan 2 {IMAGE: 355990}5022.32dual-specific nuclear matrix tyrosine protein kinase IMAGE EST {IMAGE: 354506}5032.31regulator of TGF-beta-induced activity IMAGE EST {IMAGE: 424979}5042.31ESTs {IMAGE: 697506}5052.31IMAGE EST {IMAGE: 419788}5062.30Cystatin 3 {IMAGE: 402614}5072.30serine/threonine protein kinase IMAGE EST {IMAGE: 459254}5082.30myeloid associated differentiation protein ESTs {IMAGE: 672351}5092.29PSD-95/SAP90-associated protein-4 IMAGE EST {IMAGE: 466715}5102.29ESTs, Weakly similar to QUINONE OXIDOREDUCTASE [M. musculus] {IMAGE: 735186}5112.29lipase/synthetase IMAGE EST {IMAGE: 314394}5122.28IMAGE EST {IMAGE: 748241}5132.28IMAGE EST {IMAGE: 421973}5142.28ESTs {IMAGE: 621316}5152.28ESTs {IMAGE: 404339}5162.28Mus musculus krupple-related zinc finger protein (Emzfl) mRNA, complete cds {IMAGE: 764361}5172.28metal-binding protein IMAGE EST {IMAGE: 482328}5182.28ESTs, Moderately similar to HYPOTHETICAL 13.6 KD PROTEIN IN NUP170-ILS1 INTERGENICREGION [S. cerevisiae] {IMAGE: 775912}5192.28ESTs {IMAGE: 571643}5202.27Thymoma viral proto-oncogene {IMAGE: 678740}5212.27ESTs {IMAGE: 618644}5222.27Receptor interacting protein {IMAGE: 763021}5232.27ESTs, Weakly similar to coded for by C. elegans cDNA yk86e5.5 [C. elegans] {IMAGE: 641451}5242.26alcohol dehydrogenase IMAGE EST {IMAGE: 314127}5252.26Mus musculus caveolin-1 mRNA, complete cds {IMAGE: 596968}5262.26Mus musculus parathion hydrolase (phosphotriesterase)-related protein mRNA, complete cds {IMAGE:803358}5272.26ESTs, Highly similar to T-KININOGEN II PRECURSOR [Rattus norvegicus] {IMAGE: 390390}5282.26Mus musculus G protein-coupled receptor kinase 5 (GRK5) mRNA, complete cds {IMAGE: 875444}5292.25slit protein precursor IMAGE EST {IMAGE: 820354}5302.25Laminin, alpha 4 {IMAGE: 736616}5312.24integrin beta/elastin IMAGE EST {IMAGE: 876166}5322.24ESTs, Weakly similar to schwannoma-associated protein [M. musculus] {IMAGE: 904738}5332.23Mus musculus mRNA for mtprd, complete cds {IMAGE: 775150}5342.23ESTs, Highly similar to VACUOLAR ATP SYNTHASE SUBUNIT AC45 PRECURSOR [Bos taurus]{IMAGE: 671660}5352.23CALPONIN H1, SMOOTH MUSCLE {IMAGE: 373793}5362.22ESTs {IMAGE: 596200}5372.22IMAGE EST {IMAGE: 652498}5382.22IMAGE EST {IMAGE: 658233}5392.22ESTs {IMAGE: 442842}5402.22IMAGE EST {IMAGE: 774877}5412.22ESTs, Weakly similar to PROBABLE PROTEIN DISULFIDE ISOMERASE ER-60 PRECURSOR[M. musculus] {IMAGE: 421530}5422.22filament forming steroid-interacting protein IMAGE EST {IMAGE: 419553}5432.21IMAGE EST {IMAGE: 386236}5442.21excised intron-binding RNA IMAGE EST {IMAGE: 418531}5452.21smoothened seven transmembrane receptor growth regulator IMAGE EST {IMAGE: 439010}5462.21IMAGE EST {IMAGE: 643384}5472.21IMAGE EST {IMAGE: 464245}5482.20IMAGE EST {IMAGE: 718110}5492.20similar to H. sapiens chromosome 17 ESTs {IMAGE: 902264}5502.20Erythropoietin receptor {IMAGE: 718293}5512.19Calumenin {IMAGE: 523088}5522.19phosphoeicosinoid isomerase IMAGE EST {IMAGE: 423219}5532.19ESTs {IMAGE: 762782}5542.19Mus musculus tetraspanin Tspan-6 (Tspan-6) mRNA, complete cds {IMAGE: 572156}5552.19cerebroglycan IMAGE EST {IMAGE: 763989}5562.18RNA processing IMAGE EST {IMAGE: 463860}5572.18C1 channel protein P64 IMAGE EST {IMAGE: 670375}5582.18Mus musculus metalloprotease-disintegrin MDC15 mRNA, complete cds {IMAGE: 406689}5592.18IMAGE EST {IMAGE: 466155}5602.18ESTs {IMAGE: 622792}5612.18T-cell surface protein tactile precursor IMAGE EST {IMAGE: 597729}5622.17ESTs {IMAGE: 472407}5632.17Zn-finger TATA-box-binding protein associated factor (TAF) IMAGE EST {IMAGE: 765073}5642.16protocadherin IMAGE EST {IMAGE: 922216}5652.16Mus musculus Nip21 mRNA, complete cds {IMAGE: 677412}5662.16IMAGE EST {IMAGE: 722451}5672.16IMAGE EST {IMAGE: 846131}5682.16Zn-finger DNA-binding protein IMAGE EST {IMAGE: 762142}5692.16ESTs {IMAGE: 934635}5702.15Mus musculus sphingosine-1-phosphate lyase mRNA, complete cds {IMAGE: 332091}5712.15Cadherin 3 {IMAGE: 329780}5722.15ESTs {IMAGE: 574476}5732.15IMAGE EST {IMAGE: 476342}5742.15spindlin G-protein effector chaperone IMAGE EST {IMAGE: 482943}5752.15IMAGE EST {IMAGE: 680103}5762.14IMAGE EST {IMAGE: 574134}5772.14IMAGE EST {IMAGE: 334410}5782.14ESTs, Highly similar to S-100 PROTEIN, ALPHA CHAIN [Rattus norvegicus] {IMAGE: 872869}5792.13KIAA0623 Unc-51-like kinase 2 IMAGE EST {IMAGE: 749776}5802.13ESTs, Moderately similar to Similar to a C. elegans protein in cosmid C14H10 [H. sapiens] {IMAGE:749282}5812.13Glycoprotein 49 B {IMAGE: 820498}5822.13IMAGE EST {IMAGE: 317778}5832.13Catenin Src {IMAGE: 439784}5842.13retinal protein IMAGE EST {IMAGE: 426076}5852.12KIAA0613 enigma/LIM2 IMAGE EST {IMAGE: 336726}5862.12ESTs {IMAGE: 479750}5872.12IMAGE EST {IMAGE: 353229}5882.12MADS/MEF2family transcription factor IMAGE EST {IMAGE: 777101}5892.11myosin light chain, slow-twitch isoform IMAGE EST {IMAGE: 330370}5902.11NG, NG-dimethylargine dimethylaminohydrolase IMAGE EST {IMAGE: 656701}5912.11IMAGE EST {IMAGE: 622653}5922.11kinetocore growth-associated containing B1-repeat (rodent) IMAGE EST {IMAGE: 425348}5932.11Gt12 myogenic and CNS development GPCR IMAGE EST {IMAGE: 423177}5942.11endothelin-converting enzyme-1 IMAGE EST {IMAGE: 419633}5952.10PAK2, caspase 3 substrate, apoptosis-related ESTs {IMAGE: 635569}5962.10ESTs {IMAGE: 493460}5972.10Ig lambda chain C region IMAGE EST {IMAGE: 777306}5982.10G-protein interacting receptor IMAGE EST {IMAGE: 761298}5992.10cytoskeletal protein IMAGE EST {IMAGE: 479846}6002.10IMAGE EST {IMAGE: 595978}6012.10IMAGE EST {IMAGE: 850389}6022.10Similar to tip of human chromosome 16 ESTs {IMAGE: 888687}6032.10Neurotrophic tyrosine kinase, receptor, type 3 {IMAGE: 478848}6042.10KIAA0662 RAR-inducible factor growth arrest IMAGE EST {IMAGE: 477665}6052.09IMAGE EST {IMAGE: 421653}6062.09Krupple-associated box (KRAB)-containing Zn-finger IMAGE EST {IMAGE: 622359}6072.09membrane protein IMAGE EST {IMAGE: 637536}6082.09Mast cell protease 5 {IMAGE: 425653}6092.09IMAGE EST {IMAGE: 641660}6102.09Mus musculus Ena-VASP like protein (Ev1) mRNA, complete cds {IMAGE: 477177}6112.08similar to heart-derived DNA ESTs {IMAGE: 419846}6122.08Fyn protooncogene {IMAGE: 385072}6132.08IMAGE EST {IMAGE: 935626}6142.08Thrombospondin 3 {IMAGE: 483763}6152.07semaphorin III cdc-like NAD/FAD-binding protein IMAGE EST {IMAGE: 476321}6162.07Mus musculus uncoupling protein homolog (UCPH) mRNA, complete cds {IMAGE: 748112}6172.07Zinc finger protein 36 {IMAGE: 641523}6182.07IMAGE EST {IMAGE: 422094}6192.07Mus musculus palmitoyl-protein thioesterase precursor, mRNA, complete cds {IMAGE: 637934}6202.07Mus musculus syntaxin 7 (Syn7) mRNA, complete cds {IMAGE: 468472}6212.07homeobox-containing Janus kinase (Jak3) tyrosine kinase IMAGE EST {IMAGE: 641806}6222.06Notch2-like EGF-repeat transmembrane protein IMAGE EST {IMAGE: 621352}6232.06CoA: amino acid N-acyltransferase IMAGE EST {IMAGE: 775722}6242.06voltage-gated calcium channel IMAGE EST {IMAGE: 638593}6252.06KIAA0198 myoblast Zn-finger protein IMAGE EST {IMAGE: 406222}6262.06Trg gene product IMAGE EST {IMAGE: 583823}6272.06hypothalamic estrogen-induced geme in female adult rat IMAGE EST {IMAGE: 571503}6282.06Mus musculus S182 protein mRNA, complete cds {IMAGE: 681670}6292.06ADP-ribosylation factor 2 ESTs {IMAGE: 721482}6302.06Mus musculus mRNA for NBAT, complete cds {IMAGE: 776770}6312.05neuronal glucose transporter IMAGE EST {IMAGE: 423210}6322.05glycophorin C IMAGE EST {IMAGE: 598956}6332.04CaM-1 IMAGE EST {IMAGE: 660997}6342.04KIAA0317 IMAGE EST {IMAGE: 751729}6352.04receptor tyrosine phosphatase IMAGE EST {IMAGE: 535228}6362.04IMAGE EST {IMAGE: 464134}6372.04bone morphogenic protein 5 precursor/Vgr-1 protein IMAGE EST {IMAGE: 737934}6382.04ESTs, Highly similar to unknown [M. Musculus] {IMAGE: 697509}6392.04erythrocyte protein 4.2 IMAGE EST {IMAGE: 481375}6402.03Calcium channel beta 3 subunit {IMAGE: 420487}6412.03RP58 Zn-finger POZ-domain IMAGE EST {IMAGE: 574756}6422.03Janus kinase 2 {IMAGE: 621226}6432.03IMAGE EST {IMAGE: 480431}6442.03Zn-finger protein 22 IMAGE EST {IMAGE: 427349}6452.03beta-TrCP ESTs {IMAGE: 699290}6462.03M. musculus rhoC mRNA {IMAGE: 670886}6472.03thyroid receptor interactor IMAGE EST {IMAGE: 385725}6482.03IMAGE EST {IMAGE: 818435}6492.03Mus musculus liver carnitine palmitoyltransferase I mRNA, partial cds {IMAGE: 717056}6502.03KIAA0630 IMAGE EST {IMAGE: 385435}6512.02Fos-related antigen2 IMAGE EST {IMAGE: 445817}6522.02IMAGE EST {IMAGE: 949003}6532.02retinaldehyde-binding parathyroid hormone-regulted protein IMAGE EST {IMAGE: 478711}6542.02ADP-ribosylation factor (LAK) IMAGE EST {IMAGE: 387594}6552.02IMAGE EST {IMAGE: 746888}6562.02acetylcholine-interacting channel transcription factor IMAGE EST {IMAGE: 474184}6572.02IMAGE EST {IMAGE: 423531}6582.02ESTs, Moderately similar to ACYL-COA-BINDING PROTEIN [Bos taurus] {IMAGE: 463575}6592.02similar to cab-1 gene (chlorophyll a/b-binding protein) ESTs {IMAGE: 948588}6602.01IMAGE EST {IMAGE: 464866}6612.01NAPOR neuroblastoma SH—SY-5y apoptosis RNA-binding protein IMAGE EST {IMAGE: 597832}6622.01ESTs, Weakly similar to MATRIN 3 [R. norvegicus] {IMAGE: 876381}6632.01ESTs {IMAGE: 905429}6642.01neuronal calcium sensor-1 IMAGE EST {IMAGE: 401764}6652.00GlaNAc-T2 sialytransferase IMAGE EST {IMAGE: 347921}6662.00Protein kinase, cAMP dependent regulatory, type I beta {IMAGE: 736724}6672.00GABA receptor IMAGE EST {IMAGE: 618375}6682.00RNA stability IMAGE EST {IMAGE: 402843}6692.00nucleolysin Tia-1 IMAGE EST {IMAGE: 751577}6702.00ESTs, Moderately similar to golgi peripheral membrane protein p65 [R. norvegicus] {IMAGE: 677054}6712.00liprin tyrosine phosphatase (LAR)-interacting protein IMAGE EST {IMAGE: 695231}6722.00Mouse putative guanylate binding protein mRNA, complete cds {IMAGE: 576022}6732.00regulator of G-protein signaling 12 IMAGE EST {IMAGE: 536574}6740.51brain-specific p25 alpha CGI-38 protein homolog containing huntingtin regulatory element IMAGE EST{IMAGE: 888544}6750.50KIAA0098 chaperonin-containing TCP-1 epsilon protein folding subunit IMAGE EST {IMAGE:576003}6760.50mitotic control protein IMAGE EST {IMAGE: 642330}6770.50DIFF6 PROTEIN {IMAGE: 334138}6780.50proliferation-associated mago-nashi protein homolog IMAGE EST {IMAGE: 751348}6790.50KIAA1007 RE1-silencing Zn-finger transcription factor IMAGE EST {IMAGE: 479576}6800.50TYRO3 protein tyrosine kinase 3 {IMAGE: 351163}6810.50ESTs, Highly similar to ATP SYNTHASE F CHAIN, MITOCHONDRIAL [M. musculus] {IMAGE:403660}6820.50bTF2 35 kDA subunit IMAGE EST {IMAGE: 671530}6830.50NAD(P)H menadione oxidoreductase 1, dioxin inducible {IMAGE: 532186}6840.50antisense to S-AdMet decarboxylase, c-Abl, Munc18-1, MHC locus IMAGE EST {IMAGE: 934425}6850.50Zn-finger FIZ1-B splice variant IMAGE EST {IMAGE: 476367}6860.50ESTs, Highly similar to HYPOTHETICAL 29.2 KD PROTEIN IN PHD1-PTM1 INTERGENICREGION [Saccharomyces cerevisiae] {IMAGE: 736297}6870.50SPARC-related gene IMAGE EST {IMAGE: 425523}6880.50IMAGE EST {IMAGE: 636193}6890.50ESTs, Highly similar to HYPOTHETICAL 51.6 KD PROTEIN F59B2.5 IN CHROMOSOME III[Caenorhabditis elegans] {IMAGE: 833508}6900.50ESTs, Moderately similar to cell cycle progression 2 protein [H. sapiens] {IMAGE: 656956}6910.50M. musculus mRNA for calpain-like protease {IMAGE: 733856}6920.50ESTs, Weakly similar to No definition line found [C. elegans] {IMAGE: 820430}6930.50DRIM (down-regulated in metastasis) IMAGE EST {IMAGE: 616975}6940.50ESTs, Moderately similar to 26 S protease subunit 5b {IMAGE: 418563}6950.50KIAA0402/pericentrin contains element common in erbB2/erbB3 ESTs {IMAGE: 640026}6960.50KIAA1007 RE1-silencing transcription factor IMAGE EST {IMAGE: 948662}6970.50IMAGE EST {IMAGE: 894275}6980.50ESTs {IMAGE: 737800}6990.50Early growth response 1 {IMAGE: 833284}7000.50Mus musculus calmodulin-binding protein SHA1 (Sha1) mRNA, complete cds {IMAGE: 791460}7010.50NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 1 {IMAGE: 671801}7020.50ESTs, Highly similar to ELONGATION FACTOR G, MITOCHONDRIAL PRECURSOR [Rattusnorvegicus] {IMAGE: 889470}7030.50chromodomain helicase DNA-binding protein IMAGE EST {IMAGE: 472805}7040.50ESTs {IMAGE: 597797}7050.50IMAGE EST {IMAGE: 425442}7060.50pyridoxine 5′-phospho-oxidase IMAGE EST {IMAGE: 438286}7070.50IMAGE EST {IMAGE: 424618}7080.50ESTs, Highly similar to hypothetical protein, 100 K [R. norvegicus] {IMAGE: 808777}7090.50Mus musculus RNaseP protein p30 (Rpp30) mRNA, complete cds {IMAGE: 389279}7100.50Mouse mRNA for RPA16, complete cds {IMAGE: 425081}7110.50receptor IMAGE EST {IMAGE: 749766}7120.50SNF2L global transcription activator IMAGE EST {IMAGE: 791058}7130.50nuclear SURF-6 protein IMAGE EST {IMAGE: 699378}7140.50ESTs, Weakly similar to HYPOTHETICAL 11.4 KD PROTEIN C13G6.04 IN CHROMOSOME I[Schizosaccharomyces pombe] {IMAGE: 579733}7150.49tumour suppressing subtransferable candidate 1, RB-associated p48-like protein IMAGE EST {IMAGE:640062}7160.49fetal JUMONJI protein IMAGE EST {IMAGE: 761554}7170.49ESTs, Moderately similar to progesterone receptor-related protein p23 [H. sapiens] {IMAGE: 618630}7180.49KIAA0011 general transcription factor IIIC polypeptide 2 beta subunit 110 kDa IMAGE EST {IMAGE:390118}7190.49casein kinase II alpha chain ESTs {IMAGE: 735147}7200.49Mus musculus mRNA for G-protein coupled receptor kinase 6-B {IMAGE: 640178}7210.49IMAGE EST {IMAGE: 534015}7220.49tyrosine protein kinase associated protein IMAGE EST {IMAGE: 423081}7230.49ESTs, Weakly similar to KIAA0154 gene product is related to mouse gamma adaptin. [H. sapiens]{IMAGE: 400308}7240.49ligase/peptidase IMAGE EST {IMAGE: 751619}7250.49ESTs, Highly similar to SET PROTEIN [Homo sapiens] {IMAGE: 780092}7260.49Dipeptidase 1 (renal) {IMAGE: 316237}7270.49IMAGE EST {IMAGE: 476022}7280.49intermediary metabolism ESTs {IMAGE: 597201}7290.49neuronal pentraxin receptor IMAGE EST {IMAGE: 352795}7300.49INS-1 winged helix M-phase phosphoprotein IMAGE EST {IMAGE: 465555}7310.49HSPC005 hu Chr. 11 fetal spleen ESTs {IMAGE: 807462}7320.49mitogen-activated protein kinase IMAGE EST {IMAGE: 762210}7330.49Glycerol phosphate dehydrogenase 1, mitochondrial {IMAGE: 351221}7340.49alternatively spliced brain transcript IMAGE EST {IMAGE: 472664}7350.49IMAGE EST {IMAGE: 400408}7360.49IMAGE EST {IMAGE: 350881}7370.49ESTs {IMAGE: 424559}7380.48IMAGE EST {IMAGE: 573595}7390.48GART and AML locus of human Chr. 21q22.1 ESTs {IMAGE: 699377}7400.48Mus musculus mRNA for protein L. partial cds {IMAGE: 386234}7410.48Mus musculus U4/U6 snRNP 90 kDa protein gene, complete cds {IMAGE: 576991}7420.48ESTs {IMAGE: 317597}7430.48Rac GTPase-activating protein IMAGE EST {IMAGE: 577676}7440.48ESTs, Highly similar to ATP SYNTHASE LIPID-BINDING PROTEIN P2 PRECURSOR [Rattusnorvegicus] {IMAGE: 698109}7450.48IMAGE EST {IMAGE: 437685}7460.48T-complex testis expressed 1 {IMAGE: 762306}7470.48mitochondrial ATP-binding protein IMAGE EST {IMAGE: 354969}7480.48Mus musculus carbonic anhydrase IV gene, complete cds {IMAGE: 332285}7490.48mitochondrial hydroxymethylglutaryl-CoA synthase IMAGE EST {IMAGE: 464392}7500.48IMAGE EST {IMAGE: 406706}7510.48AT-rich ESTs {IMAGE: 804212}7520.48IMAGE EST {IMAGE: 581115}7530.48IMAGE EST {IMAGE: 315536}7540.48IMAGE EST {IMAGE: 639975}7550.48HSPC007 splice variant homolog IMAGE EST {IMAGE: 580166}7560.48cytokine remodeling-associated protein IMAGE EST {IMAGE: 482432}7570.48neuronal apotosis-inhibiting nuclear receptor transcription activator IMAGE EST {IMAGE: 697208}7580.47Lamin B2 {IMAGE: 478334}7590.47ESTs, Weakly similar to PROBABLE RNA HELICASE IN WAPA-LICT INTERGENIC REGION[Bacillus subtilis] {IMAGE: 403381}7600.47IMAGE EST {IMAGE: 779373}7610.47IMAGE EST {IMAGE: 441227}7620.47IMAGE EST {IMAGE: 746908}7630.47core-binding factor alpha subunit 2 MTGR1a (MTG-8-like protein) ESTs {IMAGE: 775188}7640.47ESTs, Highly similar to P80-COILIN [Homo sapiens] {IMAGE: 351869}7650.47ESTs, Highly similar to ARGINYL-TRNA SYNTHETASE [Cricetulus longicaudatus] {IMAGE:439640}7660.47hormone-releasing factor IMAGE EST {IMAGE: 620209}7670.47Syntrophin, acidic 1 {IMAGE: 318957}7680.47DNA polymerase delta small subunit IMAGE EST {IMAGE: 468823}7690.47ESTs {IMAGE: 618926}7700.47cleavage and polyadenylation specificity factor IMAGE EST {IMAGE: 353445}7710.47Mus musculus Btk locus, complete cds {IMAGE: 920442}7720.47ESTs {IMAGE: 443441}7730.47brain region-specific adenylate kinase 4 IMAGE EST {IMAGE: 403946}7740.47Mus musculus elongation factor 1-beta homolog mRNA, complete cds {IMAGE: 442662}7750.47Endoglin {IMAGE: 484299}7760.47inhibin-related protein IMAGE EST {IMAGE: 639902}7770.47melavonate pyrophosphate decarboxylase IMAGE EST {IMAGE: 479201}7780.47Ig heavy chain IMAGE EST {IMAGE: 961056}7790.47ESTs, Highly similar to CYCLIN-DEPENDENT KINASES REGULATORY SUBUNIT 1 [Homosapiens] {IMAGE: 961282}7800.47KIAA0664 Zn-finger transglutaminase IMAGE EST {IMAGE: 373505}7810.47ring finger protein 4 IMAGE EST {IMAGE: 894169}7820.47Importin beta {IMAGE: 419193}7830.47receptor channel protein IMAGE EST {IMAGE: 720904}7840.47EYA4 gene for eyes absent ESTs {IMAGE: 671169}7850.47IMAGE EST {IMAGE: 920335}7860.47ESTs {IMAGE: 638129}7870.46DNA damage tolerance protein IMAGE EST {IMAGE: 535949}7880.46Fibroblast inducible secreted protein {IMAGE: 336325}7890.46IMAGE EST {IMAGE: 577766}7900.46M. musculus AP-2.2 gene {IMAGE: 419886}7910.46contains neuronal survivor genes'' regulatory elements (apoptosis-inhibitory) ESTs {IMAGE: 750205}7920.46mitochondrial cyclophilin IMAGE EST {IMAGE: 483584}7930.46protein kinase A anchor protein 95 IMAGE EST {IMAGE: 523965}7940.46ESTs {IMAGE: 439665}7950.46phosphatidylglycerophosphate synthase IMAGE EST {IMAGE: 642201}7960.46IMAGE EST {IMAGE: 633284}7970.46ESTs, Highly similar to TRANSCRIPTION FACTOR BTF3 [Homo sapiens] {IMAGE: 692936}7980.46DNA-binding protein IMAGE EST {IMAGE: 572463}7990.46receptor IMAGE EST {IMAGE: 581799}8000.46Mus musculus G protein-coupled receptor mRNA, complete cds {IMAGE: 493202}8010.46IMAGE EST {IMAGE: 465848}8020.46Enabled homolog (Drosophila) {IMAGE: 653622}8030.46Mus musculus mRNA for pyruvate kinase, complete cds {IMAGE: 873690}8040.46ESTs, Highly similar to transcription factor NF-AT 45K chain [H. sapiens] {IMAGE: 368164}8050.46ESTs {IMAGE: 581834}8060.46IMAGE EST {IMAGE: 837565}8070.46Mouse mRNA for ras-GTPase-activating protein SH3-domain binding protein, complete cds {IMAGE:423772}8080.46seven transmembrane GPCR IMAGE EST {IMAGE: 747167}8090.46interleukin enhancer binding factor IMAGE EST {IMAGE: 571805}8100.46annexin homolog IMAGE EST {IMAGE: 476275}8110.46cdc25A ESTs {IMAGE: 641051}8120.46integral membrane gp210 nuclear pore protein IMAGE EST {IMAGE: 355445}8130.46heomeobox containing-like protein methylase IMAGE EST {IMAGE: 818653}8140.46Mus musculus mRNA for protein L, partial cds {IMAGE: 933939}8150.46ESTs, Highly similar to ELONGATION FACTOR 1-GAMMA [Homo sapiens] {IMAGE: 671075}8160.46ESTs, Highly similar to nucleoporin Nup84 [R. norvegicus] {IMAGE: 643755}8170.46ESTs, Weakly similar to C08F8.2 [C. elegans] {IMAGE: 577312}8180.46IMAGE EST {IMAGE: 439620}8190.46M. musculus mRNA for high mobility group 2 protein {IMAGE: 747136}8200.46ribose phosphate phosphokinase I ESTs {IMAGE: 679015}8210.46oocyte-specific protein P100 IMAGE EST {IMAGE: 445310}8220.46Mus musculus rho7 (rho7) mRNA, partial cds {IMAGE: 385746}8230.46ESTs, Highly similar to MITOCHONDRIAL ELONGATION FACTOR TS PRECURSOR [Homosapiens] {IMAGE: 699237}8240.45outer mitochondrial membrane protein translocase 34 kDa IMAGE EST {IMAGE: 693114}8250.45aldehyde dehyrogenase E3 isozyme IMAGE EST {IMAGE: 572614}8260.45retinal protein IMAGE EST {IMAGE: 482138}8270.45kinase-interacting protein IMAGE EST {IMAGE: 317894}8280.45Mouse mRNA for RNA polymerase II subuunit RPB14, complete cds {IMAGE: 636513}8290.45ribosomal protein L39 IMAGE EST {IMAGE: 620239}8300.45IMAGE EST {IMAGE: 443413}8310.45M. musculus mRNA for Pr22 protein {IMAGE: 716630}8320.45Nedd-4-like ubiquitin protein ligase regulator of Notch signaling pathway IMAGE EST {IMAGE:354910}8330.45IMAGE EST {IMAGE: 580810}8340.45M. musculus mRNA for mSUG1 {IMAGE: 480685}8350.45L-asparaginase IMAGE EST {IMAGE: 550910}8360.45Mus musculus CDK-activating kinase assembly factor p36/MAT1, complete cds {IMAGE: 480395}8370.45IMAGE EST {IMAGE: 871585}8380.45SH2-containing Nsp2 antiestrogen resistance 3 protein IMAGE EST {IMAGE: 465403}8390.45Mus musculus mRNA for 26S proteasome non-ATPase subunit {IMAGE: 747059}8400.45neurotropin-3 homolog IMAGE EST {IMAGE: 760832}8410.45KIAA0518 IMAGE EST {IMAGE: 424329}8420.45IT12 in Huntingon's disease region IMAGE EST {IMAGE: 834148}8430.45ESTs, Weakly similar to PROBABLE eIF 3 RNA-BINDING SUBUNIT [C. elegans] {IMAGE: 571406}8440.45CCAAT/enhancer binding protein alpha (C/EBP), related sequence 1 {IMAGE: 680123}8450.45decarboxylase/oxidase ESTs {IMAGE: 805129}8460.45IMAGE EST {IMAGE: 576901}8470.45KIAA0595 variant IMAGE EST {IMAGE: 336684}8480.45IMAGE EST {IMAGE: 577010}8490.45IMAGE EST {IMAGE: 733738}8500.45Replication factor C, 140 kDa {IMAGE: 420302}8510.45ESTs {IMAGE: 720951}8520.45GTP phosphate-binding protein IMAGE EST {IMAGE: 421129}8530.45basic transcription element binding protein BTEB-1 IMAGE EST {IMAGE: 472332}8540.45cdc-homolog IMAGE EST {IMAGE: 550649}8550.44similar to MBP ESTs {IMAGE: 775875}8560.44ADP-ribosylation factor IMAGE EST {IMAGE: 476610}8570.44ESTs {IMAGE: 580935}8580.44Secreted phosphoprotein 1 {IMAGE: 571759}8590.44Cell division cycle 25A {IMAGE: 441394}8600.44vilin-like tumour suppressor metastasis protein IMAGE EST {IMAGE: 763352}8610.44IMAGE EST {IMAGE: 573743}8620.44hyrolase protease IMAGE EST {IMAGE: 473802}8630.44Phosphoribosylglycinamide formyltransferase {IMAGE: 535188}8640.44Regulatory factor (trans-acting) 2 {IMAGE: 388321}8650.44Enolase 3. beta muscle {IMAGE: 316967}8660.44cardiolipin synthetase IMAGE EST {IMAGE: 314456}8670.44insulin receptor substrate ATP binding protein IMAGE EST {IMAGE: 318263}8680.44Mus musculus 26S proteasome ATPase (CIP21) mRNA, complete cds {IMAGE: 466254}8690.44IMAGE EST {IMAGE: 775342}8700.44Mus musculus mRNA for prefoldin subunit 2 {IMAGE: 748879}8710.43EphB1 receptor tyrosine protein kinase (elk) IMAGE EST {IMAGE: 480205}8720.43FSH regulatory domian IMAGE EST {IMAGE: 764803}8730.43ribosomal protein L17 IMAGE EST {IMAGE: 481485}8740.43intronless highly charged protein IMAGE EST {IMAGE: 437167}8750.43UBIQUITIN-LIKE PROTEIN FUBI {IMAGE: 698100}8760.43IMAGE EST {IMAGE: 618834}8770.43ESTs, Highly similar to PROBABLE RIBOSOMAL PROTEIN B0303.15 IN CHROMOSOME III[Caenorhabditis elegans] {IMAGE: 574981}8780.43NGF-responsive SM-20 protein IMAGE EST {IMAGE: 876655}8790.43metal response element binding protein IMAGE EST {IMAGE: 779876}8800.43Mouse testis abundant mRNA sequence {IMAGE: 437994}8810.43ESTs {IMAGE: 638265}8820.43mitochondrial arginyl-tRNA synthetase precursor IMAGE EST {IMAGE: 576572}8830.43KIAA0281 IMAGE EST {IMAGE: 464800}8840.43melanoma antigen p15 IMAGE EST {IMAGE: 803541}8850.43homeobox-containing infant brain replication factor IMAGE EST {IMAGE: 427295}8860.43ESTs, Highly similar to KIAA0017 [H. sapiens] {IMAGE: 735617}8870.43Splicing factor, arginine/serine-rich 3 (SRp20) {IMAGE: 873314}8880.43suppressor of stem-loop protein IMAGE EST {IMAGE: 575067}8890.43cytoskeletal kinase substrate IMAGE EST {IMAGE: 437626}8900.43IMAGE EST {IMAGE: 353521}8910.43similar to Ssu81p and ribosomal protein L17B ESTs {IMAGE: 642467}8920.43p52 pro-apoptotic protein TNF-beta-like IMAGE EST {IMAGE: 775135}8930.43Mus musculus MSL15 gene {IMAGE: 582028}8940.43enoyl CoA hydratase/isomerase IMAGE EST {IMAGE: 523463}8950.43Eph receptor A2 {IMAGE: 459170}8960.43IMAGE EST {IMAGE: 367802}8970.43IMAGE EST {IMAGE: 337217}8980.43Mus musculus ribosomal protein L21 mRNA, complete cds {IMAGE: 748374}8990.43Mouse mRNA for 8-oxo-dGTPase, complete cds {IMAGE: 737058}9000.43IMAGE EST {IMAGE: 576686}9010.43basic transcription element binding GC-box binding Zn-finger protein IMAGE EST {IMAGE: 874192}9020.43Alkaline phosphatase 2, liver {IMAGE: 465052}9030.43KIAA0156 scamous cell carcinoma antigen SART-3 IMAGE EST {IMAGE: 367601}9040.43lysosomal pathway protein ESTs {IMAGE: 464548}9050.43ESTs, Moderately similar to PUTATIVE MITOCHONDRIAL RIBOSOMAL PROTEIN S14[Caenorhabditis elegans] {IMAGE: 419614}9060.42membrane protein IMAGE EST {IMAGE: 809055}9070.42Mus musculus selenocysteine tRNA gene transcription activating factor (m-Staf) mRNA, complete cds{IMAGE: 574939}9080.42Lymphocyte protein tyrosine kinase {IMAGE: 550845}9090.42nuclear protein IMAGE EST {IMAGE: 746994}9100.42ESTs, Highly similar to SERINE HYDROXYMETHYLTRANSFERASE, MITOCHONDRIAL[Oryctolagus cuniculus] {IMAGE: 676311}9110.42claudin-6 four transmembrane component of tight junction IMAGE EST {IMAGE: 805419}9120.42Heat shock protein, 74 kDa {IMAGE: 889543}9130.42ESTs, Weakly similar to similar to peptidase family C19 [C. elegans] {IMAGE: 313741}9140.42Mus musculus serine/threonine kinase (sak-a) mRNA, complete cds {IMAGE: 777598}9150.42ESTs, Highly similar to PROBABLE PHOSPHOSERINE AMINOTRANSFERASE [Oryctolaguscuniculus] {IMAGE: 573784}9160.42ESTs, Highly similar to KIAA0398 [H. sapiens] {IMAGE: 721931}9170.42hypothetical brain protein ESTs {IMAGE: 735607}9180.42ESTs, Weakly similar to KIAA0005 [H. sapiens] {IMAGE: 532659}9190.42Breast cancer 2 {IMAGE: 761119}9200.42IMAGE EST {IMAGE: 653427}9210.42ESTs, Weakly similar to T06D8.8 [C. elegans] {IMAGE: 354212}9220.42protamine IMAGE EST {IMAGE: 746955}9230.42TM receptor ESTs {IMAGE: 750782}9240.42Protein tyrosine phosphatase, non-receptor type 2 {IMAGE: 437517}9250.42ESTs, Highly similar to 40S RIBOSOMAL PROTEIN S4, X ISOFORM [Homo sapiens; Mus musculus]{IMAGE: 425352}9260.42tight junction zona occludens 2 protein (ZO-2) IMAGE EST {IMAGE: 427339}9270.41Zn-finger protein IMAGE EST {IMAGE: 480747}9280.41IMAGE EST {IMAGE: 466150}9290.41IMAGE EST {IMAGE: 440985}9300.41RAD51 associated protein 1 {IMAGE: 760795}9310.41ESTs, Highly similar to EUKARYOTIC TRANSLATION INITIATION FACTOR 3 BETA SUBUNIT[H. sapiens] {IMAGE: 820518}9320.41IMAGE EST {IMAGE: 775596}9330.41syntenic to GART-AML xanthine dehydrogenase locus IMAGE EST {IMAGE: 751500}9340.41IMAGE EST {IMAGE: 439542}9350.41IMAGE EST {IMAGE: 717469}9360.41Mus musculus protein kinase C inhibitor (mPKCI) mRNA, complete cds {IMAGE: 533117}9370.41KIAA0560 neuronal adaptin IMAGE EST {IMAGE: 478374}9380.41IMAGE EST {IMAGE: 439902}9390.41ESTs, Highly similar to CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN [H. sapiens] {IMAGE:874148}9400.41IMAGE EST {IMAGE: 752290}9410.41IMAGE EST {IMAGE: 443711}9420.41Plasminogen activator inhibitor, type II {IMAGE: 574835}9430.41IMAGE EST {IMAGE: 408040}9440.41protein phosphatase PP-X IMAGE EST {IMAGE: 476407}9450.41Cell division cycle 25A {IMAGE: 851054}9460.41IMAGE EST {IMAGE: 445127}9470.41dehydrogenase/transferase IMAGE EST {IMAGE: 475443}9480.41ESTs {IMAGE: 637237}9490.41Murine Glvr-1 mRNA, complete cds {IMAGE: 620195}9500.41IMAGE EST {IMAGE: 763563}9510.41IMAGE EST {IMAGE: 572869}9520.41ESTs {IMAGE: 640556}9530.41IMAGE EST {IMAGE: 427480}9540.41IMAGE EST {IMAGE: 831991}9550.40ESTs {IMAGE: 418955}9560.40tight junction zona occludens ZO-2 protein IMAGE EST {IMAGE: 419848}9570.40bisphosphate 3′ nucleotidase 1 lithium-sensitive IMAGE EST {IMAGE: 439411}9580.40Mus musculus elongation factor 1-beta homolog mRNA, complete cds {IMAGE: 733810}9590.40ESTs, Weakly similar to HYPOTHETICAL 6.3 KD PROTEIN ZK652.2 IN CHROMOSOME III[C. elegans] {IMAGE: 385341}9600.40translocation/splicing/rearrangement ‘hot spot’ IMAGE EST {IMAGE: 445230}9610.40ESTs, Highly similar to INTERFERON-RELATED PROTEIN PC4 [Mus musculus] {IMAGE: 387482}9620.40ESTs, Highly similar to ELONGATION FACTOR 1-DELTA [Homo sapiens] {IMAGE: 442585}9630.40Mus musculus UNC-51-like kinase ULK1 (Ulk1) mRNA, complete cds {IMAGE: 438917}9640.40IMAGE EST {IMAGE: 406351}9650.40ESTs, Highly similar to PUTATIVE ASPARAGINYL-TRNA SYNTHETASE DED81 [Saccharomycescerevisiae] {IMAGE: 805842}9660.40mitochondrial ribosomal protein S5 IMAGE EST {IMAGE: 574832}9670.40ESTs {IMAGE: 642145}9680.40lipoic acid synthetase precursor IMAGE EST {IMAGE: 525104}9690.40ESTs, Highly similar to PUTATIVE ADENOSINE KINASE [Saccharomyces cerevisiae] {IMAGE:748517}9700.40Transformation related protein 53 {IMAGE: 409069}9710.40Mus musculus SH3-containing protein SH3P4 mRNA, complete cds {IMAGE: 352836}9720.40T-LYMPHOCYTE ACTIVATED PROTEIN {IMAGE: 472605}9730.40transcription factor IMAGE EST {IMAGE: 635025}9740.40IMAGE EST {IMAGE: 804482}9750.40ESTs {IMAGE: 386101}9760.40homeobox protein Cup9 IMAGE EST {IMAGE: 474339}9770.40adult testis protein IMAGE EST {IMAGE: 598898}9780.40heme oxygenase-2 ESTs {IMAGE: 478167}9790.40TGF-beta1 masking protein large subunit precursor IMAGE EST {IMAGE: 733726}9800.40ESTs {IMAGE: 407997}9810.40bystin ce411 adhesion troponin and cytokeratin IMAGE EST {IMAGE: 475670}9820.40Flap structure specific endonuclease 1 {IMAGE: 467501}9830.39Mus musculus SIK similar protein mRNA, complete cds {IMAGE: 643463}9840.39ribosomal protein L13A IMAGE EST {IMAGE: 574251}9850.39fetal heart protein IMAGE EST {IMAGE: 476205}9860.39Notch gene homolog 4, (Drosophila) {IMAGE: 457150}9870.39NADH-ubiquinone oxidoreductase subunit B14.5A IMAGE EST {IMAGE: 465903}9880.39Mus musculus mRNA for ribosomal protein L35a {IMAGE: 659928}9890.39ESTs, Moderately similar to KIAA0253 [H. sapiens] {IMAGE: 573609}9900.39Mus musculus maf10 (mAF10) mRNA, complete cds {IMAGE: 736069}9910.39DNA helicase IMAGE EST {IMAGE: 720870}9920.39growth arrest differentiation induced gene IMAGE EST {IMAGE: 468633}9930.39KIAA0136 IMAGE EST {IMAGE: 575554}9940.39GTP-binding protein IMAGE EST {IMAGE: 640177}9950.39IMAGE EST {IMAGE: 834934}9960.39IMAGE EST {IMAGE: 400741}9970.39Gar1 low molecular weight neurofilament APP-binding protein IMAGE EST {IMAGE: 475814}9980.39ESTs {IMAGE: 808377}9990.39IMAGE EST {IMAGE: 583869}10000.39cytoplasmic C-1-tetrahydrofolate synthase IMAGE EST {IMAGE: 478383}10010.39Zn-finger protein RP-8 IMAGE EST {IMAGE: 763597}10020.39splicing protein (kidney) ESTs {IMAGE: 659193}10030.39Mus musculus gene for DJ-1, complete cds {IMAGE: 571278}10040.39mitotic spindle coiled-coil protein aldolase C IMAGE EST {IMAGE: 535199}10050.39ribosomal protein L17 IMAGE EST {IMAGE: 696858}10060.39Mus musculus putative histone deacetylase (HD1) mRNA, partial cds {IMAGE: 850354}10070.39ESTs, Highly similar to 40S RIBOSOMAL PROTEIN S15A [Homo sapiens; Rattus norvegicus]{IMAGE: 466295}10080.39IMAGE EST {IMAGE: 619385}10090.39IMAGE EST {IMAGE: 425049}10100.39Epoxide hydrolase 2, cytoplasmic {IMAGE: 579349}10110.39ESTs, Highly similar to NUCLEAR TRANSPORT FACTOR 2 [Homo sapiens; Rattus norvegicus]{IMAGE: 762516}10120.39intracellular hyaluronan receptor IMAGE EST {IMAGE: 676748}10130.39Acyl-CoA dehydrogenase, medium chain {IMAGE: 483333}10140.39ESTs, Highly similar to ARGINYL-TRNA SYNTHETASE [Cricetulus longicaudatus] {IMAGE:850426}10150.38cytokine receptor-like molecule IMAGE EST {IMAGE: 405779}10160.38ESTs, Highly similar to PROTEASOME 28 KD SUBUNIT 1 [Drosophila melanogaster] {IMAGE:651274}10170.38PET112 mitochondrial respiratory chain cytochrome C-oxidase regulating protein IMAGE EST {IMAGE:481576}10180.38IMAGE EST {IMAGE: 735773}10190.38M. musculus mRNA for mTGIF protein {IMAGE: 722623}10200.38Hexokinase 1 {IMAGE: 318642}10210.38nucleoporin p54 IMAGE EST {IMAGE: 595972}10220.38RAMP3 receptor activity modifying protein IMAGE EST {IMAGE: 761158}10230.38Mus musculus groucho-related gene 4 protein (Grg4) mRNA, partial cds {IMAGE: 949722}10240.38Glutathione-S-transferase, alpha 2 (Yc2) {IMAGE: 766582}10250.38NUCLEOSIDE DIPHOSPHATE KINASE A {IMAGE: 480329}10260.38oxidase serine/threonin protein kinase IMAGE EST {IMAGE: 465744}10270.38Fas-associated factor 1 {IMAGE: 481242}10280.38CGI-124 IMAGE EST {IMAGE: 577501}10290.38Mus musculus smooth muscle LIM protein (Crp2/SmLim) mRNA, complete cds {IMAGE: 763424}10300.38U1 AND U2 SMALL NUCLEAR RIBONUCLEOPROTEIN E {IMAGE: 408693}10310.387-3 K RNA polymerase III small cytoplasmic RNA 7SK IMAGE EST {IMAGE: 480196}10320.38alpha-tubulin IMAGE EST {IMAGE: 818256}10330.38cytokine-related protein IMAGE EST {IMAGE: 445439}10340.38IMAGE EST {IMAGE: 493683}10350.38IMAGE EST {IMAGE: 642165}10360.38structural protein IMAGE EST {IMAGE: 641368}10370.38alanine aminotransferase IMAGE EST {IMAGE: 425857}10380.38ESTs, Weakly similar to No definition line found [C. elegans] {IMAGE: 809206}10390.37IMAGE EST {IMAGE: 933183}10400.37IMAGE EST {IMAGE: 748639}10410.37ribosomal protein S3 ESTs {IMAGE: 747180}10420.37kinase locus IMAGE EST {IMAGE: 385358}10430.37IP3-5/6 kinase ESTs {IMAGE: 872986}10440.37ATP-binding IMAGE EST {IMAGE: 329816}10450.37repeat region IMAGE EST {IMAGE: 672656}10460.37IMAGE EST {IMAGE: 617288}10470.37IMAGE EST {IMAGE: 423327}10480.37ssDNA-binding mitochondrial protein precursor IMAGE EST {IMAGE: 459094}10490.37TFE3 transcriptional activator H-L-H & Leu zippper DNA-binding ESTs {IMAGE: 834917}10500.37receptor transcription factor IMAGE EST {IMAGE: 735089}10510.37RAB geranylgeranyl transferase, b subunit {IMAGE: 455483}10520.37KIAA0274 IMAGE EST {IMAGE: 479759}10530.37ESTs, Weakly similar to ZK856.11 [C. elegans] {IMAGE: 778381}10540.37Treacher Coffins Franceschetti syndrome 1, homolog {IMAGE: 473404}10550.37ESTs, Weakly similar to N2,N2-DIMETHYLGUANOSINE TRNA METHYLTRANSFERASEPRECURSOR [S. cerevisiae] {IMAGE: 406889}10560.37ESTs, Highly similar to SMALL NUCLEAR RIBONUCLEOPROTEIN SM D2 [Homo sapiens]{IMAGE: 351154}10570.37ALPHA-INTERNEXIN {IMAGE: 660756}10580.36ESTs, Weakly similar to Y53C12B.2 [C. elegans] {IMAGE: 678992}10590.36ESTs, Weakly similar to ORF YOR173w [S. cerevisiae] {IMAGE: 441983}10600.36MHC class III RD locus IMAGE EST {IMAGE: 483476}10610.36ESTs, Moderately similar to F28F8.3 [C. elegans] {IMAGE: 699466}10620.36uterus mRNA IMAGE EST {IMAGE: 464381}10630.36ESTs, Weakly similar to F28F8.3 [C. elegans] {IMAGE: 736584}10640.36FRUCTOSE-BISPHOSPHATE ALDOLASE A {IMAGE: 903419}10650.36Nuceoside phosphorylase {IMAGE: 607469}10660.36Mus musculus phosphomannomutase Sec53p homolog mRNA complete cds {IMAGE: 775067}10670.36ESTs, Weakly similar to HYPOTHETICAL 19.4 KD PROTEIN D2007.4 IN CHROMOSOME III[C. elegans] {IMAGE: 803817}10680.36Carbon catabolite repression 4 homolog (S. cerevisiae) {IMAGE: 438774}10690.36sorting nexin 5 ESTs {IMAGE: 317976}10700.36regulator of pantophysin IMAGE EST {IMAGE: 903284}10710.36Msx-2 transcription factor homolog IMAGE EST {IMAGE: 791433}10720.36ESTs, Moderately similar to 60S ACIDIC RIBOSOMAL PROTEIN P2 [Homo sapiens] {IMAGE:476999}10730.36pescadillo ESTs {IMAGE: 477900}10740.36DEAD-box RNA helicase-like protein IMAGE EST {IMAGE: 749569}10750.36pituitary protein IMAGE EST {IMAGE: 481469}10760.36KIAA1089 IMAGE EST {IMAGE: 480026}10770.36NADH-ubiquinone oxidoreductase subunit B14.5A IMAGE EST {IMAGE: 386766}10780.36Mus musculus von Hippel-Lindau binding protein homolog (vbp-1) mRNA, complete cds {IMAGE:693287}10790.36Notchless modulator of Notch signaling IMAGE EST {IMAGE: 404268}10800.36centaurin-alpha IP4-PIP-binding Zn-finger GTPase-activating protein IMAGE EST {IMAGE: 386122}10810.36Antigen identified by monoclonal antibodies 4F2 {IMAGE: 478301}10820.36nuclear WD40-containing P-protein periodic tryptophan protein IMAGE EST {IMAGE: 576570}10830.35myosin heavy chain beta isoform IMAGE EST {IMAGE: 466413}10840.35IMAGE EST {IMAGE: 418473}10850.35Alcohol dehydrogenase 5 {IMAGE: 636207}10860.35IMAGE EST {IMAGE: 577180}10870.35Chaperonin subunit 4 (delta) {IMAGE: 459668}10880.35DNA primase, p49 subunit {IMAGE: 746463}10890.35Mus musculus mRNA for eIF3 p66. complete cds {IMAGE: 820355}10900.35IMAGE EST {IMAGE: 761127}10910.35ESTs {IMAGE: 467873}10920.35ESTs, Moderately similar to NUCLEAR PORE COMPLEX PROTEIN NUP107 [R. norvegicus]{IMAGE: 777779}10930.35ESTs {IMAGE: 372421}10940.35ESTs, Highly similar to PROTEASOME ZETA CHAIN [Homo sapiens] {IMAGE: 572285}10950.35ESTs, Highly similar to PROTEASOME THETA CHAIN [Rattus norvegicus] {IMAGE: 571569}10960.35KIAA0017 IMAGE EST {IMAGE: 388936}10970.35KIAA0896 DD5 progestin-induced protein IMAGE EST {IMAGE: 633261}10980.35ESTs, Highly similar to herpesvirus associated ubiquitin-specific protease [H. sapiens] {IMAGE: 793038}10990.35ESTs, Highly similar to DEOXYHYPUSINE SYNTHASE [H. sapiens] {IMAGE: 736328}11000.35skin E17 DEEPEST coiled-coil protein IMAGE EST {IMAGE: 348123}11010.35calcium-binding, kinase receptor-like IMAGE EST {IMAGE: 482885}11020.35protease acetyl transferase ATP-binding IMAGE EST {IMAGE: 401741}11030.35Mus musculus epidermal growth factor receptor-binding protein GRB7 mRNA, complete cds {IMAGE:679007}11040.35ESTs, Weakly similar to ZK795.3 [C. elegans] {IMAGE: 717387}11050.35Protein-interacting protein ESTs {IMAGE: 721532}11060.35T-COMPLEX PROTEIN 1, BETA SUBUNIT {IMAGE: 439254}11070.34Enabled homolog (Drosophila) {IMAGE: 808083}11080.34Mus musculus branched-chain alpha-ketoacid dehydrogenase E1 beta-subunit mRNA sequence {IMAGE:476163}11090.34cytoskeletal Ig-like molecule IMAGE EST {IMAGE: 440715}11100.34Mus musculus FK506-binding protein 25 homolog (mFKBP25) mRNA, partial cds {IMAGE: 636888}11110.34ESTs, Highly similar to PROBABLE PHOSPHOSERINE AMINOTRANSFERASE [Oryctolaguscuniculus] {IMAGE: 746853}11120.34IMAGE EST {IMAGE: 418606}11130.34ESTs, Moderately similar to motor protein [H. sapiens] {IMAGE: 336021}11140.34IMAGE EST {IMAGE: 403220}11150.34nuclear pore complex glycoprotein p62 ESTs {IMAGE: 524367}11160.34Na/K-transporting ATPase alpha1 chain IMAGE EST {IMAGE: 351288}11170.34ESTs {IMAGE: 401221}11180.34leucyl-tRNA synthetase IMAGE EST {IMAGE: 748061}11190.34ribonuclease P 40 kDa subunit IMAGE EST {IMAGE: 831799}11200.34Mus musculus putative histone deacetylase (HD1) mRNA, partial cds {IMAGE: 374877}11210.34Fas-associated factor 1 {IMAGE: 534132}11220.34HMG box endosomal protein TOM1 IMAGE EST {IMAGE: 574459}11230.34Heat shock protein, 74 kDa {IMAGE: 444027}11240.34origin of replication recognition complex subunit 6 (Orc6), DNA repair/cell cycle checkpoint gene ESTs{IMAGE: 791176}11250.34contains leucine-rich heptad repeats expressed in proliferating tissue IMAGE EST {IMAGE: 421766}11260.34dimethylguanosinetRNA ethyltransferase precursor IMAGE EST {IMAGE: 423713}11270.33NY-REN-45 antigen K-channel protein in renal carconima IMAGE EST {IMAGE: 778447}11280.33IFN-related RNA-binding protein IMAGE EST {IMAGE: 467830}11290.33ESTs {IMAGE: 617197}11300.33Mus musculus (clone mcori-lck9) S29 ribosomal protein mRNA, complete cds {IMAGE: 793127}11310.33ESTs, Highly similar to EUKARYOTIC INITIATION FACTOR 4A-LIKE NUK-34 [Homo sapiens]{IMAGE: 779315}11320.33pescadillo IMAGE EST {IMAGE: 427222}11330.33IMAGE EST {IMAGE: 807957}11340.33Promyelocytic leukemia {IMAGE: 820560}11350.33eukaryotic initiation factor 4A-I IMAGE EST {IMAGE: 571841}11360.33M-phase P-protein 10 IMAGE EST {IMAGE: 597896}11370.33DNA ligase I, ATP-dependent {IMAGE: 388245}11380.33ESTs, Weakly similar to CYSTATHIONINE GAMMA-LYASE [Rattus norvegicus] {IMAGE: 679235}11390.33IMAGE EST {IMAGE: 874541}11400.33E-cadherin-, ankyrin-, uvomorulin-like protein IMAGE EST {IMAGE: 762237}11410.33IMAGE EST {IMAGE: 401167}11420.33KIAA0314 IMAGE EST {IMAGE: 335017}11430.33ESTs, Weakly similar to F54B3.3 [C. elegans] {IMAGE: 401821}11440.33guanine nucleotide-binding GPCR-like protein IMAGE EST {IMAGE: 425452}11450.33arsenite-translocating (resistance) ATPase IMAGE EST {IMAGE: 676921}11460.33KIAA0039 opiate octopamine receptor IMAGE EST {IMAGE: 735374}11470.33ESTs, Highly similar to THREONYL-TRNA SYNTHETASE, CYTOPLASMIC [Homo sapiens]{IMAGE: 480488}11480.33Glutamate dehydrogenase {IMAGE: 442843}11490.33ESTs, Moderately similar to PRE-MRNA SPLICING FACTOR SRP20 [Homo sapiens; Mus musculus]{IMAGE: 406282}11500.33IMAGE EST {IMAGE: 619836}11510.33eukaryotic initiation factor 2 alpha kinase IMAGE EST {IMAGE: 440053}11520.33origin of replication recognition complex subunit 6 (Orc6) ESTs {IMAGE: 426529}11530.33ESTs, Highly similar to PROBABLE ATP-DEPENDENT TRANSPORTER YER036C [Saccharomycescerevisiae] {IMAGE: 406088}11540.33lysosomal protein ESTs {IMAGE: 440194}11550.32Mus musculus C-terminal binding protein 2 mRNA, complete cds {IMAGE: 467669}11560.32ESTs, Highly similar to HYPOTHETICAL 34.7 KD PROTEIN IN SPT10-GCD14 INTERGENICREGION [S. cerevisiae] {IMAGE: 406154}11570.32Adenine nucleotide translocator 2, fibroblast {IMAGE: 465520}11580.32bisphosphate 3′ nucleotidase 1 lithium-sensitive IMAGE EST {IMAGE: 439033}11590.32ESTs {IMAGE: 639451}11600.32ESTs {IMAGE: 355454}11610.32ESTs, Weakly similar to coded for by C. elegans cDNA yk157f8.5 [C. elegans] {IMAGE: 354155}11620.32LL56-APP region ESTs {IMAGE: 619401}11630.32ESTs {IMAGE: 480204}11640.32Cell division cycle control protein 2a {IMAGE: 468792}11650.32KIAA0956 IMAGE EST {IMAGE: 573582}11660.32Mus musculus mRNA for mB1m, complete cds {IMAGE: 464447}11670.32alanyl-tRNA synthetase IMAGE EST {IMAGE: 388091}11680.32NNX3 ESTs {IMAGE: 576353}11690.32NAD(H) isocitrate dehydrogenase alpha chain IMAGE EST {IMAGE: 475796}11700.32ESTs, Highly similar to CAD PROTEIN [Homo sapiens] {IMAGE: 834541}11710.32CD97 precursor IMAGE EST {IMAGE: 573301}11720.32Mus musculus putative endo/exonuclease MmMre11b (MmMRE11) mRNA, alternative splicing product,complete cds {IMAGE: 524361}11730.31ESTs, Weakly similar to T13H5.5 [C. elegans] {IMAGE: 848702}11740.31ESTs, Highly similar to transcription factor E2F-4 [M. musculus] {IMAGE: 422188}11750.31bright and dead ringer homolog IMAGE EST {IMAGE: 422167}11760.31similar to KIAA0032 IMAGE EST {IMAGE: 596719}11770.31ESTs {IMAGE: 427594}11780.31IMAGE EST {IMAGE: 933852}11790.31similar to CGI-122 protein IMAGE EST {IMAGE: 407354}11800.31DNA polymerase delta catalytic chain IMAGE EST {IMAGE: 424021}11810.31pirin NF-1 interacting nuclear protein IMAGE EST {IMAGE: 332396}11820.31regulator of chromosome condensation IMAGE EST {IMAGE: 422799}11830.31ESTs, Moderately similar to HYPOTHETICAL 27.1 KD PROTEIN CCE1-CAP1 INTERGENICREGION [S. cerevisiae] {IMAGE: 440795}11840.31alkaline phosphatase IMAGE EST {IMAGE: 535409}11850.31arginine N-methyltransferase 3 IMAGE EST {IMAGE: 441235}11860.31centaurin alpha IMAGE EST {IMAGE: 437602}11870.31Mus musculus HS1-associating protein (mHAX-1s) mRNA, complete cds {IMAGE: 874591}11880.31ESTs {IMAGE: 583932}11890.31IMAGE EST {IMAGE: 640682}11900.31IMAGE EST {IMAGE: 580623}11910.31putative nucleotide (ATP) binding protein IMAGE EST {IMAGE: 679011}11920.31KIAA0088 IMAGE EST {IMAGE: 482910}11930.31chromatin assembly factor I p60 subunit containing WD repeats IMAGE EST {IMAGE: 373854}11940.31Mouse mRNA for RNA polymerase I 40 kD subunit, complete cds {IMAGE: 335746}11950.30Glyceraldehyde-3-phosphate dehydrogenase {IMAGE: 579715}11960.30ESTs, Highly similar to LYSYL-TRNA SYNTHETASE [Cricetulus longicaudatus] {IMAGE: 439548}11970.30DNA POLYMERASE ALPHA/PRIMASE ASSOCIATED SUBUNIT {IMAGE: 476123}11980.30ribosomal protein L7 IMAGE EST {IMAGE: 524442}11990.30DEAD-box protein DP103 putative helicase IMAGE EST {IMAGE: 533415}12000.30similar to CGI-07 protein IMAGE EST {IMAGE: 894135}12010.30ESTs, Weakly similar to C01F6.8 [C. elegans] {IMAGE: 422667}12020.30Mus musculus mRNA for rabkinesin-6 {IMAGE: 633209}12030.30ribosomal protein S6 modification protein IMAGE EST {IMAGE: 961094}12040.30ESTs, Highly similar to Cdc5-like protein [R. norvegicus] {IMAGE: 833661}12050.30situin type 1 ADP-ribosylase IMAGE EST {IMAGE: 385901}12060.30thymidylate kinase IMAGE EST {IMAGE: 760921}12070.30Mus musculus ribosomal protein S5 mRNA, complete cds {IMAGE: 775645}12080.30IMAGE EST {IMAGE: 388212}12090.30ESTs, Weakly similar to HYPOTHETICAL 47.8 KD PROTEIN B0280.9 IN CHROMOSOME III[C. elegans] {IMAGE: 441968}12100.30ESTs, Moderately similar to This sequence is almost identical to HUMRSC433.D13632. [H. sapiens]{IMAGE: 576156}12110.30IMAGE EST {IMAGE: 790122}12120.30PEPTIDYL-PROLYL CIS-TRANS ISOMERASE A {IMAGE: 920055}12130.30NAD isocitrate dehydrogenase IMAGE EST {IMAGE: 775189}12140.2960S RIBOSOMAL PROTEIN L3 {IMAGE: 570533}12150.29Mus musculus ribosomal protein L8 (RPL8) mRNA, complete cds {IMAGE: 716896}12160.29NAD/ATP binding protein IMAGE EST {IMAGE: 550869}12170.29IMAGE EST {IMAGE: 792736}12180.29House mouse; Musculusdomesticus female mammary carcinoma mRNA for mCDC47, complete cds{IMAGE: 948894}12190.29nucleolar protein p40 associated with proliferation IMAGE EST {IMAGE: 779257}12200.29steroid binding protein IMAGE EST {IMAGE: 765841}12210.29IMAGE EST {IMAGE: 355808}12220.29ESTs, Highly similar to kinesin-related protein 2 [R. norvegicus] {IMAGE: 437761}12230.28DNA primase, p58 subunit {IMAGE: 680147}12240.28receptor IMAGE EST {IMAGE: 352409}12250.28KIFC1 neural kinesin CHO2 antigen IMAGE EST {IMAGE: 388296}12260.28LAK-4p chemokine IMAGE EST {IMAGE: 387227}12270.28TUBULIN ALPHA-4 CHAIN {IMAGE: 329726}12280.28ESTs, Highly similar to herpesvirus associated ubiquitin-specific protease [H. sapiens] {IMAGE: 779598}12290.28KIAA0888 stress-induced Doc4 brain Ten-m/Odz IMAGE EST {IMAGE: 457567}12300.28transforming acidic coiled-coil containing protein 3 IMAGE EST {IMAGE: 407274}12310.28ESTs, Weakly similar to f254 [E. coli] {IMAGE: 314236}12320.28IMAGE EST {IMAGE: 834712}12330.28ESTs, Highly similar to ALPHA ENOLASE [Mus musculus] {IMAGE: 643854}12340.28IMAGE EST {IMAGE: 720554}12350.28nuclear import karyopherin beta 3/Ran GTP-binding protein 5 IMAGE EST {IMAGE: 387946}12360.28IMAGE EST {IMAGE: 478417}12370.28ESTs, Highly similar to 60S RIBOSOMAL PROTEIN L15 [Rattus norvegicus] {IMAGE: 532770}12380.28X-ray repair complementing defective repair in Chinese hamster cells 5 {IMAGE: 573725}12390.27KIAA0314 ESTs {IMAGE: 445567}12400.27IMAGE EST {IMAGE: 804963}12410.27Mus musculus Hsp70-related NST-1 (hsr.1) mRNA, complete cds {IMAGE: 574381}12420.27Lymphocyte protein tyrosine kinase {IMAGE: 438125}12430.27IMAGE EST {IMAGE: 372368}12440.27Mus musculus coding region determinant binding protein mRNA, complete cds {IMAGE: 535036}12450.27ESTs, Highly similar to 60S RIBOSOMAL PROTEIN L1A [Xenopus laevis] {IMAGE: 699417}12460.27Mouse mRNA for mMIS5, complete cds {IMAGE: 444918}12470.27Down syndrome critical region gene 2 ESTs {IMAGE: 775603}12480.27Mus musculus histone H2A.Z (H2A.Z) mRNA, complete cds {IMAGE: 831643}12490.27transferrin R IMAGE EST {IMAGE: 403681}12500.27ESTs, Weakly similar to HYPOTHETICAL 86.9 KD PROTEIN ZK945.3 IN CHROMOSOME II[Caenorhabditis elegans] {IMAGE: 331974}12510.26Apurinic/apyrimidinic endonuclease {IMAGE: 331901}12520.26ESTs, Highly similar to putative ATP/GTP-binding protein [H. sapiens] {IMAGE: 642977}12530.26cyclin B1 EST {IMAGE: 836311}12540.26arsenate resistance protein ARS2 ESTs {IMAGE: 932884}12550.26Retinoic acid receptor, gamma {IMAGE: 439731}12560.26chromatin assembly factor-I p60 subunit IMAGE EST {IMAGE: 761060}12570.26ESTs, Moderately similar to PTTG gene product [R. norvegicus] {IMAGE: 678793}12580.26nuclear protein np95 proliferation associated IMAGE EST {IMAGE: 873758}12590.26U22 snoRNA host gene (UHG) gene ESTs {IMAGE: 482641}12600.26Fibroblast growth factor 15 {IMAGE: 479758}12610.26IMAGE EST {IMAGE: 467472}12620.26Mus musculus dihydroorotate dehydrogenase mRNA, partial cds {IMAGE: 692981}12630.26Mus musculus branched-chain amino acid aminotransferase (Eca40) mRNA, nuclear gene encodingmitochondrial protein {IMAGE: 776036}12640.26RNA cyclase homolog IMAGE EST {IMAGE: 437831}12650.25Proliferating cell nuclear antigen {IMAGE: 579735}12660.25IMAGE EST {IMAGE: 467550}12670.25Mus musculus mRNA for nuclear protein SA3 {IMAGE: 493305}12680.25ESTs {IMAGE: 805386}12690.25MITOCHONDRIAL MATRIX PROTEIN P1 PRECURSOR {IMAGE: 633625}12700.25Mouse mRNA for KIFC1, complete cds {IMAGE: 426992}12710.25Early development regulator {IMAGE: 350848}12720.25serine/threonine protein kinase W IMAGE EST {IMAGE: 657961}12730.25Mus musculus Tcl1 oncogene mRNA, complete cds {IMAGE: 961083}12740.25Glutamate oxaloacetate transaminase 1, soluble {IMAGE: 481381}12750.24citrin calcium-dependant mitochondrial carrier protein IMAGE EST {IMAGE: 834225}12760.24ESTs, Highly similar to teg292 protein [M. musculus] {IMAGE: 407480}12770.24denentin 48 kDa/52 kDa subunits IMAGE EST {IMAGE: 422953}12780.24G2/MITOTIC-SPECIFIC CYCLIN B1 {IMAGE: 576166}12790.24putative ATP/GTP-binding protein IMAGE EST {IMAGE: 403005}12800.24RIBOSOMAL PROTEIN S6 KINASE II ALPHA 1 {IMAGE: 355755}12810.24Mus musculus myosin light chain 2 mRNA, complete cds {IMAGE: 466382}12820.24ESTs, Highly similar to 60S RIBOSOMAL PROTEIN L37A [Gallus gallus] {IMAGE: 466384}12830.24ESTs, Moderately similar to oriP binding protein [H. sapiens] {IMAGE: 424705}12840.24calpain p94 large isoform IMAGE EST {IMAGE: 574491}12850.23Mus musculus ribosomal protein S5 mRNA, complete cds {IMAGE: 696769}12860.23pescadillo ESTs {IMAGE: 477828}12870.23ESTs {IMAGE: 805046}12880.23RNA polymerase III IMAGE EST {IMAGE: 441327}12890.22IMAGE EST {IMAGE: 331792}12900.22IMAGE EST {IMAGE: 420278}12910.22developmental kinase 2 tyrosine protein kinase IMAGE EST {IMAGE: 426239}12920.22Poly (ADP-ribose) polymerase {IMAGE: 466241}12930.22IMAGE EST {IMAGE: 917265}12940.22Mus musculus asparagine synthetase mRNA, complete cds {IMAGE: 337748}12950.22IMAGE EST {IMAGE: 577488}12960.22mitotic checkpoint protein kinase BUB1B ESTs {IMAGE: 465804}12970.22NAD-DEPENDENT METHYLENETETRAHYDROFOLATE DEHYDROGENASE {IMAGE:406031}12980.22CCAAT-enhancer binding protein C/EBP IMAGE EST {IMAGE: 738252}12990.21Protamine 3 {IMAGE: 400035}13000.21mitosis-specific chromosome segregation protein SMC1 IMAGE EST {IMAGE: 791570}13010.21ESTs {IMAGE: 574520}13020.21IMAGE EST {IMAGE: 803622}13030.20orip-binding protein/kinesin-like IMAGE EST {IMAGE: 438886}13040.20L1 cam region IMAGE EST {IMAGE: 734665}13050.20Cadherin 1 {IMAGE: 776133}13060.20Peroxisomal sarcosine oxidase {IMAGE: 790721}13070.20ribosomal protein L15 ESTs {IMAGE: 464084}13080.20Selenophosphate synthetase 2 {IMAGE: 791719}13090.20early transposon Etn/mitochondrial selenoprotein IMAGE EST {IMAGE: 722631}13100.20IMAGE EST {IMAGE: 805579}13110.20Mus musculus E1B 19K/Bcl-2-binding protein homolog (Nip3) mRNA, nuclear gene encodingmitochondrial protein, complete cds {IMAGE: 571367}13120.20growth-related protein IMAGE EST {IMAGE: 575434}13130.19Mus musculus clone L8 variable group of 2-cell-stage gene family mRNA, complete cds {IMAGE:793218}13140.19cystatothionine gamma-lyase IMAGE EST {IMAGE: 525119}13150.19hKIAA0030 gene/minichromosome deficient/CDC L1/replication licencing factor IMAGE EST {IMAGE:441229}13160.19kruppel-like factor IMAGE EST {IMAGE: 444844}13170.19E1B 19K/Bcl-2-B homolog (Nip3)/calbindin-like IMAGE EST {IMAGE: 463388}13180.18KIAA0116/homolog of NK receptor IMAGE EST {IMAGE: 533085}13190.18pyroline-5-carboxylate reductase IMAGE EST {IMAGE: 402730}13200.18Mouse mRNA for mCDC46 protein, complete cds {IMAGE: 466047}13210.18beta-mannosidase precursor IMAGE EST {IMAGE: 641507}13220.18mismatch repair protein MutS (E. coli) homolog 2 {IMAGE: 945359}13230.18IMAGE EST {IMAGE: 765272}13240.18IMAGE EST {IMAGE: 456342}13250.18histone acetyl transferase IMAGE EST {IMAGE: 314146}13260.18ESTs {IMAGE: 316914}13270.18ESTs, Highly similar to AMIDOPHOSPHORIBOSYLTRANSFERASE PRECURSOR [Rattusnorvegicus] {IMAGE: 779343}13280.18lysophosphatydic acid phosphatase ESTs {IMAGE: 582668}13290.17IMAGE EST {IMAGE: 313254}13300.17ESTs, Weakly similar to PHF1 [H. sapiens] {IMAGE: 945218}13310.17contains regulatory elements IMAGE EST {IMAGE: 403663}13320.17Cyclin E {IMAGE: 833511}13330.17TRANSCRIPTION FACTOR S-II-RELATED PROTEIN {IMAGE: 748744}13340.16nucleolar repeats protein/ribosome biogenesis ESTs, Weakly similar to K07C5.4 [C. elegans] {IMAGE:933491}13350.16contains regulatory elements found in ribosomal RNAs IMAGE EST {IMAGE: 575290}13360.15G2/MITOTIC-SPECIFIC CYCLIN B1 {IMAGE: 751977}13370.15replication factor C (activator 1) IMAGE EST {IMAGE: 572970}13380.14Mus musculus very-long-chain acyl-CoA synthetase (VLCS) mRNA, complete cds {IMAGE: 572379}13390.14Phosphoribosylglycinamide formyltransferase {IMAGE: 476629}13400.14Phosphoribosylglycinamide formyltransferase {IMAGE: 477593}13410.14Mouse chromatin nonhistone high mobility group protein (HGM-I(Y), complete cds {IMAGE: 920268}13420.13equilibrative nucleoside transporter IMAGE EST {IMAGE: 805549}13430.13equilibrative nucleoside transporter IMAGE EST {IMAGE: 680512}13440.13contains spectrin elements IMAGE EST {IMAGE: 403735}13450.13IMAGE EST {IMAGE: 693719}13460.12Hemopoietic cell kinase {IMAGE: 638455}13470.12Carbonic anhydrase 2 {IMAGE: 579391}13480.12IMAGE EST {IMAGE: 402162}13490.12JM1 protein IMAGE EST {IMAGE: 833919}13500.12glycoamino acid (cationic) transporter IMAGE EST {IMAGE: 776058}13510.12Glutathione-S-transferase, alpha 1 (Ya) {IMAGE: 367627}13520.11KIAA0245/glycoprotein-associated amino acid (cationic) transporter IMAGE EST {IMAGE: 457955}13530.10asialoglycoprotein receptor 1 IMAGE EST {IMAGE: 949512}13540.10ESTs, Weakly similar to HYPOTHETICAL 15.4 KD PROTEIN C16C10.11 IN CHROMOSOME III[C. elegans] {IMAGE: 334182}13550.08IMAGE EST {IMAGE: 893933}13560.07RAR-alpha IMAGE EST {IMAGE: 820336}13570.07KIAA0888 IMAGE EST {IMAGE: 442396}13580.07contains regulatory element of TFs (also is in HIV envelope glycoprotein) IMAGE EST {IMAGE:442966}13590.06Myeloblastosis oncogene-like 2 {IMAGE: 833557}13600.06CYP3A1 gene 5′ GRE responsive element ESTs {IMAGE: 791079}13610.06F-Boc protein FBX15 ubiquitin ligase regulator ESTs {IMAGE: 833477}13620.04Mouse mRNA for uridine phosphorylase, complete cds {IMAGE: 445862}13630.03ETn transposon/TGR gamma locus IMAGE EST {IMAGE: 535794}13640.02ETn transposon IMAGE EST {IMAGE: 633484}13650.01ESTs, Highly similar to retinoic acid-regulated protein pH 34 [M. musculus] {IMAGE: 944963}

[0205]

5

TABLE 2

IMAGE

SEQ
Clone
GenBank
Template
SEQ
e

ID NO
ID
ID
ID
ID NO
value
Description

1
463135
g4059261
407392.37
2022
0
Human mRNA for IGF-II precursor (insulin-like growth factor).

2
671661
g1872629

3
464598
g1497693

4
427016
g4271958
380283.5
1976
0
Human mRNA for KIAA0287 gene, partial cds.

5
874833
g2200656
222420.1
1653
0
Human extracellular matrix protein 1 mRNA, complete cds.

6
420322
g1539066
245004.8
1771
0
Human mRNA for integrin beta 1 subunit.

7
478168
g1529387

8
639481
g1794338
806690.12
2164
0
Human mRNA for insulin-like growth factor binding protein-3.

9
766482
g1918383
199977.8
1607
0
Human retinal short-chain dehydrogenase/reductase retSDR1 mRNA,

complete cds.

10
678765
g1861400
222420.2
1654
0
Human extracellular matrix protein 1 mRNA, alternative splice

variant, complete cds.

11
425866
g1436827
233180.14
1679
0
Human P311 Human (3.1) mRNA, complete cds.

12
532350
g1564784
021677.7
1379
0
Human clone JkA10 mRNA induced upon T-cell activation, 3′ end.

13
374970
g1369558
233180.1
1678
0
Human P311 Human (3.1) mRNA, complete cds.

14
422746
g4199189

15
535652
g1662749
235164.4c
1713
0
Human mRNA for amyloid A4(751) protein.

16
694987
g1827280
480898.39
2127
0
Human glia-derived nexin (GDN) mRNA, 5′ end.

17
464497
g1504426
480898.39
2127
0
Human glia-derived nexin (GDN) mRNA, 5′ end.

18
418952
g1542308

19
671910
g1873455

20
367780
g1355004
334852.5
1880
0
Human transforming growth factor-beta-2 mRNA, complete cds.

21
352450
g1315693
229471.5
1660
0
Human mRNA for collagen VI alpha-1 C-terminal globular domain.

22
334132
g1290623
229471.5
1660
0
Human mRNA for collagen VI alpha-1 C-terminal globular domain.

23
313322
g1284409
1071415.1
1417
0
Human IGF-I mRNA for insulin-like growth factor I.

24
536526
g4272801
429727.5
2060
0
Human fibrillin-2 mRNA, complete cds.

25
423028
g4199193
201738.5
1622
0
Human alpha-1 type XI collagen (COL11A1) mRNA, complete cds.

26
463046
g1493665

27
672201
g1853656
347789.24
1924
0
Human alpha-B-crystallin gene, 5′ end.

28
407068
g1541149
1078208.1
1468
0
Human mRNA for carboxypeptidase E (EC 3.4.17.10).

29
482955
g1554683
201079.1
1614
0
Human full length insert cDNA clone ZD42A08.

30
402738
g1391198
285031.4
1837
0
Human collagenase type IV mRNA, 3′ end.

31
831964
g2157430
1078609.1
1470
0

32
718665
g1901788
256147.56
1815
0
Human aorta caldesmon mRNA, complete cds.

33
733420
g1896293
233180.16
1680
0
Human P311 Human (3.1) mRNA, complete cds.

34
747101
g1896969
1186377.1
1533
0
Human mRNA for calpain-like protease CANPX.

35
734305
g1905506

36
468900
g1509125
1166388.1
1512
0

37
536306
g1595337
257184.4
1819
6.00E−96
Human proalpha 1 (I) chain of type I procollagen mRNA (partial).

38
401608
g1388876

39
426890
g1446690
001821.6
1367
9.00E−05
out at first

40
580753
g1715174

41
385914
g5600038
256147.57
1816
0
Human caldesmon mRNA, complete cds.

42
401456
g1436746

43
465620
g1504196

44
620221
g1759210

45
426546
g1445943

413309.18c
2041
0
Human endonexin II mRNA, complete cds.

46
457000
g1487481
1172250.1
1522
9.00E−85
CGI-56 protein

47
367660
g1356852
1163661.1
1508
0
Human mRNA for NFI/CAAT-binding transcription factor 5 (CTF5).

48
353202
g1325849
406252.1
2019
8.00E−11
hypothetical protein

49
657264
g1865297
1109345.1
1492
0
Human (chromosome X) glypican (GPC3) mRNA, complete cds.

50
406708
g4257399

51
481927
g1553633
412793.4
2039
0
Human nuclear factor I-B2 (NFIB2) mRNA, complete cds.

52
479405
g1528806
429727.5
2060
0
Human fibrillin-2 mRNA, complete cds.

53
463207
g1497504

54
618681
g1756233
763966.1
2154
6.00E−13
Human mRNA for 80K-L protein, complete cds.

55
403597
g1539666
1071628.8
1424
0
Human procollagen C-protease (pCP-2) mRNA, complete cds.

56
463342
g1494749
252081.2
1795
0
Human antigen NY—CO-33 (NY—CO-33) mRNA, complete cds.

57
552603
g1642160
336956.3
1887
3.00E−05
putative

58
949246
g2305969
000305.1
1366
7.00E−83
Human mRNA for CDEP, complete cds.

59
400864
g1387841

60
424348
g1428536
235222.8
1717
0
Human clone 23625 mRNA sequence.

61
315581
g1284184
273994.3
1831
0
Human U6 snRNA-associated Sm-like protein LSm6 mRNA, complete

cds.

62
808000
g2116364
244973.2
1770
0
Human vascular endothelial cell growth factor 165 receptor/

neuropilin (VEGF165) mRNA, complete cds.

63
850078
g2164301
1143218.1
1497
0

64
876297
g2203612

65
820167
g2101964
1189716.1
1552
0
Human mRNA for gig1 protein.

66
427289
g1446744

67
443865
g4276693

68
478040
g4061336
334442.1c
1878
0
Human bone morphogenetic protein-3b.

69
762240
g1917691

70
464828
g1505067

71
479382
g1528480
279312.2
1834
1.00E−50
HUMMLC2At; Human; ; 593 base-pairs.

72
764513
g1912736
816464.4c
2182
0
Human NMDA receptor glutamate-binding chain (hnrgw) mRNA,

partial cds.

73
314639
g1286605
207184.1
1635
0
Human glypican-4 (GPC4) mRNA, complete cds.

74
315775
g1284389
230128.15
1662
0
Human gamma-filamin (ABPL) mRNA, complete cds.

75
476509
g1530317
350707.15
1948
0
Human mRNA for KIAA1114 protein, complete cds.

76
427319
g1446754
347875.3
1927
0
Human T-cell leukemia LERK-2 (EPLG2) mRNA, complete cds.

77
427345
g4271979

78
617200
g4443013
429995.3
2063
0
Human mRNA; cDNA DKFZp564P1664 (from clone DKFZp564P1664).

79
482995
g1554868
347084.1

80
721944
g4764924
817053.1
2183
0

81
352804
g1316581

82
333232
g1294183
1072399.3
1434
0
Human Bet1p homolog (hbet1) mRNA, complete cds.

83
634580
g1776249
049935.4
1396
6.00E−44
Human mRNA; cDNA DKFZp564C0362 (from clone DKFZp564C0362);

complete cds.

84
386417
g1371945

85
890760
g2248333
256147.46
1814
0
Human mRNA for caldesmon, 3′ UTR.

86
698181
g1863194
1073009.7
1450
1.00E−97
Human elastin mRNA, complete cds.

87
422325
g1427499
121289.1
1560
0
Human IGF-II gene exon 1 for insulin-like growth factor II

located on chromosome 11.

88
697010
g1838485
459119.1
2084
4.00E−65
Human transcobalamin II (TCII) mRNA, complete cds.

89
680894
g1882418
346219.2
1916
0
Human GDNF receptor alpha mRNA, complete cds.

90
572542
g1661694
1094500.1
1487
7.00E−64
be(a-2-microglobulin precursor

91
902923
g2258850

92
747941
g1897446
1071968.1
1429
0
Human mRNA; cDNA DKFZp434B2411 (from clone DKFZp434B2411).

93
423995
g4271836
003457.2c
1369
0
Human HOX-2.5 gene for homeodomain protein, partial.

94
807978
g2116358

95
385318
g1371476

256147.58c
1817
0
Human aorta caldesmon mRNA, complete cds.

96
352909
g1316741

97
735413
g1907885
198006.3
1596
5.00E−74
SPARC-related protein

98
746643
g1904823
1084333.3
1475
0
Human (clone FBK III 11c) protein-tyrosine kinase (DRT) mRNA,

complete cds.

99
464995
g4058663
235132.8
1710
0
Human profilin II mRNA, complete cds.

100
427642
g4061601
235197.9c
1716
0
Human protein-tyrosine phosphatase (PTPase MEG2) mRNA, complete

cds.

101
479367
g4057838
350895.2
1950
0
Human mRNA for B-HLH DNA binding protein.

102
401288
g1428210
018653.1c
1377
0

103
332477
g1282620

104
581193
g4061843
235132.8
1710
0
Human profilin II mRNA, complete cds.

105
465937
g1504589
482006.1c
2137
0
Human homeobox protein (HOX-1.3) gene, complete cds.

106
692257
g1862269
203947.1
1631
7.00E−86
Human mRNA for MIFR-2, complete cds.

107
478504
g4061265
1186377.1
1533
0
Human mRNA for calpain-like protease CANPX.

108
406897
g1394776
763639.1
2153
1.00E−57
Human cellular retinol-binding protein mRNA, complete cds.

109
578299
g1677813
814967.4
2175
0
Human mRNA for KIAA0913 protein, partial cds.

110
935557
g2292046

111
419146
g1542389

112
672424
g1853328

113
746798
g1896930
381400.4
1977
0
Human mRNA for fibulin-4.

114
330825
g1288931

115
803251
g2049321
1071520.6
1421
0
Human mRNA for RNase 4, complete cds.

116
573265
g4199851
233238.3
1683
0
Human annexin III (ANX3) gene, alternative exons 1a and 1b.

117
523686
g1564930

118
873058
g2192338
899303.1
2197
0
Human mRNA for actin-binding protein (filamin) (ABP-280).

119
695687
g1834285
1072969.1c
1443
0
Human mRNA for neutral calponin, complete cds.

120
670344
g1840495

121
481410
g1554247
235885.3
1724
2.00E−40
Human zinc-finger helicase (hZFH) mRNA, complete cds.

122
619950
g1759275
817871.1
2184
0

123
367785
g1355012

124
572510
g4059890
248640.1
1789
0

125
356215
g1339194
407061.11
2021
0
Human mRNA; cDNA DKFZp586N1922 (from clone DKFZp586N1922),

partial cds.

126
775893
g1919031
1015595.1
1411
1.00E−86
Human 26-kDa cell surface protein TAPA-1 mRNA, complete cds.

127
846536
g2138471
218425.1
1643
0

128
420641
g1542150
028443.2
1385
0
Human sarcosine dehydrogenase (SARDH) mRNA, complete cds.

129
762558
g1909824
429995.3
2063
0
Human mRNA; cDNA DKFZp564P1664 (from clone DKFZp564P1664).

130
478571
g1530979

131
617884
g1756440

132
406295
g1540698
720026.1
2138
0
SPI-2 serine protease inhibitor (AA 1-407)

133
808226
g2116510
221501.2
1648
0
Human ncx1 gene (exon 12).

134
765332
g1915642

135
888553
g2233628
253450.6
1800
0
Human mRNA for hFat protein.

136
746644
g1904820
361221.17
1963
0
Human lumican mRNA, complete cds.

137
752144
g1936155
257739.16
1824
0
Human KIAA0438 mRNA, complete cds.

138
888571
g2233635

139
424433
g1428492

140
401980
g1387738
1071605.1
1423
4.00E−36
Dlxin-1

141
734101
g1905364
245184.4
1773
0
Human transforming growth factor-beta induced gene product

(BIGH3) mRNA, complete cds.

142
367915
g1355557
343884.1

143
480684
g1558142
1073003.1
1447
0
Human talin mRNA, complete cds.

144
622914
g1758938
235797.3
1722
0
Human Ste-20 related kinase SPAK mRNA, complete cds.

145
903370
g4617450
435792.1
2069
0

146
427360
g1446763
233213.4
1682
0
Human mRNA for actin-binding protein (filamin) (ABP-280).

147
402800
g1390976

148
762159
g1917554
201589.1
1620
0

149
762339
g1913048

150
439108
g1447298
300972.5
1844
0
Human NMDA receptor glutamate-binding chain (hnrgw) mRNA,

partial cds.

151
464060
g1494424
1072990.18
1446
0
Human 40-kDa keratin intermediate filament precursor gene.

152
763103
g1909660

153
535763
g1659237
230555.19
1664
0
Human HBV associated factor (XAP4) mRNA, complete cds.

154
820204
g4320880
1035647.1
1414
3.00E−70
Human unknown mRNA.

155
373000
g1365741

156
402995
g1539222

157
891284
g2248735
039966.1
1392
0
Human antigen NY—CO-41 (NY—CO-41) mRNA, partial cds.

158
439758
g4199231
903458.2
2213
0
Human Hox2.2 gene for a homeobox protein.

159
425409
g4271890
415803.1
2045
0
Human mRNA; cDNA DKFZp564B222 (from clone DKFZp564B222).

160
334872
g1292213
1073003.16
1448
0
Human talin (TLN) gene, exons 2 through 48.

161
388477
g1379747

162
444059
g1475791
253958.8
1803
0
Human myosin alkali light chain (atrial) mRNA, complete cds.

163
619970
g4288890
384264.3
1978
0
Human mRNA for frizzled-1, complete cds.

164
421150
g1428883
351451.22
1955
0
Human CD24 signal transducer mRNA, complete cds and 3′

region.

165
420535
g4199173
244218.3
1761
0
Human v-erbA related ear-3 gene.

166
405907
g1540438
345141.2
1910
0
Human transcription factor (HTF4) mRNA, complete cds.

167
467560
g1506739
343884.8c
1900
0
Human mRNA for drebrin E, complete cds.

168
851638
g2235691

169
735527
g1908231
231011.5
1666
0
Human mRNA for membrane glycoprotein M6, complete cds.

170
422403
g4275705

171
680455
g1861199
481379.8c
2132
1.00E−96
Human mRNA fragment for receptor-like furin.

172
419756
g1538851

173
423593
g4271827

174
408110
g1538731
233213.4
1682
0
Human mRNA for actin-binding protein (filamin) (ABP-280).

175
573845
g1676557
332667.1
1871
6.00E−48
Human mRNA; cDNA DKFZp566I1247 (from clone DKFZp566I1247).

176
427205
g4271969
202094.4
1625
0

177
467313
g1506457
334685.2
1879
0
N-cadherin [Human, umbilical vein endothelial cells, mRNA,

4132 nt].

178
620546
g1759518
481101.3
2130
0
Human calmodulin-dependent protein phosphatase catalytic

subunit (PPP3CA) mRNA, complete cds and alternative exon.

179
463249
g1497515
246501.7
1784
0
Human mRNA for PDGF receptor beta-like tumor suppressor

(PRLTS), complete cds.

180
949663
g2283348
1077587.1
1467
0

181
747364
g1904956

182
482198
g1553597
198006.3
1596
5.00E−74
SPARC-related protein

183
317958
g1285908

184
669969
g1888270
201617.34
1621
0
Human mRNA for calgizzarin, complete cds.

185
736372
g1908971
197979.3
1595
0
Human mRNA for tenascin-C, 7560 bp.

186
620101
g1757223

187
777018
g1919075
413348.3c
2042
0
Human mRNA for selenoprotein P.

188
572601
g1662879

189
331264
g1288363
350895.2
1950
0
Human mRNA for B-HLH DNA binding protein.

190
478428
g4408981
763607.1
2152
3.00E−44
Human clone 24747 mRNA sequence.

191
765338
g4303241
238509.4
1743
0
Human p63 mRNA for transmembrane protein.

192
657528
g1794823

193
425279
g1435895

194
734718
g1895583

195
426146
g4061584
257213.5
1820
0
Human mRNA for Hic-5 , partial cds.

196
385763
g4256625

197
426010
g4199205

198
388233
g4613963
438075.1
2071
0

199
335572
g1294552
242309.7
1754
0
Human mRNA for dihydropyrimidinase related protein-3, complete

cds.

200
479895
g1531368
150575.11
1570
0
Human platelet-derived growth factor receptor alpha (PDGFRA)

mRNA, complete cds.

201
385581
g1371846
246037.15
1781
0
Human thyroid receptor interactor (TRIP7) mRNA, 3′ end of

cds.

202
644907
g1807566

203
482326
g4273452

204
637078
g4295283
793752.2
2161
0
Human lectomedin-1 beta (LEC1) mRNA, complete cds.

205
425777
g1436662

206
400530
g1387774
028505.3c
1386
6.00E−72
KIAA1236 protein

207
634792
g1726295

208
870973
g2186637
903105.13
2208
1.00E−23
Human Tigger1 transposable element, complete consensus

sequence.

209
699236
g1876263
481101.3
2130
0
Human calmodulin-dependent protein phosphatase catalytic

subunit (PPP3CA) mRNA, complete cds and alternative exon.

210
466591
g1500922

211
676376
g1806844
1073003.17
1449
0
Human talin mRNA, complete cds.

212
621555
g1760122
399755.3
1991
5.00E−41
Human mRNA; cDNA DKFZp586E171 (from clone DKFZp586E171).

213
671377
g1842477
1190120.1
1556
0
Human ERF-1 mRNA 3′ end.

214
833346
g4614446

235885.17c
1723
0
Human CHD3 mRNA, complete cds.

215
849762
g2180916

216
331794
g1282101
174291.1
1580
0

217
775597
g1918555
300160.24
1843
0
Human mRNA for protein p68.

218
480854
g1558222

219
404044
g1539942

220
404536
g1540287

221
368189
g1355133

222
318735
g1316330
1116916.1
1493
1.00E−92
Human Ca2+ ATPase of fast-twitch skeletal muscle

sarcoplasmic reticulum adult and neonatal isoforms

(ATP2A1) gene, exons 16 to 23 and complete cds.

223
466292
g1504813
233213.4
1682
0
Human mRNA for actin-binding protein (filamin)

(ABP-280).

224
652207
g1814770

225
807727
g2116322

226
720566
g1895126
474310.28
2094
0
Human complement C1r mRNA, complete cds.

227
871674
g2187238

228
777549
g1932671
481101.3
2130
0
Human calmodulin-dependent protein phosphatase catalytic

subunit (PPP3CA) mRNA, complete cds and alternative exon.

229
763629
g1929767
794126.3
2162
0
Human mRNA for KIAA0992 protein, partial cds.

230
803404
g2201297
040428.5
1395
0
Human Fritz mRNA, complete cds.

231
466988
g1506530

232
483148
g4604003

233
480236
g1550947
238085.1
1739
0
Human mRNA; cDNA DKFZp586F2423 (from clone DKFZp586F2423).

234
850280
g2165165
351091.26
1952
0
Human protocadherin gamma A11 (PCDH-gainma-A11) mRNA, complete

cds.

235
315962
g1283340

236
523713
g1565101

237
681615
g1861868
197599.5
1592
0
Human mRNA for protein S.

238
425344
g4061570
234223.15
1702
0
Human pro-alpha-1 (V) collagen mRNA, complete cds.

239
492502
g1642906
1071628.8
1424
0
Human procollagen C-protease (pCP-2) mRNA, complete cds.

240
407096
g1394958

241
634233
g1765588
422072.14
2048
0
Human tyrosine kinase (Tnk1) mRNA, complete cds.

242
478021
g1529144
201589.1
1620
0

243
660896
g1840319

244
426070
g4199206
429579.7
2057
0
Human jun dimerization protein gene, partial cds; cfos gene,

complete cds; and unknown gene.

245
693148
g4315599
757518.3
2142
3.00E−58
Xap89 protein

246
762791
g1909922
285031.17
1836
0
Human collagenase type IV mRNA, 3′ end.

247
465043
g1505213

248
427469
g1445795

249
334106
g1537434

250
419544
g4276184

251
479921
g1531460

252
735227
g1896055

253
618910
g4060524
410917.7c
2034
0
Human LIPA gene, exon 10.

254
426965
g1446709
474736.8
2106
0
Human E2IG1 (E2IG1) mRNA, complete cds.

255
640951
g1807777
720026.1
2138
0
SPI-2 serine protease inhibitor (AA 1-407)

256
677488
g1811883

257
846064
g2076514
400607.21
1997
5.00E−95
Human peripheral myelin protein 22 (GAS3) mRNA, complete cds.

258
330595
g1288256

259
808829
g2193674
403528.2c
2010
0
Human FZD4 mRNA for WNT receptor Frizzled-4, complete cds.

260
464915
g1500705

261
478336
g1529432

262
876326
g2203625
1010408.1
1409
0
Human mRNA for cathepsin C.

263
367947
g1355764
233829.15
1694
0
Human transcription enhancer factor-5 mRNA, complete cds.

264
581835
g1726103

265
333511
g1315889
1071467.6
1419
0
Human mRNA; cDNA DKFZp586J0917 (from clone DKFZp586J0917);

partial cds.

266
475631
g4273377
404183.1
2011
0
Human voltage-dependent calcium channel alpha 1G subunit a

isoform (CACNA1G) mRNA, complete cds.

267
643158
g1776469

268
749482
g1937342

269
480454
g1551150
362662.1
1965
0

270
760918
g2039781

271
751020
g4316657
726130.1
2139
0

272
444388
g4057723
1166856.2
1514
0
Human mRNA for reticulocalbin, complete cds.

273
751385
g4316966
349742.3
1936
0
Human transcription factor (MEF2) mRNA, complete cds.

274
402348
g1388926
765245.1
2156
6.00E−79
Human mRNA for neutral calponin, complete cds.

275
420553
g1542095
888865.1
2185
0
Human mRNA for KIAA1224 protein, partial cds.

276
622257
g1767769

277
920587
g2288403
198830.1
1599
0

278
696542
g1863765

279
464575
g1497689
233747.1
1692
0
Human clone 24670 mRNA secpaence.

280
354859
g1330557
245181.3c
1772
1.00E−95
Human mRNA for MAP kinase activated protein kinase.

281
439383
g4315259

282
764649
g1913111

283
315890
g1286831

284
876698
g2232417
300160.24
1843
0
Human mRNA for protein p68.

285
736854
g1909620
256145.6
1813
1.00E−50
Human UDP-glucose: glycogen 4-alpha-D-glycosytransferase mRNA,

complete cds.

286
722330
g1888849

287
444383
g4272013
757587.1
2145
0
Human checkpoint suppressor 1 mRNA, complete cds.

288
890486
g4373839
471800.1
2089
2.00E−85
Human mRNA for fibroblast tropomyosin TM30 (pl).

289
680191
g1861942
762190.1
2151
0

290
698175
g1863483

291
922991
g2249284
199986.1
1608
0
Human mRNA for partial NOV/plexin-A1 protein.

292
638401
g1826001
1137704.1
1496
7.00E−74
Human mRNA; cDNA DKFZp586P1622 (from clone DKFZp586P1622).

293
385853
g1369035

294
388617
g1375661

295
444842
g1478978
346516.2
1917
0
Human mRNA for MSX-2, complete cds.

296
316113
g1283096
233338.1
1685
0
Human intergenic DNA between SURF-2 and SURF-4.

297
890932
g2248891
337621.2
1891
0
Human neuronal DHP-sensitive, voltage-dependent, calcium

channel alpha-2b subunit mRNA, complete cds.

298
420591
g1542116
336834.2
1886
7.00E−98
Human clones 23549 and 23762 mRNA, complete cds.

299
331768
g4216904
371288.7
1971
0
Human mRNA for dihydropyrimidinase related protein-2, complete

cds.

300
864361
g2180856

301
574070
g1676562
1072938.4
1442
0
Human lysosomal pepstatin insensitive protease (CLN2) mRNA,

complete cds.

302
334291
g1318252
144576.1c
1568
1.00E−29
Alg2

303
482677
g1555797

304
524459
g1575935

305
466781
g1501117

306
418645
g1426772

307
418766
g1426920

308
680426
g1861189
360570.1
1960
4.00E−16
LZIP-1 and LZIP-2

309
776048
g1918653
1072938.4
1442
0
Human lysosomal pepstatin insensitive protease (CLN2) mRNA,

complete cds.

310
464603
g1497291

311
419265
g1543811

312
406999
g4257421

313
419455
g4199165

314
390016
g1380369

315
331599
g1282077
269837.11
1828
0
Human PIL protein mRNA, complete cds.

316
693244
g1882667

317
408747
g1541642

318
775514
g2041254

319
733937
g1905138

320
777555
g1919315
244823.1
1769
0
Human mRNA for protein kinase Dyrk2.

321
420049
g1541974
221055.8
1646
0
Human non-p53 regulated PA26-T1 nuclear protein (PA26) mRNA,

complete cds.

322
720937
g1904312

323
492514
g4057921

324
337618
g1294407
344617.7
1909
0
Human mRNA for nel-related protein 2, complete cds.

325
536634
g4272822

326
459284
g1497434
384264.3
1978
0
Human mRNA for frizzled-1, complete cds.

327
408381
g1541463

328
420484
g1542038
053059.6c
1397
2.00E−05
unknown protein

329
458802
g1488968
401593.14
2004
0
Human quiescin (Q6) mRNA, complete cds.

330
425742
g1436545

331
932999
g2284192
1071733.3
1427
0
Human DAP-kinase mRNA.

332
735647
g1908564
233187.1
1681
0
Human HSPC169 mRNA, complete cds.

333
634252
g1766738
474680.12
2104
0
Human mRNA for Sec24 protein (Sec24B isoform).

334
550700
g1643510

335
597249
g1714712

336
620453
g1759420
726130.1
2139
0

337
464803
g1500830
260591.6
1825
0

338
445075
g4272043

339
472722
g1513612

340
738162
g1909378
332667.1
1871
6.00E−48
Human mRNA; cDNA DKFZp56611247 (from clone DKFZp566I1247).

341
642114
g1808523
174021.1
1576
0

342
426103
g4199207

343
764212
g1931980
1072489.2
1438
0

344
523303
g4623768
233046.2
1677
0
Human mRNA for KIAA0382 gene, partial cds.

345
736017
g1908593
201056.2
1613
0
Human cytokine-inducible SH2 protein 6 (CISH6) mRNA, complete

cds.

346
803488
g2201516

347
656375
g1873357
201101.5
1615
0
Human FK506-binding protein mRNA, complete cds.

348
920701
g2284349
330970.3
1853
4.00E−38
Human reticulon gene family protein (RTN3) gene, exon 7 and

complete cds.

349
492457
g1643181

350
736232
g1908766
334418.3
1877
0
Human protein kinase mRNA, complete cds.

351
424307
g1428306
168836.3
1575
0
Human Cak receptor kinase mRNA, complete cds.

352
583186
g1726467

353
418660
g4275523
234636.5
1706
2.00E−93
Human Hox5.4 gene fragment.

354
493238
g1643708
242309.3c
1753
0
Human mRNA for dihydropyrimidinase related protein-3, complete

cds.

355
876058
g2203273

244579.27c
1765
0
Human amyloid precursor protein homolog HSD-2 mRNA, complete

cds.

356
617885
g1756444
429727.5
2060
0
Human fibrillin-2 mRNA, complete cds.

357
419185
g1542418

358
736526
g4317916

359
737898
g1917399

360
680964
g1873049

361
481883
g4057878

362
423599
g4271828
1143741.1c
1501
0

363
636407
g1765551
332404.6
1866
0

364
481450
g1554267

365
599075
g1751902

366
573052
g1676190

367
464165
g1494519

368
622039
g1767204
401619.5
2007
0
Human zinc finger protein (MBLL) mRNA, complete cds.

369
467107
g1506427
250186.6
1792
0
Human mRNA for procollagen alpha 2(V).

370
807447
g4320582
401619.11
2006
0
Human zinc finger protein (MBLL) mRNA, complete cds.

371
716523
g1901594
902565.9c
2203
0
Human plasma membrane Ca2+ pumping ATPase mRNA, complete

cds.

372
733746
g1905104
234427.5
1704
0
Human mRNA for GS3955, complete cds.

373
817954
g2192670

374
466730
g1501087
1188552.2c
1539
0
Human protein phosphatase 2A beta subunit mRNA, complete

cds.

375
763553
g1929690
002588.4
1368
1.00E−40
unknown orf, len: 393, CAI: 0.13

376
406947
g1541090
241169.5
1750
0
cyclophilin C [Human, kidney, mRNA, 883 nt].

377
622182
g1767610

378
422477
g1427462

379
949384
g2288499

380
777321
g1919540
401550.13
2002
5.00E−09
Human mRNA; cDNA DKFZp434P1217 (from clone DKFZp434P1217);

partial cds.

381
475285
g4408840

382
493702
g4273705

383
536577
g1595710

384
466255
g1504701

385
466178
g1504783
199423.6
1603
1.00E−22
copine III

386
464415
g1497650

387
423344
g4271810
399595.1
1990
0
Human full length insert cDNA clone YP83B01.

388
637333
g1768679

389
439638
g1464684
390183.3c
1980
0
Human mRNA for embryonic myosin heavy chain.

390
458712
g1488806

391
672859
g1853720
327521.13
1848
6.00E−30
Human mRNA for histidyl-tRNA synthetase (HRS).

392
467172
g1506554
137252.5
1564
0
Human parathyroid hormone/parathyroid hormone-related

peptide receptor mRNA, complete cds.

393
400571
g1387542

394
355517
g1333025
399595.1
1990
0
Human full length insert cDNA clone YP83B01.

395
777529
g1919306

396
533405
g1654747
208832.8
1636
0
Human clone 23771 mRNA sequence.

397
680761
g1873027

398
374296
g1371733
476434.16
2118
0
Human mRNA; cDNA DKFZp586B1417 (from clone DKFZp586B1417);

partial cds.

399
774810
g2039799
1071542.9c
1422
0
Human mRNA for KIAA1075 protein, partial cds.

400
582063
g1725958

401
643905
g1800364
009165.8
1371
0
Human ATP cassette binding transporter 1 (ABC1) mRNA, complete

cds.

402
484125
g1595433

403
332327
g1282454

404
717466
g2057400

405
421592
g1427003
039966.3
1393
1.00E−91
Human methyl-CpG binding protein 2 (MBD2) gene, exon 1.

406
583632
g1713380
245416.17
1774
0
Human Mad4 homolog (Mad4) mRNA, complete cds.

407
618535
g1756599

408
761605
g1910698
429406.3c
2056
4.00E−95
Human mRNA; cDNA DKFZp564C1940 (from clone DKFZp564C1940);

partial cds.

409
693542
g1863292
474928.4
2108
4.00E−50
KIAA0970 protein

410
751958
g2049346

411
749073
g1937165
475038.2
2110
0
Human AA1 mRNA.

412
484259
g1619113

413
479920
g1531457
1144093.1
1504
0
Human putative tumor suppressor protein unspliced form (Fus-2)

mRNA, complete cds.

414
891260
g2248727

415
478904
g1755298
474562.4
2100
0

416
597342
g1715393
812451.1
2167
0
Human sodium/myo-inositol cotransporter (SLC5 A3) gene,

complete cds.

417
439399
g4315264
243308.3
1757
0

418
638302
g1795880

419
524119
g1563106

420
864344
g2180931

421
695508
g1838335
1188730.2
1543
0
Human selenoprotein N mRNA, partial cds.

422
467480
g1508946
899716.1
2199
2.00E−50
Human (clone H4/H16) gamma-glutamic carboxylase mRNA,

complete cds.

423
404526
g4056811
1072584.3
1440
0
Human translocon-associated protein gamma subunit mRNA,

complete cds.

424
439732
g1475306
407061.11
2021
0
Human mRNA; cDNA DKFZp586N1922 (from clone DKFZp586N1922);

partial cds.

425
403274
g1539431

426
426493
g1445785
243293.2
1756
4.00E−24
Human ribosomal protein L37a (RPL37A) mRNA, complete cds.

427
576974
g1682062
1073084.13
1456
0
Human transforming growth factor-beta type III receptor

(TGF-beta) mRNA, complete cds.

428
720567
g4765705

429
478156
g1529273
1171690.1
1521
0
Human AF-9 mRNA, complete cds.

430
641871
g1808211
328977.5
1849
0
Human G-protein gamma-10 subunit mRNA, complete cds.

431
622319
g1758983
814644.23
2173
0
Human protein tyrosine phosphatase (PTPase-alpha) mRNA.

432
717910
g1882293
256051.1

433
476653
g1530219
238040.3c
1738
6.00E−22
thrombomodulin precursor

434
387151
g1373933

435
762532
g1909815

436
762728
g1910000
113174.4c
1494
2.00E−77
Human Sox-4 mRNA.

437
439803
g1464508
765499.1c
2157
0

438
874540
g2200305

439
831744
g4616603

440
764518
g1912735

441
436894
g4199217
1094858.1
1488
0
Human mRNA for B-FABP, complete cds.

442
473770
g1513824
762190.1
2151
0

443
438506
g4315201
347941.9
1928
0
Human mRNA for KIAA0987 protein, partial cds.

444
580505
g1700169
816318.4
2181
0
Human calcium-binding protein chp mRNA, complete cds.

445
582571
g1713535
233927.4
1697
0
Human SM-11044 binding protein mRNA, partial cds.

446
481880
g4057877

447
478521
g1529686
455057.6
2081
0
L-arginine: glycine amidinotransferase [Human, kidney

carcinoma cells, mRNA, 2330 nt].

448
421537
g4275663

081641.13c
1403
0
Human mRNA for KARP-1-binding protein 2 (KAB2),

complete cds.

449
809031
g2192179

450
390236
g1385123

451
733517
g1896508

452
597547
g1713758
903441.9
2212
0
Human P13-kinase associated p85 mRNA sequence.

453
418495
g1541869
025595.2
1384
0
Human LAMB2 mRNA for beta2 laminin.

454
331186
g1287469
345146.9
1911
0
Human caveolin 1 (CAV1) gene, exon 3 and partial cds.

455
694133
g1863090
1072976.4
1445
0
Human ezrin-radixin-moesin binding phosphoprotein-50 mRNA,

complete cds.

456
776562
g1918519

457
619201
g1756813
423565.22
2049
0
Human WSB-1 isoform mRNA, complete cds.

458
418453
g4275517
197929.1
1594
0
Human full length insert cDNA clone ZD41E06.

459
440843
g1464807
200009.2
1609
0

460
457264
g1487595
012942.16
1375
0
Human skeletal muscle LIM-protein SLIM3 mRNA, partial cds.

461
332687
g1282686

462
598305
g1740058
238120.1
1740
0
Human mRNA; cDNA DKFZp586N0721 (from clone DKFZp586N0721).

463
466905
g1501227
336968.1
1889
0.0006
ORF-3 protein

464
574888
g1676029
397963.12
1984
0
Human arginine methyltransferase mRNA, complete cds.

465
679641
g1873545
244322.33
1763
0
Human mRNA for KIAA0251 gene, partial cds.

466
734062
g1910437
241227.8
1751
0
Human unknown mRNA.

467
576216
g1677377
1006060.1
1408
0

468
620333
g1759076
474360.6
2096
0
Human Smad1 mRNA, complete cds.

469
441276
g1472901

470
476019
g1755257
074456.1
1401
0.001
salivary proline-rich protein precursor

471
354601
g1330439
1072389.2
1433
0
Human ELP-1 mRNA sequence.

472
474107
g4623821

473
420709
g1542184
404716.8
2018
0
Human desmoplakin I (DPI) mRNA, complete cds.

474
621389
g1760003

475
717316
g2057838
1071390.7
1416
1.00E−11
unknown protein

476
493109
g1642864
902527.2
2202
0
Human WDR1 protein mRNA, complete cds.

477
403384
g1539501
233660.5
1689
3.00E−32
ubiquitin-specific protease

478
483024
g1554701
075492.97
1402
0
Human alpha gene sequence.

479
572889
g1662698
1073021.18
1451
0
Human mRNA for BS69 protein.

480
733557
g1895904
814642.2
2172
0
Human partial cDNA sequence, clone bs86;.

481
478265
g1529416

482
423915
g1542742
199975.3
1606
0
Human mRNA for KIAA1249 protein, partial cds.

483
695447
g1838303

484
640875
g1807751
1073172.1
1460
6.00E−18
Human mRNA for KIAA0280 gene, partial cds.

485
480526
g4061314

486
696489
g1863752

487
639911
g1793063

488
874154
g2200262
438393.1
2072
0

489
777640
g1919644
373272.16
1972
0
Human mRNA for serum protein.

490
888624
g2233824
430153.7
2064
0
Human mRNA for 3′,5′-cyclic GMP phosphodiesterase,

complete cds.

491
762542
g1909872
287029.4c
1839
0
Human mRNA for PIG-F (phosphatidyl-inositol-glycan class F),

complete cds.

492
875543
g2203333
440122.23
2073
0
Human archvillin (SVIL) mRNA, complete cds.

493
439959
g4315296

494
749144
g1937196

495
922965
g2249219
245992.3
1780
0
Human CGI-123 protein mRNA, complete cds.

496
721040
g1904106

497
480149
g1531416

498
596754
g1700680

499
920211
g2235263
233017.4
1676
0
Human full length insert cDNA clone YB21H04.

500
457289
g1487605
196915.1
1587
0
Human mRNA; cDNA DKFZp586H0924 (from clone DKFZp586H0924).

501
355990
g1337506
1073075.15
1454
0
Human chondroitin sulfate proteoglycan versican V0 splice-

variant precursor peptide mRNA, complete cds.

502
354506
g1330567
244823.1
1769
0
Human mRNA for protein, kinase Dyrk2.

503
424979
g1435853

504
697506
g1888261

505
419788
g4276191

506
402614
g1389111
1074263.1
1463
2.00E−69
precursor cystatin C C-terminal fragment (128 AA) (1 is 2nd

base in codon)

507
459254
g1497391
306467.1
1845
0
Human mRNA for KIAA1048 protein, complete cds.

508
672351
g1853873

509
466715
g1501032
029170.7
1387
2.00E−36
Human mRNA for KIAA0964 protein, complete cds.

510
735186
g1896159
1188593.1c
1540
0
Human CGI-63 protein mRNA, complete cds.

511
314394
g1286865
110671.1
1491
0

512
748241
g1914982
234157.2
1701
0
Human chromosome 16 open reading frame 5 (C16orf5) mRNA,

complete cds.

513
421973
g4275694

514
621316
g1759898
336239.5
1884
0
Human cobalt inducable gene-18.

515
404339
g1540164

516
764361
g1917253

517
482328
g1554719
255931.2
1808
0
Human mRNA; cDNA DKFZp564O123 (from clone DKFZp564O123);

complete cds.

518
775912
g1919033
236455.25
1729
0
Human mRNA; cDNA DKFZp434P106 (from clone DKFZp434P106).

519
571643
g1660314

480992.10c
2129
0
Human 9-cis-retinol specific dehydrogenase mRNA,

complete cds.

520
678740
g1861388
425074.21
2051
0
Human rac protein kinase alpha mRNA, complete cds.

521
618644
g1748887
410523.5
2031
0
Human guanine nucleotide exchange factor mRNA,

complete cds.

522
763021
g1910069

523
641451
g1796607
476434.22
2119
0
Human mRNA; cDNA DKFZp586B1417 (from clone DKFZp586B1417);

partial cds.

524
314127
g1284229
401617.5
2005
1.00E−81
Human mRNA; cDNA DKFZp586H051 (from clone DKFZp586H051).

525
596968
g1701096

526
803358
g2201244
234748.5
1708
3.00E−18
parathion hydrolase (phosphotriesterase)-related protein

527
390390
g1380956

528
875444
g2203197
349727.7
1935
0
Human G-protein-coupled receptor kinase (GRK5) mRNA,

complete cds.

529
820354
g4320896
018683.1
1378
0
Human mRNA for Slit-3 protein, complete cds.

530
736616
g1909000
902725.1
2204
0
Human mRNA for laminin alpha 4 protein.

531
876166
g2204008
235180.8
1715
2.00E−73
Human full length insert cDNA clone ZD76G10.

532
904738
g2262509

533
775150
g2039860
340580.28
1897
0
Human genomic DNA of 21q22.2 Down Syndrome region,

segment 2/13.

534
671660
g1872625
398839.6
1985
0
Human chromosome X region from filamin (FLN) gene to

glucose-6-phosphate dehydrogenase (G6PD) gene,

complete cds's.

535
373793
g1372276
245886.11
1778
0
Human mRNA for calponin, complete cds.

536
596200
g1681701

537
652498
g1826320

538
658233
g1793900

539
442842
g1476026
331792.1
1862
0
Human mRNA; cDNA DKFZp564G2463 (from clone

DKFZp564G2463).

540
774877
g2039712

541
421530
g1427184

542
419553
g1542538

543
386236
g1372731

544
418531
g1541886

545
439010
g1464219

546
643384
g1772257

547
464245
g1504318

548
718110
g1902551

549
902264
g2256372
410012.16
2030
0
Human HSPC292 mRNA, partial cds.

550
718293
g1895306
004943.1
1370
3.00E−48
erythropoietin receptor precursor

551
523088
g1565032
235147.76
1712
0
Human calumein (Calu) mRNA, complete cds.

552
423219
g4275742
331042.1
1855
0
Human mRNA for KIAA1094 protein, complete cds.

553
762782
g1910032
1080543.1
1473
0

554
572156
g1654977
478176.6
2120
0
Human T245 protein (T245) mRNA, complete cds.

555
763989
g1929706

556
463860
g1494600

557
670375
g1840508

558
406689
g4257398

559
466155
g1504779

560
622792
g1758855

561
597729
g4060433
399489.1
1989
0
Human tactile protein mRNA, complete cds.

562
472407
g1509530
410660.21
2033
0
Human enigma gene, complete cds.

563
765073
g1912816

564
922216
g2250492
137946.2
1565
6.00E−08
ORF MSV242 putative inhibitor of apoptosis protein (IAP),

similar to Autographa californica NPV GB:D36828

565
677412
g1811582
235197.9c
1716
0
Human protein-tyrosine phosphatase (PTPase MEG2) mRNA,

complete cds.

566
722451
g1888830

567
846131
g2076192
034500.3
1390
0

568
762142
g1917792
349617.2
1933
0
Human DNA-binding protein mRNA, 3′ end.

569
934635
g2282831

570
332091
g1282177

571
329780
g1286926
331908.5
1863
0
Human mRNA for p cadherin.

572
574476
g1684321

573
476342
g1530321
1088480.1
1484
0
Human mRNA; cDNA DKFZp564A2416 (from clone DKFZp564A2416).

574
482943
g4273558
233550.1
1687
0
odd-skipped related 1 protein

575
680103
g4306694

576
574134
g1676531

577
334410
g1293946

578
872869
g2192572
399101.6c
1987
0
Human mRNA for S100 alpha protein.

579
749776
g1937662
1189233.1c
1547
0
Human mRNA for KIAA0623 protein, complete cds.

580
749282
g1937085

581
820498
g2102189

582
317778
g1287080

583
439784
g1464549

584
426076
g1436861

585
336726
g4258568
411151.3c
2037
0
Human mRNA for ZASP protein, partial.

586
479750
g1531290

587
353229
g1325860

588
777101
g1918994
349746.6
1937
0
Human MADS/MEF2-family transcription factor (MEF2C) mRNA,

complete cds.

589
330370
g4257102

590
656701
g1864627

591
622653
g1758772
292613.13
1842
5.00E−35
Human CGI-72 protein mRNA, complete cds.

592
425348
g1435908

593
423177
g1427142
814118.1
2170
0

594
419633
g1538799
345309.9
1914
0
Human mRNA for endothelin-converting enzyme, complete cds.

595
635569
g1743958
481144.8
2131
0
Human PAK2 mRNA, complete cds.

596
493460
g1630169

597
777306
g1919658

598
761298
g2041294

599
479846
g1531151

600
595978
g1699549

601
850389
g2164914

602
888687
g2233780
333812.6
1875
0

603
478848
g4057832

604
477665
g4276659
353740.3
1957
0
Human PHD-finger protein (GRC5) mRNA, complete cds.

605
421653
g1428844
1189864.1
1555
1.00E−10
agrin

606
622359
g4766055

607
637536
g1768408

608
425653
g1436197
813260.1
2168
0
Human heart chymase mRNA, complete cds.

609
641660
g1808314

610
477177
g1527804
039466.2
1391
0
Human RNB6 (RNB6) mRNA, complete cds.

611
419846
g1538910

612
385072
g1369680

350447.13c
1947
1.00E−85
Human src-like kinase (slk) mRNA, complete cds.

613
935626
g2292157

614
483763
g4057914

615
476321
g1530261
211736.9
1640
0
Human semaphorin III family homolog mRNA, complete cds.

616
748112
g1897006
093687.7
1405
0
Human uncoupling protein-2 (UCP2) gene, nuclear gene

encoding mitochondrial protein, complete cds.

617
641523
g1796629
429857.16
2062
0
Human zinc ringer transcriptional regulator (GOS24) gene,

complete cds.

618
422094
g1427202
250793.3
1793
0
growth suppressor 1L

619
637934
g1776582

620
468472
g1475255
474411.49
2097
0
Human syntaxin 7 mRNA, complete cds.

621
641806
g1808488

622
621352
g1758571

623
775722
g1918497

624
638593
g4522215
1019119.1c
1412
0

625
406222
g1540639

626
583823
g1715789
1190143.1c
1557
3.00E−17
Similar to Rat trg gene product; coded for by C. elegans cDNA

yk31e7.5; coded for by C. elegans cDNA yk40d6.5; coded for by

C. elegans
cDNA yk31e7.3; coded for by C. elegans cDNA yk40d6.3;

coded for by C. elegans cDNA yk149g5.3; coded for by C>

627
571503
g1660682

628
681670
g1862017

629
721482
g1903673

630
776770
g1913500
1079214.1
1471
1.00E−30
NBAT

631
423210
g1427173

632
598956
g1746848
900028.1
2200
6.00E−45
Human glycophorin C (PAS-2) mRNA, complete cds.

633
660997
g1888209

634
751729
g2049156
174273.1
1579
0

635
535228
g1629910
474891.5
2107
0
Human dynactin p62 subunit mRNA, complete cds.

636
464134
g1494446
435298.1
2067
0

637
737934
g1909346
406531.1
2020
0
Human bone morphogenetic protein 5 (BMP-5) mRNA, complete cds.

638
697509
g1888265
899062.1
2194
1.00E−99
Human OS-4 protein (OS-4) mRNA, complete cds.

639
481375
g1554177

640
420487
g1542044
410561.3
2032
0
Human voltage-gated calcium channel beta subunit mRNA,

complete cds.

641
574756
g1682468
116417.8
1510
0
Human RP58 gene, complete cds.

642
621226
g1759846
903485.2
2214
0
Human receptor-associated tyrosine kinase (JAK2) mRNA,

complete cds.

643
480431
g1551147

644
427349
g4271980

645
699290
g1876308
411148.2
2036
0
Human mRNA for transducin (beta) like 1 protein.

646
670886
g1841284
898101.24
2189
0
Human RHOA proto-oncogene multi-drug-resistance protein mRNA,

3′ end.

647
385725
g1371890
431802.7
2066
0

648
818435
g2139651
010652.1
1372
0

649
717056
g1904436

650
385435
g1371803
400575.4
1995
0
Human mRNA for KIAA0630 protein, partial cds.

651
445817
g4057739
411135.6
2035
0
Human fra-2 mRNA.

652
949003
g2292273

653
478711
g1531055

654
387594
g1375763

655
746888
g4616861

656
474184
g1514146

657
423531
g4271823
417948.2
2046
0

658
463575
g1500768
1072534.1
1439
0
Human peroxisomal D3,D2-enoyl-CoA isomerase (PECI) mRNA,

complete cds.

659
948588
g2305796
198215.1
1598
0

660
464866
g1497659

661
597832
g1739402
357143.4
1958
0
Human apoptosis-related RNA binding protein (NAPOR-3) mRNA,

complete cds.

662
876381
g2203656
424444.21
2050
0
Human LSFR1 gene, sixth to eigth of eight identified exons.

663
905429
g2271843

664
401764
g1388816
401705.4
2008
0
Human frequenin mRNA, complete cds.

665
347921
g1309848
903876.6
2215
0
Human protein-tyrosine kinase (JAK1) mRNA, complete cds.

666
736724
g1909293
115947.12
1507
0
Human cAMP-dependent protein kinase regulatory subunit

RI-beta mRNA, 3′ end.

667
618375
g1756304

668
402843
g1391292

669
751577
g2042938
474588.15
2101
0
Human polyadenylate binding protein (TIA-1) mRNA,

complete cds.

670
677054
g1811857
232986.4c
1675
0
Human mRNA; cDNA DKFZp434D156 (from clone DKFZp434D156);

partial cds.

671
695231
g1838312
481960.8
2136
0
Human liprin-beta1 mRNA, complete cds.

672
576022
g1676639
334355.14
1876
0
Human mRNA; cDNA DKFZp434E171 (ftom clone DKFZp434E171);

partial cds.

673
536574
g1595625
345283.14
1913
0
Human regulator of G-protein signaling RGS12 (RGS) mRNA,

complete cds.

674
888544
g2233811
236836.7
1732
0
Human CGI-38 protein mRNA, complete cds.

675
576003
g4300335

676
642330
g1768894
233910.3
1696
0
Human mRNA for KIAA1008 protein, complete cds.

677
334138
g1537441
350234.5
1944
2.00E−55
ORF

678
751348
g1937073
243989.7
1760
0
Human Mago homolog mRNA, complete cds.

679
479576
g1528656

135490.11c
1563
0
Human mRNA for KIAA1007 protein, partial cds.

680
351163
g1324773

681
403660
g1539702
401575.1

682
671530
g1865589
1175282.1
1524
0
Human mRNA for basic transcription factor 2, 34 kD subunit.

683
532186
g1566657
1072468.2
1437
0
Human, NAD(P)H: menadione oxidoreductase mRNA, complete cds.

684
934425
g4606070
239750.2
1748
0

685
476367
g1530332

686
736297
g1908935
757594.5
2146
2.00E−92
Human D38 mRNA.

687
425523
g4271900
202281.2
1627
0
SPARC-related protein

688
636193
g1766844
197486.9c
1590
0
Human mRNA for VRK2, complete cds.

689
833508
g2192120

344543.16c
1906
0
Human mRNA for 26S proteasome subunit p44.5, complete cds.

690
656956
g1864871
757538.7
2143
0
Human cell cycle progression 2 protein (CPR2) mRNA,

complete cds.

691
733856
g1904900
233958.2
1698
0
Human calpain-like protease (htra-3) mRNA, complete cds.

692
820430
g2102146
428087.2
2055
3.00E−54
Human GA17 protein mRNA, complete cds.

693
616975
g1744427
1081629.1
1474
0
Human mRNA for DRM protein.

694
418563
g1428966
474965.3
2109
0
26 S protease subunit 5b = 50 kda subunit [Human,

HeLa cells, mRNA Partial, 2253 nt].

695
640026
g1793064
421854.2
2047
0
Human centrosomal protein kendrin mRNA, complete cds.

696
948662
g2291590

135490.11c
1563
0
Human mRNA for KIAA1007 protein, partial cds.

697
894275
g2256859
1072970.5
1444
3.00E−10
mitochondrial solute carrier

698
737800
g1917863
344200.3
1903
0
Human zinc ringer DNA binding protein 99 (ZNF281) mRNA,

complete cds.

699
833284
g2191986

700
791460
g2075608

701
671801
g1872777
435550.1
2068
6.00E−90
Human full length insert cDNA clone YZ83B08.

702
889470
g2233541
331585.8
1860
6.00E−70
elongation factor G

703
472805
g4059293
903095.1
2207
7.00E−65
Human chromodomain-helicase-DNA-binding protein mRNA,

complete cds.

704
597797
g1740027
138082.1
1566
0

705
425442
g4271893
350396.1
1945
6.00E−65
Human CpG island DNA genomic Msel fragment, clone 28b4,

forward read cpg28b4.ft1a.

706
438286
g1464386
404616.2
2016
0
pyridoxine 5′-phosphate oxidase

707
424618
g4271855

708
808777
g2193625
404508.14
2014
0
Human mRNA for KIAA0896 protein, partial cds.

709
389279
g1380076
161166.2
1574
0
Human RNaseP protein p30 (RPP30) mRNA, complete cds.

710
425081
g1435802
475291.7
2113
1.00E−98
Human RNA polymerase I 16 kDa subunit mRNA, complete cds.

711
749766
g4766354

712
791058
g2075289
1185880.1c
1532
0
Human mRNA for hSNF2H, complete cds.

713
699378
g4315392

714
579733
g1671962

715
640062
g1792969
899418.2
2198
0
Human tumor suppressing STF cDNA 1 (TSSC1) mRNA,

complete cds.

716
761554
g1910664
238950.7
1745
0
Human mRNA; cDNA DKFZp566C0424 (from clone DKFZp566C0424);

partial cds.

717
618630
g1756110
476034.4
2116
2.00E−94
Human znf6 mRNA for zinc finger transcription factor.

718
390118
g1380489
394963.6
1982
0
Human mRNA for KIAA0011 gene, complete cds.

719
735147
g1895925

720
640178
g4804880

721
534015
g1594589

722
423081
g1427956
191737.1c
1585
1.00E−13
R04E5.2 gene product

723
400308
g1387448
425487.5
2052
0
Human mRNA for KIAA1080 protein, partial cds.

724
751619
g2049091

725
780092
g2074942
350100.35
1940
0
Human set gene, complete cds.

726
316237
g1283201
1094181.3c
1486
0
RDP = renal dipeptidase [Human, kidney, Genomic,

3570 nt, segment 2 of 2].

727
476022
g1755255

728
597201
g1714701

729
352795
g4258974

730
465555
g1504185

731
807462
g2071508
257179.6
1818
0
Human full length insert cDNA clone YU03D12.

732
762210
g1917812
243812.2
1759
0
Human stress-activated protein kinase 4 mRNA,

complete cds.

733
351221
g4199085
336147.1
1883
0
Human glycerol-3-phosphate dehydrogenase mRNA, nuclear

gene encoding mitochondrial protein, complete cds.

734
472664
g1513402
220839.3
1645
6.00E−89
KIAA1078 protein

735
400408
g4257438
199099.3
1602
2.00E−29
R28379_3

736
350881
g1325311
1084837.1
1477
3.00E−25
similar to carrier protein C2; cDNA EST EMBL:Z14780 comes

from this gene; cDNA EST EMBL:Z14920 comes from this gene;

cDNA EST EMBL:M89112 comes from this gene; cDNA EST

yk458c8.5 comes from this gene; cDNA EST yk458c8.3 comes

from this gene; c>

737
424559
g1428189
235169.1
1714
5.00E−93
Human HSPC316 mRNA, partial cds.

738
573595
g1662629

739
699377
g1876278
197003.1
1588
0

740
386234
g1372730
257576.34
1822
0
Human mRNA for novel heterogeneous nuclear RNP protein,

L protein.

741
576991
g1681607
201417.15
1618
0
Human U4/U6 small nuclear ribonucleoprotein hPrp3 mRNA,

complete cds.

742
317597
g1285746
350777.7
1949
0

743
577676
g4061823
407724.1
2025
0
Human mRNA for GTPase activating protein ID-GAP,

complete cds.

744
698109
g1863171
253617.12
1801
0
Human gene for mitochondrial ATP synthase c

subunit (P2 form).

745
437685
g1463796

746
762306
g1917901

747
354969
g1330700

748
332285
g1282707

749
464392
g4058645

750
406706
g1394621
024513.4
1383
2.00E−11
Ydr449cp; CAI: 0.18

751
804212
g2202679
331647.2
1861
0
Human mRNA; cDNA DKFZp434G0972 (from clone DKFZp434G0972).

752
581115
g1702222

753
315536
g1284151

754
639975
g1793232

755
580166
g1699962

756
482432
g4603968

757
697208
g1841066

758
478334
g4057824
232344.1c
1670
0
Human lamin B2 (LAMB2) gene and ppv1 gene sequence.

759
403381
g1539508
1077535.1
1466
4.00E−28
helicase

760
779373
g2074977

761
441227
g1472886
366108.8
1967
3.00E−43
Human genomic DNA fragment (clone NL2A230R).

762
746908
g1915033

763
775188
g2040160

764
351869
g1324943

765
439640
g1464685
903951.15
2217
0
ArgRS = arginyl-tRNA synthetase [Human,

ataxia-telangiectasia patients, EBV-lymphoblastoid cells,

mRNA, 2120 nt].

766
620209
g1759154
1189704.1
1551
0

767
318957
g1316157
245970.4
1779
0
Human alpha 1-syntrophin (SNT A1) mRNA, complete cds.

768
468823
g1509030
230893.12
1665
0
Human DNA polymerase delta small subunit mRNA,

complete cds.

769
618926
g1756624

770
353445
g1325643
474244.9
2093
0
Human cleavage and polyadenylation specificity factor mRNA,

complete cds.

771
920442
g2284501
346108.11
1915
2.00E−96
Human BTK region clone 2f10-rpi mRNA.

772
443441
g1475077
333506.1
1874
0
Human nuclear FMRP interacting protein 1 (NUFIP1) mRNA,

complete cds.

773
403946
g1539872

774
442662
g1476176
1086324.1
1483
0
Human mRNA for elongation factor-1-beta.

775
484299
g1619178
282761.6c
1835
0
Human end mRNA for endoglin.

776
639902
g1792952
1188855.2
1544
6.00E−08
eyelid

111
479201
g4273404

778
961056
g4401577

779
961282
g2308846
233889.3
1695
0
Human ckshs1 mRNA for Cks1 protein homologue.

780
373505
g1365775

781
894169
g2256632

782
419193
g1542420
474597.1
2103
0
Human nuclear factor p97 (NTF97) gene, complete cds.

783
720904
g4765743

784
671169
g1842625
233723.2
1691
0

785
920335
g4405504

786
638129
g4296087
399465.4
1988
0
Human mRNA for KIAA0136 gene, partial cds,

787
535949
g4060161
205575.15
1633
0
Human activation of Sentrin/SUMO protein AOS1 (AOS1) mRNA,

complete cds.

788
336325
g1537507
255781.16
1805
0
Human mRNA for connective tissue growth factor.

789
577766
g1701429
898733.2
2191
2.00E−32
Prodos protein

790
419886
g4199169

791
750205
g2049494
760717.1
2149
2.00E−76
Human YEAF1 mRNA for YY1 and E4TF1 associated factor 1,

complete cds.

792
483584
g1555700
475486.1
2114
9.00E−82
Human cyclophilin isoform (hCyP3) mRNA, complete cds.

793
523965
g1566011
233592.5
1688
0
Human mRNA for A-kinase anchoring protein AKAP95.

794
439665
g1475372
413452.77
2043
0

795
642201
g4304497

796
633284
g1759730
1188225.1
1537
0

797
692936
g1862500
816001.1
2179
0
Human mRNA for transcription factor BTF 3.

798
572463
g1662557

799
581799
g1725895
273186.6c
1830
0

800
493202
g4057933
404509.1
2015
0
Human G-protein-coupled receptor GPR-NGA gene, complete cds.

801
465848
g1504234
890191.3c
2187
0

802
653622
g1826650
344071.13
1902
0
Human mRNA; cDNA DKFZp434L2015 (from clone DKFZp434L2015);

partial cds.

803
873690
g2199651
222689.1c
1655
0
Human pyruvate kinase type L mRNA, complete cds.

804
368164
g1355113
125472.24
1562
1.00E−97
Human nuclear factor NF45 mRNA, complete cds.

805
581834
g1726099

806
837565
g2116248

807
423772
g1428470
1031520.1
1413
0

808
747167
g1896984
221880.2
1652
8.00E−26
predicted using Genefinder; cDNA EST yk462d1.5 comes from

this gene; cDNA EST yk391f12.5 comes from this gene;

cDNA EST CEMSH93R comes from this gene; cDNA EST yk204g10.5

comes from this gene; cDNA EST yk668d11.3 comes from

this gene

809
571805
g1660393
232313.17
1669
0
Human double-stranded RNA-binding nuclear protein

NFAR-2 mRNA, partial cds.

810
476275
g1530247
351237.1
1954
0

811
641051
g1800965
481411.3
2133
0
Human cdc25A mRNA, complete cds.

812
355445
g1333443

813
818653
g2192789
246727.18
1785
0
Human HSPC133 mRNA, complete cds.

814
933939
g2306707
257576.16
1821
0
Human mRNA for novel heterogeneous nuclear RNP protein,

L protein.

815
671075
g1865354
256011.77
1809
0
Human mRNA for protein homologous to elongation factor

1-gamma from A. salina.

816
643755
g1800406
244231.11
1762
0
Human mRNA for unknown protein of uterine endometrium.

817
577312
g1671585
023418.6
1381
0
Human putative ATP-dependent mitochondrial RNA helicase

(SUV3) mRNA, nuclear gene encoding mitochondrial protein,

complete cds.

818
439620
g1464672
289947.2
1840
0
Human Tax1 binding protein mRNA, partial cds.

819
747136
g1915371
367984.1
1969
7.00E−72
Human HMG-2 inRN A.

820
679015
g1876763

821
445310
g1479957
376249.1
1974
8.00E−31
egg-specific protein

822
385746
g5600036

823
699237
g1876267
1169034.2
1515
0
Human elongation factor Ts mRNA, nuclear gene encoding

mitochondrial protein, complete cds.

824
693114
g1882608
197889.2
1593
3.00E−65
Human putative outer mitochondrial membrane 34 kDa

translocase hTOM34 mRNA, complete cds.

825
572614
g1661715
247658.3
1787
0
Human aldehyde dehydrogenase E3′ mRNA, partial cds.

826
482138
g1553330
1169216.1
1516
2.00E−31
hypothetical protein

827
317894
g1287003
1143436.1
1499
0
Human HSPC160 mRNA, complete cds.

828
636513
g1765705
474208.52
2092
1.00E−92
Human mRNA for RNA polymerase II hRPB11 subunit.

829
620239
g4289212
443251.36
2074
0
Human mRNA for ribosomal protein L39, complete cds.

830
443413
g1475020

831
716630
g1901484
476265.36
2117
0
Human p18 protein mRNA, complete cds.

832
354910
g1330620
474132.3c
2090
0
Human Nedd-4-like ubiquitin-protein ligase WWP2 mRNA,

complete cds.

833
580810
g1715434

834
480685
g1558145
1073112.28
1459
0
Human thyroid receptor interactor (TRIP1) mRNA,

complete cds.

835
550910
g1643472
1084760.3
1476
8.00E−13
L-asparaginase

836
480395
g4057853

837
871585
g2187114
1144501.1
1505
6.00E−29
Unknown protein

838
465403
g1505274
232831.6
1674
0
Human SH2-containing protein Nsp2 mRNA, complete cds.

839
747059
g1915247
361088.4c
1962
0
Human 26S proteasome-associated pad1 homolog (POH1) mRNA,

complete cds.

840
760832
g2039616
253870.6c
1802
0
Novel Human gene mapping to chomosome 1.

841
424329
g4271845
404262.2
2012
0
Human mRNA for KIAA0518 protein, partial cds.

842
834148
g2071655
815566.6
2176
0
Human unknown protein IT12 mRNA, partial cds.

843
571406
g1660535
1005811.1
1407
0
Human translation initiation factor eIF3 p44 subunit mRNA,

complete cds.

844
680123
g1875722
109657.9
1490
0
Human CCAAT-box-binding factor (CBF) mRNA, complete cds.

845
805129
g2201461
337822.11
1892
0
Human mRNA for M96A protein.

846
576901
g1681507

847
336684
g4258562
1185071.1
1528
0
Human mRNA for KIAA0595 protein, partial cds.

848
577010
g1681609
174363.1
1581
0

849
733738
g1907494

850
420302
g1539052

851
720951
g1903498

852
421129
g4275640
252872.1
1796
7.00E−49
Rhesus monkey B2 repetitive sequence.

853
472332
g1509475
1072451.3
1436
0
Human mRNA for GC box bindig protein, complete cds.

854
550649
g1643499

855
775875
g1918772
814508.1
2171
0

856
476610
g4061243

857
580935
g1702122
233411.6
1686
0

858
571759
g1660379
352406.7
1956
0
Human mRNA for osteopontin.

859
441394
g1464991
481411.6c
2134
0
Human cdc25 A mRNA, complete cds.

860
763352
g1910788
350412.4
1946
0
Human mRNA for villin-like protein, complete cds.

861
573743
g4299578
346645.6
1918
0
Human mRNA for cytosolic serine hydroxymethyltransferase,

clone pUS1206.

862
473802
g1513848
1188616.2
1541
0

863
535188
g1629951
1170290.3c
1518
0
Human mRNA for GARS-AIRS-GART.

864
388321
g1379666

865
316967
g1286269
255816.6
1806
0
Human mRNA for muscle specific enolase (MSE)

(EC 4.2.1.11).

866
314456
g1285038
349989.12
1938
0.0004
putative carboxypeptidase

867
318263
g1287290

868
466254
g1504699
023985.1
1382
5.00E−62
Human 26S proteasome ATPase subunit mRNA, complete cds.

869
775342
g2039947

870
748879
g1935976
480310.59
2122
0
Human prefoldin subunit 2 mRNA, complete cds.

871
480205
g4061306
350231.5
1943
0
Human (clone FBK III 16) protein tyrosine kinase

(NET PTK) mRNA, complete cds.

872
764803
g1912793
228845.4
1658
0

873
481485
g1553995
199098.4
1601
7.00E−05
rplQ homologue (identity of 84% to B. sublilis)

874
437167
g4272253
086968.3
1404
0
Human D13S106 mRNA for a highly charged amino acid

sequence.

875
698100
g1863458

876
618834
g1748970

877
574981
g1684446
236100.1
1725
7.00E−95
Human CGI-113 protein mRNA, complete cds.

878
876655
g2232384
1093970.1
1485
2.00E−23
SM-20

879
779876
g2074938
337822.2
1893
0
Human PHD finger DNA binding protein isoform 1 (M96) mRNA,

alternatively spliced, complete cds.

880
437994
g1463778
235247.38
1718
0
Human clone H41 unknown mRNA.

881
638265
g1796544
333506.1
1874
0
Human nuclear FMRP interacting protein 1 (NUFIP1) mRNA,

complete cds.

882
576572
g4061800
1071477.14
1420
0

883
464800
g1500827
804409.14
2163
0
Human mRNA for KIAA0281 gene, complete cds.

884
803541
g2201576
1075277.1
1465
2.00E−67
Human melanoma antigen p15 mRNA, complete cds.

885
427295
g4271974
154692.2

886
735617
g1907914

391068.20c
1981
0
Human mRNA for SAP 130 spliceosomal protein.

887
873314
g2202021
1071453.5
1418
0
Human pre-mRNA splicing factor (SFRS3) mRNA, complete cds.

888
575067
g4061769

400539.18c
1994
0
Human full length insert cDNA clone ZD65D11.

889
437626
g1447178

890
353521
g1325221

891
642467
g1776773
138528.7
1567
0
Human transforming acidic coiled-coil containing

protein 3 (TACC3) mRNA, complete cds.

892
775135
g2040007
453970.1
2080
7.00E−48
p52 pro-apototic protein

893
582028
g1725824
1185744.1
1531
0
Human SL15 protein mRNA, complete cds.

894
523463
g1619172
457998.1
2083
0
Human testis-specific chromodomain Y-like protein

(CDYL) mRNA, alternatively processed, complete cds.

895
459170
g4057763

896
367802
g1355017

897
337217
g4258592

898
748374
g1915433
1011653.1
1410
0
Human ribosomal protein L21 mRNA, complete cds.

899
737058
g1910473
211575.1c
1638
3.00E−38
Human mRNA for MTH1b (p22), MTH1c (p21), MTH1d (p18),

complete cds.

900
576686
g1682139

901
874192
g2200290
1072451.3
1436
0
Human mRNA for GC box bindig protein, complete cds.

902
465052
g5599406
409135.14
2029
0
Human mRNA for alkalin phosphatase, complete cds.

903
367601
g1355494
202224.1
1626
0
Human mRNA for KIAA0156 gene, complete cds.

904
464548
g1497679
337870.3c
1894
0

905
419614
g1538782
480931.2
2128
7.00E−36
Human CpG island DNA genomic Mse1 fragment, clone 26g5,

forward read cpg26g5.ft1b.

906
809055
g2192192

907
574939
g1675885
336999.2
1890
0
Human zinc finger protein (ZNF143) mRNA, complete eels.

908
550845
g1643555
245648.11
1775
0
Human lck mRNA for membrane associated protein tyrosine

kinase.

909
746994
g1896854
361528.3
1964
2.00E−34
cerebellar postnatal development protein-1

910
676311
g1806829

911
805419
g2202726
475524.1
2115
0
Human CLDN6 gene for claudin-6.

912
889543
g2233736

913
313741
g1285068
202016.6c
1623
0
Human mRNA; cDNA DKFZp566I0947 (from clone

DKEZp566I0947).

914
777598
g1919634
332518.2
1868
0
Human mRNA for serine/threonine protein kinase SAK.

915
573784
g1662934
1074101.1
1462
9.00E−16
Human phosphoserine aminotransferase (PSA) mRNA,

complete cds.

916
721931
g1904713
345268.3
1912
0
Human hCMT1c mRNA for mRNA (guanine-7-)methyltransferase,

partial cds.

917
735607
g1908557
765534.1
2158
9.00E−31
hypothetical protein

918
532659
g1575892
222798.1
1656
3.00E−88
Human HSPC028 mRNA, complete cds.

919
761119
g2040631
347294.1
1923
0
Human breast cancer susceptibility (BRCA2) mRNA,

complete cds.

920
653427
g1864742

921
354212
g1328570
234908.13
1709
0
Human mRNA activated in tumor suppression, clone

TSAP13 extended.

922
746955
g1915334
1190365.1c
1559
0
Human CpG island DNA genomic Mse1 fragment, clone 187d3,

reverse read cpg187d3.rt1a.

923
750782
g1936808
903389.6
2211
0.001
contains Pro-rich Px motifs: SPKPP (20X), PEPPA (9X); similar

to soybean pro-rich cell wall protein, corresponds to

Swiss-Prot Accession Number P13993

924
437517
g1447055
234124.11
1700
0
Human protein tyrosine phosphatase (PTPase) mRNA,

complete cds.

925
425352
g1435946
243474.28
1758
0
Human ribosomal protein S4 (RPS4X) isoform mRNA,

complete cds.

926
427339
g1446760

927
480747
g4273433
236654.2
1731
2.00E−22
zinc finger protein

928
466150
g1504746

929
440985
g1465026
228845.9
1659
0
Human mRNA for thrombospondin.

930
760795
g2039745

931
820518
g2102208
346898.5
1921
0
Human eukaryotic translation initiation factor (eIF3) mRNA,

complete cds.

932
775596
g1918551
1189704.1
1551
0

933
751500
g4316979
447885.1
2078
0

934
439542
g4315275
335511.3
1882
0.0002
KIAA0337

935
717469
g2057407

936
533117
g1576271
412999.3

937
478374
g1529455
1085430.3
1478
0
Human mRNA for KIAA0560 protein, partial cds.

938
439902
g1464733
200115.6
1610
0.0009
subunit of RNA polymerase II transcription factor TFIID

939
874148
g2199752
404705.9c
2017
0
Human chromosome segregation gene homolog CAS mRNA,

complete cds.

940
752290
g1936231
233795.1
1693
6.00E−07
unknown protein

941
443711
g4056914
1144009.2
1502
2.00E−54
CGI-89 protein

942
574835
g1684043

943
408040
g1538690
337894.3
1895
5.00E−05
nucleolar phosphoprotein

944
476407
g1529858
429681.1
2059
3.00E−72
Human protein phosphatase X (PPX) mRNA, complete cds.

945
851054
g2187435

946
445127
g1487454

947
475443
g4273372
067329.4
1400
0

948
637237
g1776625

949
620195
g1759202
474592.5
2102
0
Human leukemia virus receptor 1 (GLVR1) mRNA, complete cds.

950
763563
g1932058
1072248.1
1431
0
Human histone acetyltransferase (HBO1) mRNA, complete cds.

951
572869
g1662692

952
640556
g1800824

953
427480
g4271985

954
831991
g2157465

955
418955
g1542313

956
419848
g1538911
898228.8
2190
0
Human X104 mRNA, complete cds.

957
439411
g1447604
236544.2
1730
0

958
733810
g1904886
235147.66
1711
0
Human mRNA for elongation factor-1-beta.

959
385341
g1385099
764831.1
2155
8.00E−89
Human full length insert cDNA clone ZD55G12.

960
445230
g4272049
378633.7
1975
0
Human mRNA for motor protein, complete cds.

961
387482
g1373969
236996.6
1733
0
Human mRNA for inteferon related IFRD2 (PC4-B) protein

(TFRD2 gene), SM15 homologue.

962
442585
g1476397
1085501.1
1480
0
Human EF-1delta gene encoding Human elongation

factor-1-delta.

963
438917
g1463839
339157.14
1896
0
Human serine/threonine kinase ULK1 (ULK1) mRNA,

complete cds.

964
406351
g1540744
118726.1
1535
0
Human mRNA; cDNA DKFZp434K0410 (from clone DKFZp434K0410);

partial cds.

965
805842
g2053335

966
574832
g1684038
205655.4
1634
7.00E−09
predicted using Genefinder; Similarity to Yeast

mitochondrial ribosomal protein S5 (SW:RT05_YEAST);

cDNA EST EMBL:D65461 comes from this gene; cDNA

EST EMBL:D68901 comes from this gene; cDNA

EST yk432a4.3 conies from this gene; cDNA

EST yk432a4>

967
642145
g1810800

1073074.196c
1453
0
Human mRNA; cDNA DKFZp434P1514 (from clone DKFZp434P1514);

partial cds.

968
525104
g4060086
274401.5
1833
0
Human mRNA for putative lipoic acid synthetase,

partial.

969
748517
g1907820
331555.1
1859
0
Human adenosine kinase mRNA, complete cds.

970
409069
g1541765
430224.2
2065
0
Human p53 (TP53) gene, complete cds.

971
352836
g4199091

972
472605
g1513459
237553.1
1737
1.00E−59
Human transcription factor ETR101 mRNA,

complete cds.

973
635025
g1739192

974
804482
g2202569

975
386101
g1369148
257593.2
1823
0

976
474339
g1514227
010794.4
1374
0
Human mRNA for TGIF protein.

977
598898
g1746705

978
478167
g1529286
189289.8
1584
0
Human tumorous imaginal discs protein Tid56 homolog

(TID1) mRNA, complete cds.

979
733726
g1905098
349663.16
1934
0
Human clone IMAGE Consortium 302831 latent transforming

growth factor-beta binding protein 4 mRNA, partial cds.

980
407997
g1538669
1144078.2
1503
5.00E−08
proline-rich mucin homolog

981
475670
g4061215

982
467501
g4057800

983
643463
g1772281

984
574251
g4444704
228150.48
1657
0
Human RPL13A, U32, U33, U34, U35, RPS11, U35 genes for

ribosomal protein L13a and S11, U32, U33, U34, U35, and

U35 snoRNA, complete cds and sequence.

985
476205
g1530366

986
457150
g4057750

987
465903
g1504656
247977.4c
1788
9.00E−53
Human CI-B14.5a homolog mRNA, complete cds.

988
659928
g1840271
040038.51
1394
0
Human mRNA for ribosomal protein L35a.

989
573609
g1676392
1072876.2
1441
0
Human mRNA for KIAA0253 gene, partial cds.

990
736069
g1908611
202489.22
1628
0
Human zinc finger/leucine zipper protein (AF10) mRNA,

complete cds.

991
720870
g1903917
899209.8c
2196
0
Human mRNA for erythrocyte cytosolic protein of 51 kDa.

992
468633
g1475438
252872.2
1797
9.00E−23
Rhesus monkey B2 repetitive sequence.

993
575554
g4299879
399465.4
1988
0
Human mRNA for KIAA0136 gene, partial cds.

994
640177
g1793165

995
834934
g2193407

996
400741
g4256936
1171111.5
1519
0
Human colin carcinoma laminin-binding protein mRNA,

complete cds.

997
475814
g4061223
444662.7
2075
2.00E−39
similar GAR1 related proteins (small nucleolar protein

required for pre-rRNA splicing)

998
808377
g2192845

999
583869
g1715201
232279.4
1668
0
Human mRNA for KIAA1177 protein, partial cds.

1000
478383
g4061346
1079863.1
1472
2.00E−65
Human methylenetetrahydrofolate dehydrogenase-

methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate

synthetase mRNA, complete cds.

1001
763597
g1932074
200727.3c
1612
1.00E−08
contains similarity to several apoptosis or programmed

cell death proteins such as rat apoptosis protein

RP-8 (GB:M80601)

1002
659193
g1827385
060445.3

1003
571278
g1660261
256051.39
1812
0
Human RNA-bindiag protein regulatory subunit mRNA,

complete cds.

1004
535199
g1630005
407870.4
2026
0
Human coiled-coil related protein DEEPEST (DEEPEST)

mRNA, complete cds.

1005
696858
g1838388
902879.1
2206
0
Human mRNA for HL23 ribosomal protein homologue.

1006
850354
g2164878
347805.31
1925
0
Human mRNA for RPD3 protein, complete cds.

1007
466295
g1504818
241630.21
1752
0
Human mRNA for ribosomal protein (homologuous to

Yeast S24).

1008
619385
g1751569

1009
425049
g1435873

1010
579349
g4058103

1011
762516
g1909864
368651.1
1970
0
Human gene for PP15 (placental protein 15).

1012
676748
g1811238
480496.13
2125
0

1013
483333
g1555497
236142.6
1726
0
Human medium-chain acyl-CoA dehydrogenase (ACADM) mRNA,

complete cds.

1014
850426
g2164943
903951.15
2217
0
ArgRS = arginyl-tRNA synthetase [Human,

ataxia-telangiectasia patients, EBV-lymphoblastoid cells,

mRNA, 2120 nt].

1015
405779
g1540353

1016
651274
g1814515
902159.16
2201
0
Human proteasome subunit XAPC7 mRNA, complete cds.

1017
481576
g4604547
344598.3
1907
0
Human cytochrome oxidase assembly factor (PET112) mRNA,

complete cds.

1018
735773
g4317871
175394.1
1583
0

1019
722623
g1897138
010794.1
1373
0
Human mRNA for TGIF protein.

1020
318642
g1285873
893157.1
2188
0
Human L23 mRNA for putative ribosomal protein.

1021
595972
g1699453
359995.18
1959
0
Human mRNA; cDNA DKFZp434L1613 (from clone DKFZp434L1613);

partial cds.

1022
761158
g2040800
398965.2
1986
0
Human mRNA encoding RAMP3.

1023
949722
g2283423
349293.3
1930
0
Human mRNA for KIAA1261 protein, partial cds.

1024
766582
g1915467
903243.2
2210
0
Human glutathione transferase (GSTA3) mRNA, partial cds.

1025
480329
g1550921
902858.2

1026
465744
g1504292
331520.8
1858
0
Human mRNA; cDNA DKFZp566D143 (from clone DKFZp556D143);

partial cds.

1027
481242
g1554197
237495.4
1736
0
Human Fas associated factor 1 mRNA, complete cds.

1028
577501
g4061820
1190255.1c
1558
9.00E−56
Human HepG2 3′ region cDNA, clone hmd2g04.

1029
763424
g1910590
1189812.1
1554
0
Human cysteine and glycine-rich protein 2 (CSRP2) mRNA,

complete cds.

1030
408693
g1541609
238614.9
1744
0
Human small nuclear RNA protein E mRNA, complete cds.

1031
480196
g1550881
1186614.1c
1534
0
Human CC chemokine gene cluster, complete sequence.

1032
818256
g2140196
814647.3
2174
0
Human HALPHA44 gene for alpha-tubulin, exons 1-3.

1033
445439
g1481110

1034
493683
g1630415
1071820.3
1428
0
Human mRNA; cDNA DKFZp434P1215 (from clone DKFZp434P1215);

partial cds.

1035
642165
g1810961
233723.16
1690
0

1036
641368
g1796686

1037
425857
g1436705
447819.1
2077
2.00E−59
alanine aminotransferase

1038
809206
g2139623
230408.9
1663
0
Human HSPC179 mRNA, complete cds.

1039
933183
g2284211
232279.11
1667
0
Human mRNA for KIAA1177 protein, partial cds.

1040
748639
g1908078

1041
747180
g1896883

1042
385358
g1380989
480452.6c
2123
0
Human mRNA for protein D123, complete cds.

1043
872986
g2192375

1044
329816
g1288172
246387.2
1783
0
Human NTF2-related export protein NXT1 (NXT1) mRNA,

complete cds.

1045
672656
g1853779

1046
617288
g4298653

1047
423327
g4271809
332777.8
1873
0
Human mRNA for KIAA1259 protein, partial cds.

1048
459094
g4272149

1049
834917
g2193409

1050
735089
g1896247

1051
455483
g1484291
246336.9
1782
0
Human geranylgeranyl trartsferase type II beta-subunit

mRNA, complete cds.

1052
479759
g4061296
460283.5c
2085
0
Human mRNA for KIAA0274 gene, complete cds.

1053
778381
g2073712
385182.12
1979
0
Human barrier-to-autointegration factor mRNA,

complete cds.

1054
473404
g1513959
350905.4
1951
0
Human Treacher Collins syndrome (TCOF1) mRNA,

complete cds.

1055
406889
g1541054
760699.15
2148
0
Human RSU-1/RSP-1 mRNA, complete cds.

1056
351154
g1325565
197067.3
1589
0
Human SnRNP core protein Sm D2 mRNA, complete cds.

1057
660756
g1827284
1085450.1
1479
0
neurofilament-66 [Human, fetal brain, mRNA,

3197 nt].

1058
678992
g1875229
813771.1
2169
0
Human (clone p5-23-3) mRNA.

1059
441983
g1476453
021846.3
1380
0
Human HSPC015 mRNA, complete cds.

1060
483476
g4273580

1061
699466
g1876365
1189599.1
1550
1.00E−70
Human mRNA for Lsm5 protein.

1062
464381
g1497540
344603.4
1908
0
Human mRNA; cDNA DKFZp586K0919 (from clone DKFZp586K0919);

complete cds.

1063
736584
g1908983

1064
903419
g2259182
255824.44
1807
0
Human aldolase A mRNA, complete cds.

1065
607469
g1751918
237409.8
1734
0
Human purine nucleoside phosphorylase gene, exons 3, 4 and 5.

1066
775067
g2040315
903115.9
2209
0
Human phosphomannomutase mRNA, complete cds.

1067
803817
g2101798
1072439.1
1435
0
Human HSPC071 mRNA, complete cds.

1068
438774
g1530821
335173.1
1881
0
Human carbon catabolite repression 4 protein homolog mRNA,

complete cds.

1069
317976
g1285920
145503.16
1569
0
Human sorting nexin 5 (SNX5) mRNA, complete cds.

1070
903284
g2259542
1169639.1
1517
2.00E−17
Human CpG island DNA genomic Mse1 fragment, clone 134c10,

forward read cpg134c10.ft1a.

1071
791433
g2075599

1072
476999
g1527784
244097.3

1073
477900
g1528332
898830.7
2193
0
Human pescadillo mRNA, complete cds.

1074
749569
g2041641
351159.3
1953
0
Human DEAD box RNA helicase-like protein mRNA,

complete cds.

1075
481469
g4272199

1076
480026
g1531178

274401.21c
1832
0
Human mRNA for KIAA1089 protein, partial cds.

1077
386766
g1372077
247977.4c
1788
9.00E−53
Human CI-B14.5a homolog mRNA, complete cds.

1078
693287
g2050114
221819.3
1650
0
Human von Hippel-Lindau binding protein (VBP-1) mRNA,

complete cds.

1079
404268
g5599332

1080
386122
g1369154

1081
478301
g1529366
348196.18
1929
0
Human 4F2 glycosylated heavy chain (4F2HC) antigen gene,

exon 1 and 2.

1082
576570
g1677315
124921.6
1561
0
Human IEF SSP 9502 mRNA, complete cds.

1083
466413
g1506394

1084
418473
g1541855
1143289.1
1498
0
Human HSPC260 mRNA, partial cds.

1085
636207
g1766849
462958.8
2086
0
Human class III alcohol dehydrogenase (ADH5) chi

subunit mRNA, complete cds.

1086
577180
g1682379
330919.4
1852
1.00E−11
cytoplasmic linker protein CLIP-170

1087
459668
g1493594
331018.14
1854
0
Human chaperonin containing t-complex polypeptide 1,

delta subunit (Cctd) mRNA, complete cds.

1088
746463
g1896502
253235.1
1798
6.00E−74
Human mRNA for DNA primase (subunit p48).

1089
820355
g2102111
1143532.1
1500
1.00E−18
Human translation initiation factor eIF3 p66 subunit mRNA,

complete cds.

1090
761127
g2040635

1091
467873
g1509701

1092
777779
g1932483
221834.6
1651
0
BcDNA.LD18761

1093
372421
g1357464
235314.2
1719
0
Human basic transcription factor 2 p44 (btf2p44) gene,

partial cds, neuronal apoptosis inhibitory protein (naip)

and survival motor neuron protein (smn) genes,

complete cds.

1094
572285
g1662010
437025.16
2070
0
Human mRNA for macropain subunit zeta.

1095
571569
g4061378
401484.3
2000
0
Human mRNA for proteasome subunit HsC10-II, complete cds.

1096
388936
g1375971

391068.20c
1981
0
Human mRNA for SAP 130 spliceosomal protein.

1097
633261
g1759726
404508.1

1098
793038
g2156889
060356.7
1398
0
Human mRNA for herpesvirus associated ubiquitin-specific

protease (HAUSP).

1099
736328
g1908947
1073050.1
1452
0
Human deoxyhypusine synthase 2 mRNA, complete cds.

1100
348123
g4199071
407870.9c
2027
0
Human mRNA; cDNA DKFZp434H1210 (from clone DKFZp434H1210);

partial cds.

1101
482885
g4273555

1102
401741
g1388813
889830.1
2186
0

1103
679007
g1875341
332516.9c
1867
0
Human squamous cell carcinama of esophagus mRNA for

GRB-7 SH2 domain protein, complete cds.

1104
717387
g2057367
474316.9
2095
0
Human clone 23783 mRNA sequence.

1105
721532
g1904392
474711.5
2105
0.001
RPGR protein

1106
439254
g1447384

1107
808083
g2157030
344071.13
1902
0
Human mRNA; cDNA DKFZp434L2015 (from clone DKFZp434L2015);

partial cds.

1108
476163
g1530276
1189576.1
1549
0
Human branched chain alpha-keto acid dehydrogenase (BCKDHB)

E1-beta subunit mRNA, complete cds.

1109
440715
g1465189

1110
636888
g1766814
400607.2c
1998
2.00E−77
Human FK506-binding protein 25 (FKBP25) mRNA,

complete cds.

1111
746853
g1915241

1112
418606
g1429121

1113
336021
g1318304
378633.7
1975
0
Human mRNA for motor protein, complete cds.

1114
403220
g1539385

1115
524367
g1563312

1116
351288
g1324854
1074529.1
1464
6.00E−29
Human mRNA for KIAA0778 protein, partial cds.

1117
401221
g1428051

1118
748061
g1915292
475248.5
2112
7.00E−88
similar to leucyl-tRNA synthetase; cDNA EST EMBL:D64208

comes from this gene; cDNA EST EMBL:D65056 comes from

this gene; cDNA EST MBL:D68348 comes from this gene;

cDNA EST yk377h12.3 comes from this gene; cDNA EST

yk377h12.5 comes from this g>

1119
831799
g2157099
407574.5
2024
0
Human ribonuclease P protein subunit p40 (RPP40) gene,

complete cds.

1120
374877
g1369506
347805.36
1926
0
Human histone deacetylase HD1 mRNA, complete cds.

1121
534132
g1594370
237495.3
1735
0
Human CGI-03 protein mRNA, complete cds.

1122
574459
g4284012
238296.6
1742
0
Human mRNA for HMGBCG protein.

1123
444027
g1475778
244633.5
1768
2.00E−45
Human mitochondrial HSP75 mRNA, complete cds.

1124
791176
g2075474
903920.6
2216
0
Human origin recognition complex subunit 6 (ORC6) mRNA,

complete cds.

1125
421766
g4275680

1126
423713
g4271832
760699.13
2147
0
Human RSU-1/RSP-1 mRNA, complete cds.

1127
778447
g2073832
342283.7
1898
0
Human NY-REN-45 antigen mRNA, complete cds.

1128
467830
g1509690

1129
617197
g1755906
1004597.1
1406
0

1130
793127
g2142796
244382.2
1764
0
Human ribosomal protein L9 mRNA, complete cds.

1131
779315
g2074235
793531.1
2160
0
Human mRNA for KIAA0111 gene, complete cds.

1132
427222
g1446540
898830.2c
2192
0
Human CST gene for cerebroside sulfotransferase, exon

1, 2, 3, 4, 5.

1133
807957
g2116355
732479.1
2140
2.00E−57
/prediction = (method:

1134
820560
g2102295

1135
571841
g4274762

1136
597896
g4060437
244612.2
1767
2.00E−95
Human A1S9 mRNA for A1S9 protein of unknown function.

1137
388245
g1375543
816212.1
2180
0
Human DNA ligase I mRNA, complete cds.

1138
679235
g1876797
174032.1
1577
0

1139
874541
g4614274
331937.4
1864
3.00E−12
NTR

1140
762237
g1917885

1141
401167
g1427988
400607.14
1996
0
Human mRNA for KIAA0589 protein, partial cds.

1142
335017
g1537473
331114.4
1856
0
Human mRNA for KIAA0314 gene, partial cds.

1143
401821
g1388915
401887.47
2009
0
Human mRNA for KIAA1273 protein, partial cds.

1144
425452
g4061573
1189743.1
1553
0

1145
676921
g1811610

238242.21c
1741
0
Human hASNA-I mRNA, complete cds.

1146
735374
g4765142

1147
480488
g1558048
350181.7
1942
5.00E−69
Human threonyl-tRNA synthetase mRNA, complete cds.

1148
442843
g1476028
350106.12
1941
0
Human glutamate dehydrogenase gene, complete cds.

1149
406282
g1540681
400837.9
1999
0
Human splicing factor, atginine/serine-rich 7 (SERS7)

gene, complete cds.

1150
619836
g1759124

1151
440053
g4058501
1178685.1
1525
0
Human partial mRNA for putative eIF2 alpha kinase

(GCN2 gene).

1152
426529
g1445840
220551.1
1644
0
Human origin recognition complex subunit 6 (ORC6) mRNA,

complete cds.

1153
406088
g1540555
198907.11
1600
0
Human mRNA for putative ABC transporter, partial.

1154
440194
g1478815
337870.3c
1894
0

1155
467669
g4060664
480462.1
2124
0
Human C-terminal binding protein 2 mRNA, complete cds.

1156
406154
g1540601
1041769.1
1415
7.00E−13
putative amidohydrolase

1157
465520
g1504514
373719.5
1973
0
Human ADP/ATP carrier protein mRNA, complete cds.

1158
439033
g1464229
1173266.1
1523
0
Human bisphosphate 3′-nucleotidase mRNA, complete cds.

1159
639451
g1795853
221390.8
1647
8.00E−47
Human CpG island DNA genomic Mse1 fragment, done 91b2,

forward read cpg91b2.ft1a.

1160
355454
g1333441

1161
354155
g1328412

1162
619401
g1756740
246762.1
1786
0

1163
480204
g1550998
272721.32
1829
5.00E−06
predicted using Genefinder; cDNA EST yk551g5.3 comes

from this gene

1164
468792
g1509016
1182186.1
1526
0
Human CDC2 gene involved in cell cycle control.

1165
573582
g1676863
407488.2
2023
6.00E−71
Human mRNA for KIAA0956 protein, partial cds.

1166
464447
g1497572
336738.1
1885
0
Human Bloom's syndrome protein (BLM) mRNA, complete cds.

1167
388091
g1380598
263336.9c
1827
0
Human mRNA for alanyl-tRNA synthetase, complete cds.

1168
576353
g1677104
1133155.1
1495
0
Human NNX3 (C19orf2) mRNA, complete cds.

1169
475796
g1529806
197563.7
1591
0
Human mRNA for KIAA0631 protein, partial cds.

1170
834541
g2192898
209635.5
1637
0
Human CAD mRNA for multifunctional protein CAD,

complete cds.

1171
573301
g1676207

1172
524361
g4058216
314873.5
1846
0
Human DNA recombination and repair protein (MRE11B) mRNA,

complete cds.

1173
848702
g2158118
765792.1
2159
2.00E−51
Human PTD017 mRNA, complete cds.

1174
422188
g1427355
249443.1
1791
9.00E−93
Human mRNA for E2F-4 protein.

1175
422167
g1427225
291494.1
1841
0
Human bright and dead ringer gene product homologous protein

Bdp mRNA, complete cds.

1176
596719
g1715941
1188194.6
1536
0
Human mRNA; cDNA DKFZp564G092 (from clone DKFZp564G092);

partial cds.

1177
427594
g1445982
235749.9
1721
0

1178
933852
g2305399
234088.1
1699
1.00E−74
/prediction = (method:

1179
407354
g1542220
201424.1
1619
0
Human HSPC037 protein mRNA, complete cds.

1180
424021
g1542780

1181
332396
g1282795
1073934.1
1461
0
Human mRNA for Pirin, isolate 17.

1182
422799
g1427033
1071969.5
1430
0
Human mRNA for cell cycle gene RCC1.

1183
440795
g1465253
1171439.1
1520
0
Human 60S acidic ribosomal protein PO mRNA, complete cds.

1184
535409
g4308335

1185
441235
g1465225
1189175.1
1546
0
Human protein arginine N-methyltransferase 3 (PRMT3) mRNA,

partial cds.

1186
437602
g1447172
202075.4
1624
0
Human phosphatidylinositol(3,4,5)trisphosphate binding

protein p42IP4 mRNA, complete cds.

1187
874591
g2200428
474418.2
2098
0
Human HS1 binding protein HAX-1 mRNA, nuclear gene

encoding mitochondrial protein, complete cds.

1188
583932
g1725561

1189
640682
g1800372
350016.4
1939
3.00E−48
Human clone 23585 mRNA sequence.

1190
580623
g1701915
236260.1
1727
0

1191
67901 1
g1876761
234639.5
1707
0
Human putative nucleotide binding protein mRNA,

complete cds.

1192
482910
g4061421
215053.3
1642
2.00E−12
Human CpG island DNA genomic Mse1 fragment, clone 151f3,

reverse read cpg151f3.rt1a.

1193
373854
g4257160

1194
335746
g1297406
199944.6
1605
0
Human RNA polymerase I subunit hRPA39 mRNA, complete cds.

1195
579715
g1680952
1073079.41
1455
0
Human liver mRNA for glyceraldehyde-3-phosphate

dehydrogenase (G3PD, EC 1.2.1.12).

1196
439548
g1447669
1145579.1
1506
2.00E−48
Human mRNA for Lysyl tRNA Synthetase, complete cds.

1197
476123
g1530066
346653.9
1919
0
Human DNA polymerase alpha mRNA, complete cds.

1198
524442
g4060069
1188285.1
1538
0
Human mRNA for ribosomal protein L7.

1199
533415
g4060866
211628.2
1639
0
Human DEAD box RNA helicase Gemin3 mRNA, complete cds.

1200
894135
g2256434
1189159.1
1545
0
Human CGI-07 protein mRNA, complete cds.

1201
422667
g1427746
1072334.1
1432
0
Human PTD007 mRNA, complete cds.

1202
633209
g1759709
1185605.1c
1530
0
Human rabkinesin6 mRNA, complete cds.

1203
961094
g4401581
815596.1

1204
833661
g2192978
332056.2
1865
0
Human KIAA0432 mRNA, complete cds.

1205
385901
g1369058
469699.3
2087
0
Human sirtuin type 1 (SIRT1) mRNA, complete cds.

1206
760921
g4316563

1207
775645
g1918571
1086066.1
1482
0
Human ribosomal protein S5 mRNA, complete cds.

1208
388212
g1375493
234313.1
1703
1.00E−96
Human clone 24804 mRNA sequence.

1209
441968
g1475584
237553.1
1737
1.00E−59
Human transcription factor ETR101 mRNA, complete cds.

1210
576156
g1677291
346707.6
1920
0
Human mRNA for KIAA0007 gene, partial cds.

1211
790122
g2041159
1094883.1
1489
0

1212
920055
g2234893
1166415.1
1513
0
Human cyclophilin-related processed pseudogene.

1213
775189
g2040164
451018.1
2079
3.00E−11
Human mRNA for KIAA0631 protein, partial cds.

1214
570533
g1659855
1073107.67
1458
0
Human mRNA for ribosomal protein L3.

1215
716896
g1902413
415052.2
2044
0
Human mRNA for ribosomal protein L8.

1216
550869
g1643563
360645.13
1961
0.0006
cDNA EST yk255b9.3 comes from this gene; cDNA EST yk255b9.5

comes from this gene; cDNA EST EMBL:M75923 comes from this gene

1217
792736
g4320734

1218
948894
g2306022
234618.5
1705
0
Human p85Mcm mRNA.

1219
779257
g2158458
261069.1
1826
3.00E−97
Human nucleolar protein p40 mRNA, complete cds.

1220
765841
g1915853
479908.35
2121
0

1221
355808
g1332851

1222
437761
g1463860

1223
680147
g1861916
400428.2
1993
0
Human mRNA for DNA primase (subunit p58).

1224
352409
g1315739
201145.5
1616
0
Human DEAD-box protein abstrakt (ABS) mRNA, complete cds.

1225
388296
g4613966

1226
387227
g1374141
408351.1
2028
5.00E−57
Human mRNA for LAK-4p, complete cds.

1227
329726
g1286049
1078216.1
1469
1.00E−97
Macaque mRNA for alpha-tubulin.

1228
779598
g2073952
060356.7
1398
0
Human mRNA for herpesvirus associated ubiquitin-specific

protease (HAUSP).

1229
457567
g4276631
1184163.1c
1527
0
Human mRNA for KIAA0888 protein, partial cds.

1230
407274
g1541250

1231
314236
g1284324
1165545.1
1511
2.00E−35
similar to alpha/beta hydrolase fold; cDNA EST EMBL:T02320

comes from this gene

1232
834712
g2193193
205348.2
1632
4.00E−09
sconB

1233
643854
g1800840
255261.31
1804
0
Human alpha enolase mRNA, complete cds.

1234
720554
g1895480

1235
387946
g1375726
256026.1
1810
0
Human karyopherin beta 3 mRNA, complete cds.

1236
478417
g1529491
343938.1
1901
3.00E−23
Human CpG island DNA genomic Mse1 fragment, clone 68g2,

forward read cpg68g2.ft1a.

1237
532770
g1576204
1073101.5
1457
0
Human ribosomal protein L10 mRNA, complete cds.

1238
573725
g1676454
242626.4
1755
0
Human mRNA for nuclear factor IV.

1239
445567
g1481167
331114.4
1856
0
Human mRNA for KIAA0314 gene, partial cds.

1240
804963
g2050203

1241
574381
g1677144
1164111.1
1509
0
Human heat shock protein hsp70-related protein mRNA,

complete cds.

1242
438125
g1464002
245648.12
1776
0
Human T-cell-specific mRNA (YT16) for PTK homologous

protein PTK = protein-tyrosine kinase.

1243
372368
g1357434

1244
535036
g1595304
457674.1
2082
0
Human IGF-II mRNA-binding protein 1 (IMP-1) mRNA,

complete cds.

1245
699417
g1876237
761531.1
2150
0
Human mRNA for ribosomal protein, complete cds.

1246
444918
g1478999
330801.4
1850
0
Human mRNA for HsMcm6, complete cds.

1247
775603
g1918411
248870.1
1790
0
Human mRNA for leucine rich protein.

1248
831643
g2192227
253358.2
1799
2.00E−77
Human mRNA for histone H2A.Z.

1249
403681
g1539725

1250
331974
g1282346
239973.5
1749
0
Human mRNA for KIAA0020 gene, complete cds.

1251
331901
g1282303

1252
642977
g1768522
201253.1
1617
0
Human putative ATP/GTP-binding protein (HEAB) mRNA,

complete cds.

1253
836311
g4614140

1254
932884
g2288304
1071666.2
1425
0
Human mRNA; cDNA DKFZp564H2023 (from clone DKFZp564H2023).

1255
439731
g4199230
349456.3
1932
0
Human retinoic acid receptor (gamma-7) mRNA.

1256
761060
g2040531
332678.2
1872
0
Human chromatin assembly factor-I p60 subunit mRNA,

complete cds.

1257
678793
g1882231

1258
873758
g2199920

1259
482641
g1555782
175142.1
1582
0

1260
479758
g1531348

1261
467472
g1506720

1262
692981
g1862437

1263
776036
g1932193
239320.11
1747
0
Human branched chain aminotransferase precursor (BCATm)

mRNA, nuclear gene encoding mitochondrial protein,

complete cds.

1264
437831
g1463987
214443.12
1641
0
Human HSPC338 mRNA, partial cds.

1265
579735
g1671963
445101.5
2076
0
Human cyclin protein gene, complete cds.

1266
467550
g1506490

1267
493305
g1643728
480656.47
2126
0
Human mRNA for stromal antigen 3 (STAG3 gene).

1268
805386
g2201432

1269
633625
g1768163
429732.35
2061
0
Human mitochondrial matrix protein P1 (nuclear encoded) mRNA,

complete cds.

1270
426992
g1446657
1188644.1
1542
0
Human mRNA for kinesin-related protein, partial cds.

1271
350848
g1325096

232795.18c
1673
0
Human polyhomeotic 1 homolog (HPH1) mRNA, partial cds.

1272
657961
g1793977
200541.2
1611
0
Human mRNA for putative transcription factor, partial.

1273
961083
g2308499

1274
481381
g1554180
481594.12
2135
0
Human cytosolic aspartate aminotransferase mRNA,

complete cds.

1275
834225
g2071749
362675.1
1966
0

1276
407480
g1542266
154551.8
1572
2.00E−07
tex292

1277
422953
g1427888

1278
576166
g1682440

1279
403005
g1539226
150712.6
1571
0
Human mRNA for putative ATP(GTP)-binding protein,

partial.

1280
355755
g1332827
429649.5
2058
0
Human ribosomal protein S6 kinase 1 (RPS6KA1) mRNA,

complete cds.

1281
466382
g1504972
815574.1c
2177
0
Human regulatory myosin light chain (MYL5) mRNA,

complete cds.

1282
466384
g4056994

1283
424705
g1436780
1071715.6
1426
0
Human KNSL4 and MAZ genes for kinesin-like DNA binding

protein and Myc-associated zinc finger protein,

complete cds.

1284
574491
g4058034

1285
696769
g1864669
1086066.1
1482
0
Human ribosomal protein S5 mRNA, complete cds.

1286
477828
g1528290
221749.3
1649
0.0007
RS21-C6

1287
805046
g2050228

1288
441327
g1465322
1085840.2
1481
0
Human RNA polymerase III subunit (RPC32) mRNA,

complete cds.

1289
331792
g1282100
336961.1
1888
0
Human growth arrest specific 11 (GAS11) mRNA,

complete cds.

1290
420278
g4275596
899124.11
2195
0
Human mRNA for mitochondrial DNA polymerase gamma,

complete cds.

1291
426239
g4271934
198198.2c
1597
0
Human Cctg mRNA for chaperonin.

1292
466241
g1504958
474444.2
2099
0
Human poly(ADP-ribose) polymerase mRNA, complete cds.

1293
917265
g2222496

1294
337748
g1309637
812158.1
2166
0
Human asparagine synthetase mRNA, complete cds.

1295
577488
g1701407
474711.5
2105
0.001
RPGR protein

1296
465804
g1504222
399899.2
1992
0
Human mitotic checkpoint kinase Mad3L (MAD3L) mRNA,

complete cds.

1297
406031
g1540518
236330.2
1728
0
Human mRNA for NAD-dependent methylene tetrahydrofolate

dehydrogenase cyclohydrolase (EC 1.5.1.15).

1298
738252
g1909743

1299
400035
g1387154
474194.11
2091
0
Human immunophilin (FKBP52) mRNA, complete cds.

1300
791570
g2142370
239001.1
1746
0

1301
574520
g1684335

1302
803622
g2101604

1303
438886
g4061634
1071715.6
1426
0
Human KNSL4 and MAZ genes for kinesin-like DNA binding

protein and Myc-associated zinc finger protein,

complete cds.

1304
734665
g1895550

1305
776133
g1918740
427922.1
2054
0

1306
790721
g2041524
203263.1
1630
0
sarcosine oxidase

1307
464084
g1494430
196661.2
1586
0
Human HSPC145 mRNA, complete cds.

1308
791719
g2074809
199439.1
1604
0
Human selenophosphate synthetase 2 (SPS2) mRNA,

complete cds.

1309
722631
g4764843

1310
805579
g4320452
317119.1
1847
0

1311
571367
g1655110

1312
575434
g1684086

1313
793218
g4320660

1314
525119
g5598244
174035.1
1578
5.90E−42
cystathionine gamma-lyase

1315
441229
g1472887
395096.3
1983
0
Human mRNA for DNA replication licensing factor (huMCM2),

complete cds.

1316
444844
g1478979
809348.1
2165
0
Human colon Kruppel-like factor (CKLF) mRNA,

complete cds.

1317
463388
g1497812

1318
533085
g1576043
232772.6
1672
0
Human mRNA for KIAA0116 gene, partial cds.

1319
402730
g1391116
245863.6
1777
0
Human pyrroline 5-carboxylate reductase isoform (P5CR2) mRNA,

complete cds.

1320
466047
g1501086
331403.12
1857
0
Human P1-Cdc46 mRNA.

1321
641507
g1796677
029777.3
1388
0
Human beta-mannosidase mRNA, complete cds.

1322
945359
g2307964
251562.5
1794
0
Human mutator gene (hMSH2) mRNA, complete cds.

1323
765272
g1913230

1324
456342
g1487245

1325
314146
g4258079
229683.19
1661
0
Human histone acetyltransferase 1 mRNA, complete cds.

1326
316914
g1286251
232662.7
1671
0
Human clone 25116 mRNA sequence.

1327
779343
g2074241
344520.3
1905
0
Human glutamine PRPP amidotransferase (GPAT) mRNA,

complete cds.

1328
582668
g4284644
332649.7
1870
0
Human LPAP mRNA for lysophosphatidic acid phosphatase,

complete cds.

1329
313254
g1286209
233307.2
1684
8.00E−77
ubiquitin-specific processing protease

1330
945218
g2306681
337822.11
1892
0
Human mRNA for M96A protein.

1331
403663
g1539711

1332
833511
g2192127
344297.4
1904
0
Human cyclin mRNA.

1333
748744
g1934363
1189351.1
1548
0
Human mRNA for transcription elongation factor TFIIS.h.

1334
933491
g2288782
757504.15
2141
0
Human mRNA for nucleolar protein hNop56.

1335
575290
g1684581

1336
751977
g2049363
286623.1
1838
5.00E−81
Human cyclin B mRNA, 3′ end.

1337
572970
g1662435
330872.4
1851
0
Human replication factor C, 36-kDa subunit mRNA,

complete cds.

1338
572379
g1659837
475213.1
2111
0
Human mRNA for very-long-chain acyl-CoA synthetase,

complete cds.

1339
476629
g1530212
1185387.1
1529
0
Human mRNA for GARS-AIRS-GART.

1340
477593
g1528231
1170290.3c
1518
0
Human mRNA for GARS-AIRS-GART.

1341
920268
g2284236

427797.38c
2053
0
Human hmgI mRNA for high mobility group protein I.

1342
805549
g2050293
235420.3
1720
0
Human equilibrative nucleoside transporter 1 (ENT1) gene,

complete cds.

1343
680512
g4306841
235420.3
1720
0
Human equilibrative nucleoside transporter 1 (ENT1) gene,

complete cds.

1344
403735
g1539760
029997.1
1389
0

1345
693719
g1901373
332649.4
1869
0
Human LPAP mRNA for lysophosphatidic acid phosphatase,

complete cds.

1346
638455
g1826018
411296.5
2038
0
Human hemopoietic cell protein-tyrosine kinase (HCK) gene,

complete cds, clone lambda-a2/1a.

1347
579391
g1680969

1348
402162
g1387914

1349
833919
g2071845
366398.4
1968
0
Human mRNA for JM1 protein, complete cds (clone

LLNLc110M0111Q7 (RZPD Berlin) and LLNLc110K2140Q7

(RZPD Berlin)).

1350
776058
g4318153

1351
367627
g1355503

1352
457955
g4058612

1353
949512
g2283100
349423.5
1931
0
Human asialoglycoprotein receptor H2 mRNA, complete cds.

1354
334182
g1537449
244606.5
1766
0
Human genomic DNA, chromosome 22q11.2, clone N27C7.

1355
893933
g2256530

1356
820336
g2102082

1357
442396
g1474858
1184163.1c
1527
0
Human mRNA for KIAA0888 protein, partial cds.

1358
442966
g1476058

1359
833557
g2116381
757572.1
2144
0
Human mRNA for B-myb gene.

1360
791079
g2075275
017194.2
1376
0

1361
833477
g2192112
401524.1
2001
5.00E−43
F-box protein FBX15

1362
445862
g1483937
470468.6
2088
0
Human mRNA for uridine phosphorylase.

1363
535794
g1656688

1364
633484
g1768070

1365
944963
g2283154
203237.1
1629
0
Human jun dimerization protein gene, partial cds;

cfos gene, complete cds; and unknown gene.

	Number	Date	Country
Parent	09625102	Jul 2000	US
Child	10062674	Jan 2002	US

Markers of neuronal differentiation and morphogenesis

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Parent Case Info

Continuation in Parts (1)